

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 July 2002 (11.07.2002)

PCT

(10) International Publication Number
WO 02/053588 A2

(51) International Patent Classification⁷: **C07K 14/195**

KALTENBOECK, Bernhard [US/US]; 1205 Sunnyslope Court, Auburn, AL 36832 (US).

(21) International Application Number: PCT/US01/48715

(22) International Filing Date:
17 December 2001 (17.12.2001)

(74) Agent: **WILSON, Mark, B.**; Fulbright & Jaworski L.L.P., 600 Congress Avenue, Suite 2400, Austin, TX 78701 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/738,269 15 December 2000 (15.12.2000) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 09/738,269 (CIP)
Filed on 15 December 2000 (15.12.2000)

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM** [US/US]; 201 West Seventh Street, Austin, TX 78701 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **JOHNSTON, Stephen, A.** [US/US]; 10519 Les Jardins, Dallas, TX 75229 (US). **STEMKE-HALE, Katherine** [US/US]; P.O. Box 35913, Dallas, TX 75235 (US). **SYKES, Kathryn, F.** [US/US]; 10519 Les Jardins, Dallas, TX 75229 (US).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND COMPOSITIONS FOR VACCINATION COMPRISING NUCLEIC ACID AND/OR POLYPEPTIDE SEQUENCES OF CHLAMYDIA PSITTACI

(57) Abstract: The instant invention relates to antigens and nucleic acids encoding such antigens obtainable by screening the *Chlamydia psittaci* genome. In more specific aspects, the invention relates to methods of isolating such antigens and nucleic acids and to methods of using such isolated antigens for producing immune responses in bovines or other non-human animals. The ability of an antigen to produce an immune response may be employed in vaccination of bovines or antibody preparation techniques.



WO 02/053588 A2

APPLICATION FOR UNITED STATES LETTERS PATENT
for
METHODS AND COMPOSITIONS FOR VACCINATION COMPRISING
NUCLEIC ACID AND/OR POLYPEPTIDE SEQUENCES OF
CHLAMYDIA PSITTACI

by
Stephen A. Johnston
Katherine Stemke-Hale
Kathryn F. Sykes
and
Bernhard Kaltenboeck

BACKGROUND OF THE INVENTION

The government owns rights in the present invention pursuant to DARPA grant number MDA 972-97-1-0013. Incorporated herein by reference is the entire text of the patent application filed on December 17, 2001 in the United States by the same inventors as the present application and entitled "Methods And Compositions For Vaccination Comprising Nucleic Acid And/Or Polypeptide Sequences of *Chlamydia*."

1. Field of the Invention

The present invention relates generally to the fields of immunology, bacteriology and molecular biology. More particularly, the invention relates to methods for screening and obtaining vaccines generated from the administration of expression libraries constructed from a *Chlamydia psittaci* genome. In particular embodiments, it concerns methods and compositions for the vaccination of vertebrate animals against *Chlamydia psittaci* bacterial infections, wherein vaccination of the animal is *via* a protein or gene derived from part or all of the genes validated as vaccines.

2. Description of Related Art

Intracellular bacteria of the genus *Chlamydia* are important pathogens in both man and vertebrate animals, causing blindness in man, sexually transmitted disease, and community-acquired pneumonia, and most likely act as co-factors in atherosclerotic plaque formation in human coronary heart disease.

Ubiquitous *Chlamydia (C) psittaci* infections in cattle cause mastitis, infertility and abortion. A primary economic impact of *Chlamydia psittaci* in dairy cattle is the loss of milk production and quality. Serological evidence for infection with ruminant *C. psittaci* is found in virtually all cattle (Kaltenbock *et al.*, 1997). These infections typically do not cause overt signs of disease, but under stress of the host animal may elicit transient inflammation of the mammary gland and uterus. These stress-related herd health problems, while not clinically pronounced, result in major losses for animal agriculture due to reduced output and quality of animal products like milk.

Most existing vaccines for the treatment of bacterial infections are composed of live/attenuated or killed pathogens (Babiuk, 1999). Live/attenuated vaccines present the risk of residual, or reacquisition of, pathogenicity, and are associated with a high cost of production. In addition, efficacious live/attenuated vaccines cannot be developed against many pathogens, or are impractical to produce. Killed pathogens typically have less utility than live/attenuated vaccines, as they are not usually effective in eliciting cellular immune responses. An alternative is subunit vaccines that consist of one or a few proteins of the pathogen (Babiuk, 1999; Ellis, 1999). The proteins being developed for these vaccines are typically based on a dominant immune response in infected hosts, and/or on surmised importance in the disease process. Due to the high genetic complexity of bacteria or protozoa, the empirical approach to identify these proteins often requires extensive research on the pathogen's biology and produces a small, biased set of potential vaccine candidates. However, this is currently the only practical method when proteins are the commodity for testing a vaccine.

The development of genetic (DNA) immunization (Tang et al., 1992) not only offers a new method of vaccine delivery, but also enables a new, unbiased, approach to vaccine discovery. One of the inventors proposed that the whole genome of a pathogen could be searched for protein vaccine candidates by directly assessing protection from challenge, termed expression library immunization (ELI) (U.S. Patent 5,703,057, specifically incorporated herein by reference). It involves making an expression library representing the whole genome of the pathogen in a genetic immunization vector. The library is subdivided into smaller groups, and DNA from each library is used to vaccinate animals that are subsequently challenged. The advantage of this approach is that all of the potentially protective genes could be discovered and used in any useful combination to reconstitute a vaccine devoid of non-protective, immunopathological, or immunosuppressive antigens. The potential of ELI was demonstrated in a murine *Mycoplasma pulmonis* infection, against which random *M. pulmonis* libraries were protective (Barry et al., 1995). Since then, others have reported on protective libraries

(Brayton *et al.*, 1998; Piedrafita *et al.*, 1999), but the reduction of these libraries to individual genes has not been demonstrated.

As described above, the widespread human and animal infections by the genus
5 *Chlamydia psittaci* represents a particular challenge for vaccinology. *C. psittaci*
infections in cattle cause mastitis, infertility and abortion. A primary economic impact of
Chlamydia psittaci in dairy cattle is the loss of milk production and quality. Thus, an
effective vaccine against *Chlamydia psittaci* bacterial infections in cattle would be of
great economic importance. However, there presently have been no effective
10 vaccines developed against *Chlamydia psittaci*.

SUMMARY OF THE INVENTION

In some embodiments, the invention relates to isolated polynucleotides having a
region that comprises a sequence of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ
15 ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:24, SEQ ID
NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID
NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID
NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:58, or SEQ ID
NO:60, a complement of any of these sequences or fragments thereof. In some more
20 specific embodiments, the invention relates to such polynucleotide comprising a region
having a sequence comprising at least 17, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100,
125, 150, 200, or more contiguous nucleotides in common with at least one of SEQ ID
NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16,
SEQ ID NO:18, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ
25 ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID
NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:58, or SEQ ID NO:60, or its
complement. Of course, such polynucleotides may comprise a region having all
nucleotides in common with at least one of SEQ ID NO:6, SEQ ID NO:8, SEQ ID
NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID
30 NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID

NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:58, or SEQ ID NO:60, or its complement.

5 In other aspect, the invention relates to polypeptides having sequences of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:59, SEQ ID NO:61 or fragments
10 thereof. The invention also relates to methods of producing such polypeptides using recombinant methods, for example, using the polynucleotides described above.

 The invention relates to antibodies against *Chlamydia psittaci* antigens, including those directed against an antigen having sequences of SEQ ID NO:7, SEQ ID NO:9, SEQ
15 ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, or SEQ ID
20 NO:61, or an antigenic fragment thereof. The antibodies may be polyclonal or monoclonal and produced by methods known in the art.

 The invention relates to vaccines for the immunization of an animal against *Chlamydia psittaci*. Such vaccines may comprise a pharmaceutically acceptable carrier,
25 and at least one polynucleotide having a *Chlamydia psittaci* sequence. Such vaccines may be further defined as a vaccine for the immunization of a bovine. Such vaccines may comprise at least one polynucleotide that has a sequence isolated from a *Chlamydia psittaci* genomic DNA expression library. In some preferred embodiments, the vaccine comprises at least one polynucleotide having a sequence of SEQ ID NO:6, SEQ ID NO:8,
30 SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID

NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, or SEQ ID NO:60, or fragment thereof. In some specific preferred embodiments, the vaccine comprises at least one polynucleotide having a sequence of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, or SEQ ID NO:26, or fragment thereof, while in some even more specific embodiments, the vaccine comprises at least one polynucleotide having a sequence of SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, SEQ ID NO:20, or SEQ ID NO:24. The polynucleotide may be comprised in a genetic immunization vector. Some vectors useful in the invention comprise a gene encoding a mouse ubiquitin fusion polypeptide and/or a promoter operable in eukaryotic cells, for example a CMV promoter. The polynucleotide may be cloned into a viral expression vector, for example, a viral expression vector selected from the group consisting of adenovirus, adeno-associated virus, retrovirus and herpes-simplex virus.

In some embodiments, the vaccine comprises at least a first polynucleotide having a *Chlamydia psittaci* sequence and a second polynucleotide having a *Chlamydia psittaci* sequence, wherein the first polynucleotide and the second polynucleotide have different *Chlamydia psittaci* sequences. In some preferred embodiments, the first polynucleotide has a sequence of SEQ ID NO:50.

Other embodiments of vaccines for the immunization of an animal against *Chlamydia psittaci* comprise a pharmaceutically acceptable carrier and at least one *Chlamydia psittaci* antigen; and may be further defined as a vaccine for the immunization of a bovine. The at least one *Chlamydia psittaci* antigen can be an antigen having a sequence of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID

NO:55, SEQ ID NO:57, SEQ ID NO:59, or SEQ ID NO:61, or an antigenic fragment thereof. In some specific embodiments, the vaccine comprises at least one *Chlamydia psittaci* antigen having a sequence of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:21, SEQ ID NO:23, SEQ ID
5 NO:25, or SEQ ID NO:27 or an antigenic fragment thereof. In some even more specific embodiments, the at least one *Chlamydia psittaci* antigen has a sequence of SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:21, or SEQ ID NO:25.

The invention contemplates methods of immunizing an animal comprising
10 providing to the bovine at least one *Chlamydia psittaci* antigen, or antigenic fragment thereof, in an amount effective to induce an immune response. The antigens described above are examples of particularly useful antigens in this regard. The provision of at least one *Chlamydia psittaci* antigen may comprise: (a) preparing a cloned expression library from fragmented genomic DNA, cDNA or sequenced genes of *Chlamydia*
15 *psittaci*; (b) administering at least one clone of the library in a pharmaceutically acceptable carrier into the bovine; and (c) expressing at least one *Chlamydia psittaci* antigen in the bovine. The polynucleotide may be administered, for example, by a intramuscular injection or epidermal injection or intravenous, subcutaneous, intralesional, intraperitoneal, oral or inhaled routes of administration. An intramuscular injection may
20 comprise least 1.0 µg to 200 µg of the polynucleotide, whereas an epidermal injection may comprise at least 0.01 µg to 5.0 µg of the polynucleotide. Second intramuscular injection or epidermal injections may be administered, for example, at least about three weeks after the first injection. The polynucleotide may be comprised in a viral expression vector.

25

Alternatively, the provision of the *Chlamydia* antigen(s) may comprise: (a) preparing a pharmaceutical composition comprising at least one polynucleotide having a sequence of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID
30 NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID

NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO: 58, or SEQ ID NO:60, or fragment thereof; (b) administering one or more clones of the library in a pharmaceutically acceptable carrier into the bovine; and (c) expressing one or more *Chlamydia* antigens in the bovine. The antigen may be administered in much the same manner as described for polynucleotides above, and other manners known to those of skill in the art.

In another alternative, the provision of the *Chlamydia* antigen(s) may comprise: (a) preparing a pharmaceutical composition of at least one *Chlamydia* antigen having a sequence of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, or SEQ ID NO:61, or an antigenic fragment thereof; and (b) administering the at least one antigen or fragment into the animal.

This specification discloses methods of obtaining polynucleotide sequences effective for generating an immune response against *Chlamydia psittaci* comprising: (a) preparing a cloned expression library from fragmented genomic DNA of the species *Chlamydia psittaci*; (b) administering one or more clones of the library in a pharmaceutically acceptable carrier into the animal in an amount effective to induce an immune response; and (c) selecting from the library the polynucleotide sequences that induce an immune response, wherein the immune response in the animal is protective against *Chlamydia psittaci* infection. Such methods may further comprise testing the animal for immune resistance against a *Chlamydia psittaci* bacterial infection by challenging the animal with *Chlamydia psittaci*. The genomic DNA is fragmented physically or by restriction enzymes, and in some preferred embodiments, the fragments are about 200-1000 base pairs. In some cases each clone in the library may comprise a gene encoding a mouse ubiquitin fusion polypeptide designed to link the expression library polynucleotides to the ubiquitin gene. In some embodiments, the library is about

1x10³ to about 1x10⁶ clones, with some preferred embodiments using a library having 1x10⁵ clones. In some cases, about 0.01 µg to about 200 µg of DNA, cDNA or sequenced gene from the clones is administered into the animal, for example by intramuscular injection or epidermal injection. In many cases, the cloned expression
5 library further comprises a promoter operably linked to the DNA that permits expression in a vertebrate animal cell.

The invention also relates to methods of assaying for the presence of *Chlamydia psittaci* infection in an animal comprising: (a) obtaining an antibody directed against a
10 *Chlamydia psittaci* antigen; (b) obtaining a sample from the bovine; (c) admixing the antibody with the sample; and (d) assaying the sample for antigen-antibody binding, wherein the antigen-antibody binding indicates *Chlamydia psittaci* infection in the bovine. In some embodiments the animal is a bovine. In many cases, the antibody directed against the antigen is a monoclonal antibody. In some preferred embodiments,
15 assaying the sample for antigen-antibody binding is done by precipitin reaction, radioimmunoassay, ELISA, Western blot or immunofluorescence. The invention also relates to kits for assaying animals such as bovines for a *Chlamydia psittaci* infection comprising, in a suitable container: (a) a pharmaceutically acceptable carrier; and (b) an antibody directed against a *Chlamydia psittaci* antigen. The method also relates to a
20 method of assaying for the presence of a *Chlamydia psittaci* infection in a bovine comprising: (a) obtaining an oligonucleotide probe comprising a sequence comprised within one of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID
25 NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO: 58, or SEQ ID NO:60, or a complement thereof; and (b) employing the probe in a PCR detection protocol. Kits for such protocols are also within the scope of the invention.

30

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the
5 detailed description of specific embodiments presented herein.

FIG. 1. Scheme for Expression Library Immunization.

FIG. 2. Production of the *C. psittaci* Library. The *C. psittaci* library was
10 produced by first physically shearing the genomic DNA, strain BGM/B577, and size selecting fragments of 300-800 base pairs. The fragments were ligated into the *Bgl* II site of pCMVi-Ubs(+P3); see Sykes and Johnston, 1999 for details. The nucleotide sequence shown in this figure is given as SEQ ID NO:1.

FIG. 3. Flowchart depicting the process for deconvolution of the libraries.
15 Each round consists of preparation of DNA samples, vaccination of mice, challenge and determination of the relative protection in each group.

FIG. 4. Results of protection assays in Rounds 1, 2 and 3. Protection was
20 scored as lung weight relative to average of the vaccinated, maximum protection, positive control and the non-vaccinated, challenged, maximum disease, negative control. The relative protection score was calculated by assigning the score 1 to animals with lung weight equal to the vaccinated control and the score 0 to animals with lung weights equal to the challenged, non-vaccinated control. These points define a line; animals with lower
25 lung weight, hence better protection, have a higher relative protection score. Animals that have worse disease than challenged, non-vaccinated controls, i.e. heavier lungs, will have a negative relative protection score. The unchallenged Naïve group consistently had lung weights slightly lower than the maximum protection, positive controls (Vaccinated) due to the peribronchiolar accumulation of lymphatic cells. In Rounds 2 and 3 the pools
30 of plasmids from columns in the two-dimensional arrays are assigned numbers and the

rows assigned letters. The solid bars indicate pools that were designated as protective and entered into the subsequent round. The error bars represent one standard deviation on either side of the mean.

FIG. 5. Results of protection assays of testing individual gene fragments in Round 4. Protection was scored as lung weight relative to the average of the vaccinated, maximum protection, positive control (Vaccinated=1) and the non-vaccinated, challenged, maximum disease, negative control (Challenged=0). The Pool<50AA is the DNA consisting of the pool of the 32 plasmids from Round 3 having predicted open-reading frames less than 50 amino acids long. Pool>50AA is the DNA consisting of all the 14 plasmids containing *C. psittaci* inserts encoding in-frame proteins more than 50 amino acids long. The numbers of each individual gene fragment tested correspond to the numbers in FIG. 4. The error bars represent one standard deviation of the mean.

FIG. 6. Summary of characterization of the single gene fragments of Round 4. The Relative Protection score of each *C. psittaci* (CP) gene fragment is provided along with the designation of the gene in *C. pneumonia* that has the highest similarity (*C. pneumonia* homolog). In two cases, gene fragment CP #4 and CP #12, the *C. psittaci* gene could also be identified. On the right is a linear map showing the location in each gene of the fragment that conferred protection (shaded).

FIG. 7. Protection data from DNA pools. CP1-6 is a negative pool from round 1. To test whether a single protective gene could be detected in a negative pool, 25 ng of either CP4 #4 or CP4 #11 was added to 50 µg of CP1-6.

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

The present invention provides compositions and methods for the immunization of vertebrate animals, including humans, against infections using nucleic acid sequences and polypeptides elucidated by screening *Chlamydia psittaci*. These compositions and methods will be useful for immunization against *Chlamydia psittaci* bacterial infections

and other infections and disease states.. In particular embodiments, a vaccine composition directed against *Chlamydia psittaci* infections is provided. The vaccine according to the present invention comprises *Chlamydia psittaci* genes and polynucleotides identified by the inventors, that confer protective resistance in vertebrate animals to *Chlamydia psittaci* bacterial infections, and other infections. In other embodiments, the invention provides methods for immunizing an animal against *Chlamydia psittaci* infections, methods for preparing a cloned library via expression library immunization and methods for screening and identifying *Chlamydia psittaci* genes that confer protection against infection.

A. Expression Library Immunization

In particular embodiments, the immunization of vertebrate animals according to the present invention includes a cloned library of *Chlamydia psittaci* expression constructs. In specific embodiments, a cloned expression library of *Chlamydia psittaci* is provided. Expression library immunization, ELI herein, is well known in the art (U. S. Patent 5,703,057, specifically incorporated herein by reference). In certain embodiments, the invention provides an ELI method applicable to virtually any pathogen and requires no knowledge of the biological properties of the pathogen. The method operates on the assumption, generally accepted by those skilled in the art, that all the potential antigenic determinants of any pathogen are encoded in its genome. The inventors have previously devised methods of identifying vaccines using a genomic expression library representing all of the antigenic determinants of a pathogen (U. S. Patent 5,703,057). The method uses to its advantage the simplicity of genetic immunization to sort through a genome for immunological reagents in an unbiased, systematic fashion.

The preparation of an expression library is performed using the techniques and methods familiar one of skill in the art. The pathogen's genome, may or may not be known or possibly may even have been cloned. Thus one obtains DNA (or cDNA), representing substantially the entire genome of the pathogen (*e.g.*, *Chlamydia psittaci*). The DNA is broken up, by physical fragmentation or restriction endonuclease, into segments of some length so as to provide a library of about 10^5 (approximately 18x the

genome size) members. The library is then tested by inoculating a subject with purified DNA of the library or sub-library and the subject challenged with a pathogen, wherein immune protection of the subject from pathogen challenge indicates a clone that confers a protective immune response against infection.

5

B. Nucleic Acids

The present invention provides *Chlamydia psittaci* polynucleotide compositions and methods that induce a protective immune response in vertebrate animals challenged with a *Chlamydia psittaci* bacterial infection. The preparation and purification of antigenic *Chlamydia psittaci* polypeptides, or fragments thereof (Section C) and antibody preparations directed against *Chlamydia psittaci* antigens, or fragments thereof (Section E) are described below.

Thus, in certain embodiments of the present invention, genes or polynucleotides encoding *Chlamydia psittaci* polypeptides or fragments thereof are provided. It is contemplated in other embodiments, that a polynucleotide encoding a *Chlamydia psittaci* polypeptide or polypeptide fragment will be expressed in prokaryotic or eukaryotic cells and the polypeptides purified for use as anti-*Chlamydia psittaci* antigens in the vaccination of vertebrate animals or in generating antibodies immunoreactive with *Chlamydia psittaci* polypeptides (*i.e.*, antigens). The genomes of *C. pneumoniae* and *C. trachomatis* have been completely sequenced. The *Chlamydia* genes are quite similar, with the four most protective genes identified being 30-71% identical and 45-85% similar in amino acid sequence.

1. Nucleic Acids Encoding *Chlamydia psittaci* Polypeptides

The present invention provides polynucleotides encoding antigenic *Chlamydia psittaci* polypeptides capable of inducing a protective immune response in vertebrate animals and for use as an antigen to generate anti-*Chlamydia psittaci* or other pathogen antibodies. In certain instances, it may be desirable to express *Chlamydia psittaci* polynucleotides encoding a particular antigenic *Chlamydia psittaci* polypeptide domain or sequence to be used as a vaccine or in generating anti-*Chlamydia psittaci* or other pathogen antibodies. Nucleic acids according to the present invention may encode an entire

Chlamydia psittaci gene, or any other fragment of the *Chlamydia psittaci* sequences set forth herein. The nucleic acid may be derived from genomic DNA, *i.e.*, cloned directly from the genome of a particular organism. In other embodiments, however, the nucleic acid may comprise complementary DNA (cDNA). A protein may be derived from the
5 designated sequences for use in a vaccine or to isolate useful antibodies.

The term "cDNA" is intended to refer to DNA prepared using messenger RNA (mRNA) as template. The advantage of using a cDNA, as opposed to genomic DNA or DNA polymerized from a genomic, non- or partially-processed RNA template, is that the
10 cDNA primarily contains coding sequences of the corresponding protein. There may be times when the full or partial genomic sequence is preferred, such as where the non-coding regions are required for optimal expression.

It also is contemplated that a given *Chlamydia psittaci* polynucleotide may be
15 represented by natural variants that have slightly different nucleic acid sequences but, nonetheless, encode the same polypeptide (see Table 2 below). In addition, it is contemplated that a given *Chlamydia psittaci* polypeptide may be generated using alternate codons that result in a different nucleic acid sequence but encodes the same polypeptide.

As used in this application, the term "a nucleic acid encoding a *Chlamydia psittaci*
20 polynucleotide" refers to a nucleic acid molecule that has been isolated free of total cellular nucleic acid. The term "functionally equivalent codon" is used herein to refer to codons that encode the same amino acid, such as the six codons for arginine or serine (Table 2, below), and also refers to codons that encode biologically equivalent amino acids, as discussed in
25 the following pages.

TABLE 1

| Amino Acids | | | Codons | | | | | |
|---------------|-----|---|--------|-----|-----|-----|-----|-----|
| Alanine | Ala | A | GCA | GCC | GCG | GCU | | |
| Cysteine | Cys | C | UGC | UGU | | | | |
| Aspartic acid | Asp | D | GAC | GAU | | | | |
| Glutamic acid | Glu | E | GAA | GAG | | | | |
| Phenylalanine | Phe | F | UUC | UUU | | | | |
| Glycine | Gly | G | GGA | GGC | GGG | GGU | | |
| Histidine | His | H | CAC | CAU | | | | |
| Isoleucine | Ile | I | AUA | AUC | AUU | | | |
| Lysine | Lys | K | AAA | AAG | | | | |
| Leucine | Leu | L | UUA | UUG | CUA | CUC | CUG | CUU |
| Methionine | Met | M | AUG | | | | | |
| Asparagine | Asn | N | AAC | AAU | | | | |
| Proline | Pro | P | CCA | CCC | CCG | CCU | | |
| Glutamine | Gln | Q | CAA | CAG | | | | |
| Arginine | Arg | R | AGA | AGG | CGA | CGC | CGG | CGU |
| Serine | Ser | S | AGC | AGU | UCA | UCC | UCG | UCU |
| Threonine | Thr | T | ACA | ACC | ACG | ACU | | |
| Valine | Val | V | GUA | GUC | GUG | GUU | | |
| Tryptophan | Trp | W | UGG | | | | | |
| Tyrosine | Tyr | Y | UAC | UAU | | | | |

5 Allowing for the degeneracy of the genetic code, sequences that have at least about 50%, usually at least about 60%, more usually about 70%, most usually about 80%, preferably at least about 90% and most preferably about 95% of nucleotides that are identical to the nucleotides of given *Chlamydia psittaci* gene or polynucleotide. Sequences that are essentially the same as those set forth in a *Chlamydia psittaci* gene or polynucleotide may also be functionally defined as sequences that are capable of

hybridizing to a nucleic acid segment containing the complement of a *Chlamydia psittaci* polynucleotide under standard conditions.

The DNA segments of the present invention include those encoding functional and/or immunologically equivalent *Chlamydia psittaci* proteins and peptides, as described above. Such sequences may arise as a consequence of codon redundancy and amino acid functional equivalency that are known to occur naturally within nucleic acid sequences and the proteins thus encoded. Alternatively, functionally and/or immunogenically equivalent proteins or peptides may be created via the application of recombinant DNA technology, in which changes in the protein structure may be engineered, based on considerations of the properties of the amino acids being exchanged. Changes designed by man may be introduced through the application of site-directed mutagenesis techniques or may be introduced randomly and screened later for the desired function, as described below.

2. Oligonucleotide Sequences

Naturally, the present invention also encompasses DNA segments that are complementary, or essentially complementary to the sequences of a *Chlamydia psittaci* polynucleotide. Nucleic acid sequences that are "complementary" are those that are capable of base-pairing according to the standard Watson-Crick complementary rules. As used herein, the term "complementary sequences" means nucleic acid sequences that are substantially complementary, as may be assessed by the same nucleotide comparison set forth above, or as defined as being capable of hybridizing to the nucleic acid segment of a *Chlamydia psittaci* polynucleotide under relatively stringent conditions such as those described herein. Such sequences may encode the entire *Chlamydia psittaci* polypeptide or functional or non-functional fragments thereof.

Alternatively, the hybridizing segments may be shorter oligonucleotides. Sequences of 17 bases long should occur only once in the human genome and, therefore, suffice to specify a unique target sequence. Although shorter oligomers are easier to make and increase *in vivo* accessibility, numerous other factors are involved in determining the specificity of hybridization. Both binding affinity and sequence specificity of an

oligonucleotide to its complementary target increases with increasing length. It is contemplated that exemplary oligonucleotides of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more base pairs will be used, although others are contemplated. Longer polynucleotides encoding 250, 500, 1000, 1212, 1500, 2000, 2500, 3000 or 3500 bases and longer are contemplated as well. Such oligonucleotides will find use, for example, as probes in Southern and Northern blots and as primers in amplification reactions, or for vaccines..

Suitable hybridization conditions will be well known to those of skill in the art. In certain applications, for example, substitution of amino acids by site-directed mutagenesis, it is appreciated that lower stringency conditions are required. Under these conditions, hybridization may occur even though the sequences of probe and target strand are not perfectly complementary, but are mismatched at one or more positions. Conditions may be rendered less stringent by increasing salt concentration and decreasing temperature. For example, a medium stringency condition could be provided by about 0.1 to 0.25 M NaCl at temperatures of about 37°C to about 55°C, while a low stringency condition could be provided by about 0.15 M to about 0.9 M salt, at temperatures ranging from about 20°C to about 55°C. Thus, hybridization conditions can be readily manipulated, and thus will generally be a method of choice depending on the desired results.

20

In other embodiments, hybridization may be achieved under conditions of, for example, 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl₂, 10 mM dithiothreitol, at temperatures between approximately 20°C to about 37°C. Other hybridization conditions utilized could include approximately 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl₂, at temperatures ranging from approximately 40°C to about 72°C. Formamide and SDS also may be used to alter the hybridization conditions.

25

One method of using probes and primers of the present invention is in the search for genes related to *Chlamydia psittaci* or, more particularly, homologs of *Chlamydia psittaci* from other species. Normally, the target DNA will be a genomic or cDNA library, although screening may involve analysis of RNA molecules. By varying the stringency of

30

hybridization, and the region of the probe, different degrees of homology may be discovered.

Another way of exploiting probes and primers of the present invention is in site-directed, or site-specific mutagenesis. Site-specific mutagenesis is a technique useful in the preparation of individual peptides, or biologically functional equivalent proteins or peptides, through specific mutagenesis of the underlying DNA. The technique further provides a ready ability to prepare and test sequence variants, incorporating one or more of the foregoing considerations, by introducing one or more nucleotide sequence changes into the DNA. Site-specific mutagenesis allows the production of mutants through the use of specific oligonucleotide sequences which encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed. Typically, a primer of about 17 to 25 nucleotides in length is preferred, with about 5 to 10 residues on both sides of the junction of the sequence being altered.

The technique typically employs a bacteriophage vector that exists in both a single stranded and double stranded form. Typical vectors useful in site-directed mutagenesis include vectors such as the M13 phage. These phage vectors are commercially available and their use is generally well known to those skilled in the art. Double stranded plasmids are also routinely employed in site directed mutagenesis, which eliminates the step of transferring the gene of interest from a phage to a plasmid.

In general, site-directed mutagenesis is performed by first obtaining a single-stranded vector, or melting of two strands of a double stranded vector which includes within its sequence a DNA sequence encoding the desired protein. An oligonucleotide primer bearing the desired mutated sequence is synthetically prepared. This primer is then annealed with the single-stranded DNA preparation, taking into account the degree of mismatch when selecting hybridization conditions, and subjected to DNA polymerizing enzymes such as *E. coli* polymerase I Klenow fragment, in order to

complete the synthesis of the mutation-bearing strand. Thus, a heteroduplex is formed wherein one strand encodes the original non-mutated sequence and the second strand bears the desired mutation. This heteroduplex vector is then used to transform appropriate cells, such as *E. coli* cells, and clones are selected that include recombinant vectors
5 bearing the mutated sequence arrangement.

The preparation of sequence variants of the selected gene using site-directed mutagenesis is provided as a means of producing potentially useful species and is not meant to be limiting, as there are other ways in which sequence variants of genes may be
10 obtained. For example, recombinant vectors encoding the desired gene may be treated with mutagenic agents, such as hydroxylamine, to obtain sequence variants.

C. Polypeptides and Antigens

For the purposes of the present invention a *Chlamydia psittaci* polypeptide used as
15 an antigen may be a naturally-occurring *Chlamydia psittaci* polypeptide that has been extracted using protein extraction techniques well known to those of skill in the art. In particular embodiments, a *Chlamydia psittaci* antigen is identified by ELI and prepared in a pharmaceutically acceptable carrier for the vaccination of an animal against *Chlamydia psittaci* infection.

20

In alternative embodiments, the *Chlamydia psittaci* polypeptide or antigen may be a synthetic peptide. In still other embodiments, the peptide may be a recombinant peptide produced through molecular engineering techniques. The present section describes the methods and compositions involved in producing a composition of *Chlamydia psittaci*
25 polypeptides for use as antigens in the present invention.

1. *Chlamydia psittaci* Polypeptides as Antigens

Section A describes methods for preparing a cloned *Chlamydia psittaci* library for ELI. Described also are methods for screening and identifying *Chlamydia psittaci* genes
30 that confer protection against *Chlamydia psittaci* infection. Thus, *Chlamydia psittaci* polypeptide encoding genes or their corresponding cDNA identified in the present invention

can be inserted into an appropriate cloning vehicle for the production of *Chlamydia psittaci* polypeptides as antigens for the present invention. In addition, sequence variants of the polypeptide can be prepared. These may, for instance, be minor sequence variants of the polypeptide that arise due to natural variation within the population or they may be
5 homologues found in other species. They also may be sequences that do not occur naturally, but that are sufficiently similar that they function similarly and/or elicit an immune response that cross-reacts with natural forms of the polypeptide. Sequence variants can be prepared by standard methods of site-directed mutagenesis such as those described below in the following section.

10 Another synthetic or recombinant variation of a *Chlamydia psittaci*-antigen is a polyepitopic moiety comprising repeats of epitopic determinants found naturally on *Chlamydia psittaci* proteins. Such synthetic polyepitopic proteins can be made up of several homomeric repeats of any one *Chlamydia psittaci* protein epitope; or can comprise
15 of two or more heteromeric epitopes expressed on one or several *Chlamydia psittaci* protein epitopes.

Amino acid sequence variants of the polypeptide can be substitutional, insertional or deletion variants. Deletion variants lack one or more residues of the native protein which
20 are not essential for function or immunogenic activity, and are exemplified by the variants lacking a transmembrane sequence described above. Another common type of deletion variant is one lacking secretory signal sequences or signal sequences directing a protein to bind to a particular part of a cell.

25 Substitutional variants typically contain the exchange of one amino acid for another at one or more sites within the protein, and may be designed to modulate one or more properties of the polypeptide such as stability against proteolytic cleavage. Substitutions preferably are conservative, that is, one amino acid is replaced with one of similar shape and charge. Conservative substitutions are well known in the art and include, for example, the
30 changes of: alanine to serine; arginine to lysine; asparagine to glutamine or histidine; aspartate to glutamate; cysteine to serine; glutamine to asparagine; glutamate to aspartate;

glycine to proline; histidine to asparagine or glutamine; isoleucine to leucine or valine; leucine to valine or isoleucine; lysine to arginine; methionine to leucine or isoleucine; phenylalanine to tyrosine, leucine or methionine; serine to threonine; threonine to serine; tryptophan to tyrosine; tyrosine to tryptophan or phenylalanine; and valine to isoleucine or
5 leucine.

Insertional variants include fusion proteins such as those used to allow rapid purification of the polypeptide and also can include hybrid proteins containing sequences from other proteins and polypeptides which are homologues of the polypeptide. For
10 example, an insertional variant could include portions of the amino acid sequence of the polypeptide from one species, together with portions of the homologous polypeptide from another species. Other insertional variants can include those in which additional amino acids are introduced within the coding sequence of the polypeptide. These typically are smaller insertions than the fusion proteins described above and are introduced, for example,
15 into a protease cleavage site.

In one embodiment, major antigenic determinants of the polypeptide may be identified by an empirical approach in which portions of the gene encoding the polypeptide are expressed in a recombinant host, and the resulting proteins tested for their ability to elicit
20 an immune response. For example, the polymerase chain reaction (PCR) can be used to prepare a range of cDNAs encoding peptides lacking successively longer fragments of the C-terminus of the protein. The immunogenic activity of each of these peptides then identifies those fragments or domains of the polypeptide that are essential for this activity. Further experiments in which only a small number of amino acids are removed or added at
25 each iteration then allows the location of other antigenic determinants of the polypeptide. Thus, the polymerase chain reaction, a technique for amplifying a specific segment of DNA via multiple cycles of denaturation-renaturation, using a thermostable DNA polymerase, deoxyribonucleotides and primer sequences is contemplated in the present invention (Mullis, 1990; Mullis *et al.*, 1992).

Another embodiment for the preparation of the polypeptides according to the invention is the use of peptide mimetics. Mimetics are peptide-containing molecules that mimic elements of protein secondary structure. Because many proteins exert their biological activity *via* relatively small regions of their folded surfaces, their actions can be reproduced by much smaller designer (mimetic) molecules that retain the bioactive surfaces and have potentially improved pharmacokinetic/dynamic properties (Fairlie *et al.*, 1998).

The underlying rationale behind the use of peptide mimetics is that the peptide backbone of proteins exists chiefly to orient amino acid side chains in such a way as to facilitate molecular interactions, such as those of antibody and antigen. However, unlike proteins, peptides often lack well defined three dimensional structure in aqueous solution and tend to be conformationally mobile. Progress has been made with the use of molecular constraints to stabilize the bioactive conformations. By affixing or incorporating templates that fix secondary and tertiary structures of small peptides, synthetic molecules (protein surface mimetics) can be devised to mimic the localized elements of protein structure that constitute bioactive surfaces. Methods for mimicking individual elements of secondary structure (helices, turns, strands, sheets) and for assembling their combinations into tertiary structures (helix bundles, multiple loops, helix-loop-helix motifs) have been reviewed (Fairlie *et al.*, 1998; Moore, 1994).

Methods for predicting, preparing, modifying, and screening mimetic peptides are described in U.S. Patent 5,933,819 and U.S. Patent 5,869,451 (each specifically incorporated herein by reference). It is contemplated in the present invention, that peptide mimetics will be useful in screening modulators of an immune response.

Modifications and changes may be made in the structure of a gene and still obtain a functional molecule that encodes a protein or polypeptide with desirable characteristics. The following is a discussion based upon changing the amino acids of a protein to create an equivalent, or even an improved, second-generation molecule. The amino acid changes may be achieved by changing the codons of the DNA sequence, according to the following data.

For example, certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of interactive binding capacity with structures such as, for example, antigen-binding regions of antibodies or binding sites on substrate molecules. Since it is the interactive capacity and nature of a protein that defines that protein's biological functional activity, certain amino acid substitutions can be made in a protein sequence, and its underlying DNA coding sequence, and nevertheless obtain a protein with like properties. It is thus contemplated by the inventor that various changes may be made in the DNA sequences of genes without appreciable loss of their biological utility or activity. Table 1 shows the codons that encode particular amino acids.

In making such changes, the hydropathic index of amino acids may be considered. The importance of the hydropathic amino acid index in conferring interactive biologic function on a protein is generally understood in the art (Kyte & Doolittle, 1982).

It is accepted that the relative hydropathic character of the amino acid contributes to the secondary structure of the resultant protein, which in turn defines the interaction of the protein with other molecules, for example, enzymes, substrates, receptors, DNA, antibodies, antigens, and the like.

Each amino acid has been assigned a hydropathic index on the basis of their hydrophobicity and charge characteristics (Kyte & Doolittle, 1982), these are: Isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

It is known in the art that certain amino acids may be substituted by other amino acids having a similar hydropathic index or score and still result in a protein with similar biological activity, *i.e.*, still obtain a biological functionally equivalent protein. In making such changes, the substitution of amino acids whose hydropathic indices are within ± 2 is

preferred, those which are within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.

5 It also is understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U.S. Patent 4,554,101, incorporated herein by reference, states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with a biological property of the protein.

10 As detailed in U.S. Patent 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0 \pm 1); glutamate (+3.0 \pm 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5 \pm 1); alanine (-0.5); histidine *-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3);
15 phenylalanine (-2.5); tryptophan (-3.4).

It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent and immunologically equivalent protein. In such changes, the substitution of amino acids whose hydrophilicity
20 values are within ± 2 is preferred, those that are within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.

As outlined above, amino acid substitutions generally are based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity,
25 hydrophilicity, charge, size, and the like. Exemplary substitutions that take various of the foregoing characteristics into consideration are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.

2. Synthetic Polypeptides

Contemplated in the present invention are *Chlamydia psittaci* proteins and related peptides for use as antigens. In certain embodiments, the synthesis of a *Chlamydia psittaci* peptide fragment is considered. The peptides of the invention can be synthesized
5 in solution or on a solid support in accordance with conventional techniques. Various automatic synthesizers are commercially available and can be used in accordance with known protocols. See, for example, Stewart and Young, (1984); Tam *et al.*, (1983); Merrifield, (1986); and Barany and Merrifield (1979), each incorporated herein by reference. Alternatively, recombinant DNA technology may be employed wherein a
10 nucleotide sequence which encodes a peptide of the invention is inserted into an expression vector, transformed or transfected into an appropriate host cell and cultivated under conditions suitable for expression.

3. *Chlamydia psittaci* Polypeptide/Antigen Purification

Chlamydia psittaci polypeptides of the present invention are used as antigens for
15 inducing a protective immune response in an animal and for the preparation of anti-*Chlamydia psittaci* antibodies. Thus, certain aspects of the present invention concern the purification, and in particular embodiments, the substantial purification, of a *Chlamydia psittaci* polypeptide that is described herein above. The term “purified protein or peptide
20 “ as used herein, is intended to refer to a composition, isolatable from other components, wherein the protein or peptide is purified to any degree relative to its naturally-obtainable state. A purified protein or peptide therefore also refers to a protein or peptide, free from the environment in which it may naturally occur.

Generally, “purified” will refer to a protein or peptide composition that has been
25 subjected to fractionation to remove various other components, and which composition substantially retains its expressed biological activity. Where the term “substantially purified” is used, this designation will refer to a composition in which the protein or peptide forms the major component of the composition, such as constituting about 50%
30 or more of the proteins in the composition.

Various methods for quantifying the degree of purification of the protein or peptide will be known to those of skill in the art in light of the present disclosure. These include, for example, determining the specific activity of an active fraction, or assessing the number of polypeptides within a fraction by SDS/PAGE analysis. A preferred method for assessing the purity of a fraction is to calculate the specific activity of the fraction, to compare it to the specific activity of the initial extract, and to thus calculate the degree of purity, herein assessed by a “-fold purification number.” The actual units used to represent the amount of activity will, of course, be dependent upon the particular assay technique chosen to follow the purification and whether or not the expressed protein or peptide exhibits a detectable activity.

Various techniques suitable for use in protein purification will be well known to those of skill in the art. These include, for example, precipitation with ammonium sulphate, PEG, antibodies and the like or by heat denaturation, followed by centrifugation; chromatography steps such as ion exchange, gel filtration, reverse phase, hydroxylapatite and affinity chromatography; isoelectric focusing; gel electrophoresis; and combinations of such and other techniques. As is generally known in the art, it is believed that the order of conducting the various purification steps may be changed, or that certain steps may be omitted, and still result in a suitable method for the preparation of a substantially purified protein or peptide.

There is no general requirement that the protein or peptide always be provided in their most purified state. Indeed, it is contemplated that less substantially purified products will have utility in certain embodiments. Partial purification may be accomplished by using fewer purification steps in combination, or by utilizing different forms of the same general purification scheme. For example, it is appreciated that a cation-exchange column chromatography performed utilizing an HPLC apparatus will generally result in a greater-fold purification than the same technique utilizing a low pressure chromatography system. Methods exhibiting a lower degree of relative purification may have advantages in total recovery of protein product, or in maintaining the activity of an expressed protein.

It is known that the migration of a polypeptide can vary, sometimes significantly, with different conditions of SDS/PAGE (Capaldi *et al.*, 1977). It will therefore be appreciated that under differing electrophoresis conditions, the apparent molecular weights of purified or partially purified expression products may vary.

High Performance Liquid Chromatography (HPLC) is characterized by a very rapid separation with extraordinary resolution of peaks. This is achieved by the use of very fine particles and high pressure to maintain an adequate flow rate. Separation can be accomplished in a matter of minutes, or at most an hour. Moreover, only a very small volume of the sample is needed because the particles are so small and close-packed that the void volume is a very small fraction of the bed volume. Also, the concentration of the sample need not be very great because the bands are so narrow that there is very little dilution of the sample.

Gel chromatography, or molecular sieve chromatography, is a special type of partition chromatography that is based on molecular size. The theory behind gel chromatography is that the column, which is prepared with tiny particles of an inert substance that contain small pores, separates larger molecules from smaller molecules as they pass through or around the pores, depending on their size. As long as the material of which the particles are made does not adsorb the molecules, the sole factor determining rate of flow is the size. Hence, molecules are eluted from the column in decreasing size, so long as the shape is relatively constant. Gel chromatography is unsurpassed for separating molecules of different size because separation is independent of all other factors such as pH, ionic strength, temperature, *etc.* There also is virtually no adsorption, less zone spreading and the elution volume is related in a simple manner to molecular weight.

Affinity Chromatography is a chromatographic procedure that relies on the specific affinity between a substance to be isolated and a molecule that it can specifically bind to. This is a receptor-ligand type interaction. The column material is synthesized by

covalently coupling one of the binding partners to an insoluble matrix. The column material is then able to specifically adsorb the substance from the solution. Elution occurs by changing the conditions to those in which binding will not occur (alter pH, ionic strength, temperature, *etc.*).

5

D. Gene Delivery

In certain embodiments of the invention, an expression construct comprising a *Chlamydia psittaci* gene or polynucleotide segment under the control of a heterologous promoter operable in eukaryotic cells is provided. The general approach in certain aspects of the present invention is to provide a cell with an expression construct encoding a specific *Chlamydia psittaci* protein, polypeptide or peptide fragment, thereby permitting the antigenic expression of the protein, polypeptide or peptide fragment to take effect in the cell. Following delivery of the expression construct, the protein, polypeptide or peptide fragment encoded by the expression construct is synthesized by the transcriptional and translational machinery of the cell, as well as any that may be provided by the expression construct.

Viral and non-viral vector systems are the two predominate categories for the delivery of an expression construct encoding a therapeutic protein, polypeptide, polypeptide fragment. Both vector systems are described in the following sections. There also are two primary approaches utilized in the delivery of an expression construct for the purposes of gene therapy; either indirect, *ex vivo* methods or direct, *in vivo* methods. *Ex vivo* gene transfer comprises vector modification of (host) cells in culture and the administration or transplantation of the vector modified cells to a gene therapy recipient. *In vivo* gene transfer comprises direct introduction of the vector (*e.g.*, injection, inhalation) into the target source or therapeutic gene recipient.

In certain embodiments of the invention, the nucleic acid encoding the gene or polynucleotide may be stably integrated into the genome of the cell. In yet further embodiments, the nucleic acid may be stably or transiently maintained in the cell as a separate, episomal segment of DNA. Such nucleic acid segments or “episomes” encode sequences sufficient to permit maintenance and replication independent of or in

30

synchronization with the host cell cycle. How the expression construct is delivered to a cell and/or where in the cell the nucleic acid remains is dependent on the type of vector employed. The following gene delivery methods provide the framework for choosing and developing the most appropriate gene delivery system for a preferred application.

5

1. Non-Viral Polynucleotide Delivery

In one embodiment of the invention, a polynucleotide expression construct consists of naked recombinant DNA or plasmids. In preferred embodiments of the invention, a *Chlamydia psittaci* polynucleotide is administered to a subject via injection and/or particle bombardment (e.g., a gene gun). Thus, in one preferred embodiment, polynucleotide expression constructs are transferred into cells by accelerating DNA-coated microprojectiles to a high velocity, allowing the DNA-coated microprojectiles to pierce cell membranes and enter cells. In another preferred embodiment, polynucleotides are administered to a subject by injection. Injection of a polynucleotide expression construct may be given by intramuscular, intravenous, subcutaneous, or intraperitoneal injection, as long as the polynucleotide expression construct can effectively be delivered to a desired target.

10

15

a. Particle Bombardment

20

25

Particle Bombardment depends on the ability to accelerate DNA-coated microprojectiles to a high velocity allowing them to pierce cell membranes and enter cells without killing them (Klein *et al.*, 1987). Several devices for accelerating small particles have been developed. The most commonly used forms rely on high-pressure helium gas (Sanford *et al.*, 1991), of which one of the present inventors is a co-inventor. The microprojectiles used have consisted of biologically inert substances such as tungsten or gold beads.

30

For microprojectile bombardment transformation using the constructs of the instant invention, both physical and biological parameters may be optimized. Physical factors are those that involve manipulating the DNA/microprojectile precipitate or those that affect the flight and velocity of either the macro- or microprojectiles. Biological

factors include all steps involved in manipulation of cells before and immediately after bombardment, such as the osmotic adjustment of target cells to help alleviate the trauma associated with bombardment, the orientation of an immature embryo or other target tissue relative to the particle trajectory, and also the nature of the transforming DNA, such as linearized DNA or intact supercoiled plasmids.

Accordingly, it is contemplated that one may wish to adjust various bombardment parameters in small scale studies to fully optimize the conditions. One may particularly wish to adjust physical parameters such as DNA concentration, gap distance, flight distance, tissue distance, and helium pressure. It is further contemplated that the grade of helium may effect transformation efficiency. One also may optimize the trauma reduction factors (TRFs) by modifying conditions which influence the physiological state of the recipient cells and which may therefore influence transformation and integration efficiencies. For example, the osmotic state, tissue hydration and the subculture stage or cell cycle of the recipient cells may be adjusted for optimum transformation.

Other physical factors include those that involve manipulating the DNA/microprojectile precipitate or those that affect the flight and velocity of either the macro- or microprojectiles. Biological factors include all steps involved in manipulation of cells immediately before and after bombardment. The pre-bombardment culturing conditions, such as osmotic environment, the bombardment parameters, and the plasmid configuration have been adjusted to yield the maximum numbers of stable transformants.

For microprojectile bombardment, one will attach (*i.e.*, "coat") DNA to the microprojectiles such that it is delivered to recipient cells in a form suitable for transformation thereof. In this respect, at least some of the transforming DNA must be available to the target cell for transformation to occur, while at the same time during delivery the DNA must be attached to the microprojectile. Therefore, availability of the transforming DNA from the microprojectile may comprise the physical reversal of interactions between transforming DNA and the microprojectile following delivery of the microprojectile to the target cell. This need not be the case, however, as availability to a

target cell may occur as a result of breakage of unbound segments of DNA or of other molecules which comprise the physical attachment to the microprojectile. Availability may further occur as a result of breakage of bonds between the transforming DNA and other molecules, which are either directly or indirectly attached to the microprojectile. It is further contemplated that transformation of a target cell may occur by way of direct illegitimate or homology-dependent recombination between the transforming DNA and the genomic DNA of the recipient cell. Therefore, as used herein, a "coated" microprojectile will be one which is capable of being used to transform a target cell, in that the transforming DNA will be delivered to the target cell, yet will be accessible to the target cell such that transformation may occur.

Any technique for coating microprojectiles which allows for delivery of transforming DNA to the target cells may be used. Methods for coating microprojectiles which have been demonstrated to work well with the current invention have been specifically disclosed herein. DNA may be bound to microprojectile particles using alternative techniques, however. For example, particles may be coated with streptavidin and DNA end labeled with long chain thiol cleavable biotinylated nucleotide chains. The DNA adheres to the particles due to the streptavidin-biotin interaction, but is released in the cell by reduction of the thiol linkage through reducing agents present in the cell.

Alternatively, particles may be prepared by functionalizing the surface of a gold oxide particle, providing free amine groups. DNA, having a strong negative charge, binds to the functionalized particles. Furthermore, charged particles may be deposited in controlled arrays on the surface of mylar flyer disks used in the PDS-1000 Biolistics device, thereby facilitating controlled distribution of particles delivered to target tissue.

b. Other Non-Viral Methods of Polynucleotide Delivery

Transfer of a cloned expression construct in the present invention also may be performed by any of the methods which physically or chemically permeabilize the cell membrane (e.g., calcium phosphate precipitation, DEAE-dextran, electroporation, direct microinjection, DNA-loaded liposomes and lipofectamine-DNA complexes, cell

sonication, gene bombardment using high velocity microprojectiles and receptor-mediated transfection.

5 In certain embodiments, the use of lipid formulations and/or nanocapsules is contemplated for the introduction of a *Chlamydia psittaci* polynucleotide or polypeptide, or a gene therapy vector into host cells.

10 Nanocapsules can generally entrap compounds in a stable and/or reproducible way. To avoid side effects due to intracellular polymeric overloading, such ultrafine particles (sized around 0.1 μm) should be designed using polymers able to be degraded *in vivo*. Biodegradable polyalkyl-cyanoacrylate nanoparticles that meet these requirements are contemplated for use in the present invention, and/or such particles may be easily made.

15 In a preferred embodiment of the invention, the polynucleotide or polypeptide may be associated with a lipid. The polynucleotide or polypeptide associated with a lipid may be encapsulated in the aqueous interior of a liposome, interspersed within the lipid bilayer of a liposome, attached to a liposome via a linking molecule that is associated with both the liposome and the oligonucleotide, entrapped in a liposome, complexed with
20 a liposome, dispersed in a solution containing a lipid, mixed with a lipid, combined with a lipid, contained as a suspension in a lipid, contained or complexed with a micelle, or otherwise associated with a lipid. The lipid or lipid/ polynucleotide or polypeptide associated compositions of the present invention are not limited to any particular structure in solution. For example, they may be present in a bilayer structure, as micelles,
25 or with a "collapsed" structure. They may also simply be interspersed in a solution, possibly forming aggregates which are not uniform in either size or shape.

Lipids suitable for use according to the present invention can be obtained from commercial sources. For example, dimyristyl phosphatidylcholine ("DMPC") can be
30 obtained from Sigma Chemical Co., dicetyl phosphate ("DCP") is obtained from K & K

Laboratories (Plainview, NY); cholesterol ("Chol") is obtained from Calbiochem-Behring; dimyristyl phosphatidylglycerol ("DMPG") and other lipids may be obtained from Avanti Polar Lipids, Inc. (Birmingham, Ala.). Stock solutions of lipids in chloroform or chloroform/methanol can be stored at about -20°C. Preferably, chloroform
5 is used as the only solvent since it is more readily evaporated than methanol.

"Liposome" is a generic term encompassing a variety of single and multilamellar lipid vehicles formed by the generation of enclosed lipid bilayers or aggregates. Liposomes may be characterized as having vesicular structures with a phospholipid
10 bilayer membrane and an inner aqueous medium. Multilamellar liposomes have multiple lipid layers separated by aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers (Ghosh and Bachhawat, 1991).
15 However, the present invention also encompasses compositions that have different structures in solution than the normal vesicular structure. For example, the lipids may assume a micellar structure or merely exist as non-uniform aggregates of lipid molecules. Also contemplated are lipofectamine-nucleic acid complexes.

20 Liposomes within the scope of the present invention can be prepared in accordance with known laboratory procedures, for example: the method of Bangham *et al.* (1965), the contents of which are incorporated herein by reference; the method of Gregoriadis, as described in *DRUG CARRIERS IN BIOLOGY AND MEDICINE*, G. Gregoriadis ed. (1979) pp. 287-341, the contents of which are incorporated herein by
25 reference; the method of Deamer and Uster (1983), the contents of which are incorporated by reference; and the reverse-phase evaporation method as described by Szoka and Papahadjopoulos (1978).

Other vector delivery systems which can be employed to deliver a nucleic acid
30 encoding a therapeutic gene into cells are receptor-mediated delivery vehicles. These

take advantage of the selective uptake of macromolecules by receptor-mediated endocytosis in almost all eukaryotic cells. Because of the cell type-specific distribution of various receptors, the delivery can be highly specific (Wu and Wu, 1993).

5 Receptor-mediated gene targeting vehicles generally consist of two components: a cell receptor-specific ligand and a DNA-binding agent. Several ligands have been used for receptor-mediated gene transfer. The most extensively characterized ligands are asialoorosomucoid (ASOR) (Wu and Wu, 1987) and transferrin (Wagner *et al.*, 1990). Recently, a synthetic neoglycoprotein, which recognizes the same receptor as ASOR, has
10 been used as a gene delivery vehicle (Ferkol *et al.*, 1993; Perales *et al.*, 1994) and epidermal growth factor (EGF) has also been used to deliver genes to squamous carcinoma cells (Myers, EPO 0273085).

 In other embodiments, the delivery vehicle may comprise a ligand and a
15 liposome. For example, Nicolau *et al.* (1987) employed lactosyl-ceramide, a galactose-terminal asialganglioside, incorporated into liposomes and observed an increase in the uptake of the insulin gene by hepatocytes. Thus, it is feasible that a nucleic acid encoding a therapeutic gene also may be specifically delivered into a cell type such as prostate, epithelial or tumor endothelial cells, by any number of receptor-ligand systems
20 with or without liposomes. For example, the human prostate-specific antigen (Watt *et al.*, 1986) may be used as the receptor for mediated delivery of a nucleic acid in prostate tissue.

 In another embodiment of the invention, the expression construct may simply
25 consist of naked recombinant DNA or plasmids. Transfer of the construct may be performed by any of the methods mentioned above which physically or chemically permeabilize the cell membrane. This is applicable particularly for transfer *in vitro*, however, it may be applied for *in vivo* use as well. Dubensky *et al.* (1984) successfully injected polyomavirus DNA in the form of CaPO₄ precipitates into liver and spleen of
30 adult and newborn mice demonstrating active viral replication and acute infection. Benvenisty and Neshif (1986) also demonstrated that direct intraperitoneal injection of

CaPO₄ precipitated plasmids results in expression of the transfected genes. It is envisioned that DNA encoding a *Chlamydia psittaci* gene or polynucleotide of interest may also be transferred in a similar manner *in vivo* and express the gene or polynucleotide product.

5

2. Viral Vectors

In certain embodiments, it is contemplated that a *Chlamydia psittaci* gene or polynucleotide that confers immune resistance to infection may be delivered by a viral vector. The capacity of certain viral vectors to efficiently infect or enter cells, to
10 integrate into a host cell genome and stably express viral genes, have led to the development and application of a number of different viral vector systems (Robbins *et al.*, 1998). Viral systems are currently being developed for use as vectors for *ex vivo* and *in vivo* gene transfer. For example, adenovirus, herpes-simple virus, retrovirus and adeno-associated virus vectors are being evaluated currently for treatment of diseases
15 such as cancer, cystic fibrosis, Gaucher disease, renal disease and arthritis (Robbins and Ghivizzani, 1998; Imai *et al.*, 1998; U. S. Patent 5,670,488). The various viral vectors described below, present specific advantages and disadvantages, depending on the particular gene-therapeutic application.

20

a. Adenoviral Vectors

In particular embodiments, an adenoviral expression vector is contemplated for the delivery of expression constructs. "Adenovirus expression vector" is meant to include those constructs containing adenovirus sequences sufficient to (a) support packaging of the construct and (b) to ultimately express a tissue or cell-specific construct that has been
25 cloned therein.

30

Adenoviruses comprise linear double stranded DNA, with a genome ranging from 30 to 35 kb in size (Reddy *et al.*, 1998; Morrison *et al.*, 1997; Chillon *et al.*, 1999). An adenovirus expression vector according to the present invention comprises a genetically
engineered form of the adenovirus. Advantages of adenoviral gene transfer include the ability to infect a wide variety of cell types, including non-dividing cells, a mid-sized

genome, ease of manipulation, high infectivity and they can be grown to high titers (Wilson, 1996). Further, adenoviral infection of host cells does not result in chromosomal integration because adenoviral DNA can replicate in an episomal manner, without potential genotoxicity associated with other viral vectors. Adenoviruses also are structurally stable (Marienfeld *et al.*, 1999) and no genome rearrangement has been detected after extensive amplification (Parks *et al.*, 1997; Bett *et al.*, 1993).

Salient features of the adenovirus genome are an early region (E1, E2, E3 and E4 genes), an intermediate region (pIX gene, Iva2 gene), a late region (L1, L2, L3, L4 and L5 genes), a major late promoter (MLP), inverted-terminal-repeats (ITRs) and a ψ sequence (Zheng, *et al.*, 1999; Robbins *et al.*, 1998; Graham and Prevec, 1995). The early genes E1, E2, E3 and E4 are expressed from the virus after infection and encode polypeptides that regulate viral gene expression, cellular gene expression, viral replication, and inhibition of cellular apoptosis. Further on during viral infection, the MLP is activated, resulting in the expression of the late (L) genes, encoding polypeptides required for adenovirus encapsidation. The intermediate region encodes components of the adenoviral capsid. Adenoviral inverted terminal repeats (ITRs; 100-200 bp in length), are *cis* elements, function as origins of replication and are necessary for viral DNA replication. The ψ sequence is required for the packaging of the adenoviral genome.

A common approach for generating an adenoviruses for use as a gene transfer vector is the deletion of the E1 gene (E1⁻), which is involved in the induction of the E2, E3 and E4 promoters (Graham and Prevec, 1995). Subsequently, a therapeutic gene or genes can be inserted recombinantly in place of the E1 gene, wherein expression of the therapeutic gene(s) is driven by the E1 promoter or a heterologous promoter. The E1⁻ replication-deficient virus is then proliferated in a "helper" cell line that provides the E1 polypeptides *in trans* (e.g., the human embryonic kidney cell line 293). Thus, in the present invention it may be convenient to introduce the transforming construct at the position from which the E1-coding sequences have been removed. However, the position of insertion of the construct within the adenovirus sequences is not critical to the invention. Alternatively, the E3 region, portions of the E4 region or both may be deleted,

wherein a heterologous nucleic acid sequence under the control of a promoter operable in eukaryotic cells is inserted into the adenovirus genome for use in gene transfer (U. S. Patent 5,670,488; U. S. Patent 5,932,210, each specifically incorporated herein by reference).

5

Although adenovirus based vectors offer several unique advantages over other vector systems, they often are limited by vector immunogenicity, size constraints for insertion of recombinant genes and low levels of replication. The preparation of a recombinant adenovirus vector deleted of all open reading frames, comprising a full length dystrophin gene and the terminal repeats required for replication (Haecker *et al.*, 1997) offers some potentially promising advantages to the above mentioned adenoviral shortcomings. The vector was grown to high titer with a helper virus in 293 cells and was capable of efficiently transducing dystrophin in mdx mice, in myotubes *in vitro* and muscle fibers *in vivo*. Helper-dependent viral vectors are discussed below.

15

A major concern in using adenoviral vectors is the generation of a replication-competent virus during vector production in a packaging cell line or during gene therapy treatment of an individual. The generation of a replication-competent virus could pose serious threat of an unintended viral infection and pathological consequences for the patient. Armentano *et al.*, describe the preparation of a replication-defective adenovirus vector, claimed to eliminate the potential for the inadvertent generation of a replication-competent adenovirus (U. S. Patent 5,824,544, specifically incorporated herein by reference). The replication-defective adenovirus method comprises a deleted E1 region and a relocated protein IX gene, wherein the vector expresses a heterologous, mammalian gene.

25

Other than the requirement that the adenovirus vector be replication defective, or at least conditionally defective, the nature of the adenovirus vector is not believed to be crucial to the successful practice of the invention. The adenovirus may be of any of the 42 different known serotypes and/or subgroups A-F. Adenovirus type 5 of subgroup C is the preferred starting material in order to obtain the conditional replication-defective

30

adenovirus vector for use in the present invention. This is because adenovirus type 5 is a human adenovirus about which a great deal of biochemical and genetic information is known, and it has historically been used for most constructions employing adenovirus as a vector.

5

As stated above, the typical vector according to the present invention is replication defective and will not have an adenovirus EI region. Adenovirus growth and manipulation is known to those of skill in the art, and exhibits broad host range *in vitro* and *in vivo* (U. S. Patent 5,670,488; U. S. Patent 5,932,210; U. S. Patent 5,824,54). This group of viruses can be obtained in high titers, *e.g.*, 10^9 to 10^{11} plaque-forming units per ml, and they are highly infective. The life cycle of adenovirus does not require integration into the host cell genome. The foreign genes delivered by adenovirus vectors are episomal and, therefore, have low genotoxicity to host cells. Many experiments, innovations, preclinical studies and clinical trials are currently under investigation for the use of adenoviruses as gene delivery vectors. For example, adenoviral gene delivery-based gene therapies are being developed for liver diseases (Han *et al.*, 1999), psychiatric diseases (Lesch, 1999), neurological diseases (Smith, 1998; Hermens and Verhaagen, 1998), coronary diseases (Feldman *et al.*, 1996), muscular diseases (Petrof, 1998), gastrointestinal diseases (Wu, 1998) and various cancers such as colorectal (Fujiwara and Tanaka, 1998; Dorai *et al.*, 1999), pancreatic (Carrion *et al.*, 1999), bladder (Irie *et al.*, 1999), head and neck (Blackwell *et al.*, 1999), breast (Stewart *et al.*, 1999), lung (Batra *et al.*, 1999) and ovarian (Vanderkwaak *et al.*, 1999).

10

15

20

b. Retroviral Vectors

In certain embodiments of the invention, the use of retroviruses for gene delivery are contemplated. Retroviruses are RNA viruses comprising an RNA genome. When a host cell is infected by a retrovirus, the genomic RNA is reverse transcribed into a DNA intermediate which is integrated into the chromosomal DNA of infected cells. This integrated DNA intermediate is referred to as a provirus. A particular advantage of retroviruses is that they can stably infect dividing cells with a gene of interest (*e.g.*, a therapeutic gene) by integrating into the host DNA, without expressing immunogenic viral proteins. Theoretically, the integrated retroviral vector will be maintained for the life of the infected host cell, expressing the gene of interest.

The retroviral genome and the proviral DNA have three genes: *gag*, *pol*, and *env*, which are flanked by two long terminal repeat (LTR) sequences. The *gag* gene encodes the internal structural (matrix, capsid, and nucleocapsid) proteins; the *pol* gene encodes the RNA-directed DNA polymerase (reverse transcriptase) and the *env* gene encodes viral envelope glycoproteins. The 5' and 3' LTRs serve to promote transcription and polyadenylation of the virion RNAs. The LTR contains all other cis-acting sequences necessary for viral replication.

A recombinant retrovirus of the present invention may be genetically modified in such a way that some of the structural, infectious genes of the native virus have been removed and replaced instead with a nucleic acid sequence to be delivered to a target cell (U. S. Patent 5,858,744; U. S. Patent 5,739,018, each incorporated herein by reference). After infection of a cell by the virus, the virus injects its nucleic acid into the cell and the retrovirus genetic material can integrate into the host cell genome. The transferred retrovirus genetic material is then transcribed and translated into proteins within the host cell. As with other viral vector systems, the generation of a replication-competent retrovirus during vector production or during therapy is a major concern. Retroviral vectors suitable for use in the present invention are generally defective retroviral vectors that are capable of infecting the target cell, reverse transcribing their RNA genomes, and integrating the reverse transcribed DNA into the target cell genome, but are incapable of

replicating within the target cell to produce infectious retroviral particles (e.g., the retroviral genome transferred into the target cell is defective in gag, the gene encoding virion structural proteins, and/or in pol, the gene encoding reverse transcriptase). Thus, transcription of the provirus and assembly into infectious virus occurs in the presence of
5 an appropriate helper virus or in a cell line containing appropriate sequences enabling encapsidation without coincident production of a contaminating helper virus.

The growth and maintenance of retroviruses is known in the art (U. S. Patent 5,955,331; U. S. Patent 5,888,502, each specifically incorporated herein by reference).
10 Nolan *et al.* describe the production of stable high titre, helper-free retrovirus comprising a heterologous gene (U. S. Patent 5,830,725, specifically incorporated herein by reference). Methods for constructing packaging cell lines useful for the generation of helper-free recombinant retroviruses with amphoteric or ecotropic host ranges, as well as methods of using the recombinant retroviruses to introduce a gene of interest into
15 eukaryotic cells *in vivo* and *in vitro* are contemplated in the present invention (U. S. Patent 5,955,331).

Currently, the majority of all clinical trials for vector mediated gene delivery use murine leukemia virus (MLV)-based retroviral vector gene delivery (Robbins *et al.*,
20 1998; Miller *et al.*, 1993). Disadvantages of retroviral gene delivery includes a requirement for ongoing cell division for stable infection and a coding capacity that prevents the delivery of large genes. However, recent development of vectors such as lentivirus (e.g., HIV), simian immunodeficiency virus (SIV) and equine infectious-anemia virus (EIAV), which can infect certain non-dividing cells, potentially allow the *in*
25 *vivo* use of retroviral vectors for gene therapy applications (Amado and Chen, 1999; Klimatcheva *et al.*, 1999; White *et al.*, 1999; Case *et al.*, 1999). For example, HIV-based vectors have been used to infect non-dividing cells such as neurons (Takashi *et al.*, 1999; Miyake *et al.*, 1999), islets (Leibowitz *et al.*, 1999) and muscle cells (Johnston *et al.*, 1999). The therapeutic delivery of genes *via* retroviruses are currently being assessed for
30 the treatment of various disorders such as inflammatory disease (Moldawer *et al.*, 1999),

AIDS (Amado *et al.*, 1999; Engel and Kohn, 1999), cancer (Clay *et al.*, 1999), cerebrovascular disease (Weihl *et al.*, 1999) and hemophilia (Kay, 1998).

c. Herpes-Simplex Viral Vectors

5 Herpes simplex virus (HSV) type I and type II contain a double-stranded, linear DNA genome of approximately 150 kb, encoding 70-80 genes. Wild type HSV are able to infect cells lytically and to establish latency in certain cell types (*e.g.*, neurons). Similar to adenovirus, HSV also can infect a variety of cell types including muscle (Yeung *et al.*, 1999), ear (Derby *et al.*, 1999), eye (Kaufman *et al.*, 1999), tumors (Yoon
10 *et al.*, 1999; Howard *et al.*, 1999), lung (Kohut *et al.*, 1998), neuronal (Garrido *et al.*, 1999; Lachmann and Efsthathiou, 1999), liver (Miyake *et al.*, 1999; Kooby *et al.*, 1999) and pancreatic islets (Rabinovitch *et al.*, 1999).

HSV viral genes are transcribed by cellular RNA polymerase II and are
15 temporally regulated, resulting in the transcription and subsequent synthesis of gene products in roughly three discernable phases or kinetic classes. These phases of genes are referred to as the Immediate Early (IE) or alpha genes, Early (E) or beta genes and Late (L) or gamma genes. Immediately following the arrival of the genome of a virus in the nucleus of a newly infected cell, the IE genes are transcribed. The efficient
20 expression of these genes does not require prior viral protein synthesis. The products of IE genes are required to activate transcription and regulate the remainder of the viral genome.

For use in therapeutic gene delivery, HSV must be rendered replication-defective.
25 Protocols for generating replication-defective HSV helper virus-free cell lines have been described (U. S. Patent 5,879,934; U. S. Patent 5,851,826, each specifically incorporated herein by reference in its entirety). One IE protein, Infected Cell Polypeptide 4 (ICP4), also known as alpha 4 or Vmw175, is absolutely required for both virus infectivity and the transition from IE to later transcription. Thus, due to its complex, multifunctional
30 nature and central role in the regulation of HSV gene expression, ICP4 has typically been the target of HSV genetic studies.

Phenotypic studies of HSV viruses deleted of ICP4 indicate that such viruses will be potentially useful for gene transfer purposes (Krisky *et al.*, 1998a). One property of viruses deleted for ICP4 that makes them desirable for gene transfer is that they only
5 express the five other IE genes: ICP0, ICP6, ICP27, ICP22 and ICP47 (DeLuca *et al.*, 1985), without the expression of viral genes encoding proteins that direct viral DNA synthesis, as well as the structural proteins of the virus. This property is desirable for minimizing possible deleterious effects on host cell metabolism or an immune response following gene transfer. Further deletion of IE genes ICP22 and ICP27, in addition to
10 ICP4, substantially improve reduction of HSV cytotoxicity and prevented early and late viral gene expression (Krisky *et al.*, 1998b).

The therapeutic potential of HSV in gene transfer has been demonstrated in various *in vitro* model systems and *in vivo* for diseases such as Parkinson's (Yamada *et al.*, 1999), retinoblastoma (Hayashi *et al.*, 1999), intracerebral and intradermal tumors
15 (Moriuchi *et al.*, 1998), B cell malignancies (Suzuki *et al.*, 1998), ovarian cancer (Wang *et al.*, 1998) and Duchenne muscular dystrophy (Huard *et al.*, 1997).

d. Adeno-associated Viral Vectors

Adeno-associated virus (AAV), a member of the parvovirus family, is a human
20 virus that is increasingly being used for gene delivery therapeutics. AAV has several advantageous features not found in other viral systems. First, AAV can infect a wide range of host cells, including non-dividing cells. Second, AAV can infect cells from different species. Third, AAV has not been associated with any human or animal disease
25 and does not appear to alter the biological properties of the host cell upon integration. For example, it is estimated that 80-85% of the human population has been exposed to AAV. Finally, AAV is stable at a wide range of physical and chemical conditions which lends itself to production, storage and transportation requirements.

30 The AAV genome is a linear, single-stranded DNA molecule containing 4681 nucleotides. The AAV genome generally comprises an internal non-repeating genome

flanked on each end by inverted terminal repeats (ITRs) of approximately 145 bp in length. The ITRs have multiple functions, including origins of DNA replication, and as packaging signals for the viral genome. The internal non-repeated portion of the genome includes two large open reading frames, known as the AAV replication (rep) and capsid (cap) genes. The rep and cap genes code for viral proteins that allow the virus to replicate and package the viral genome into a virion. A family of at least four viral proteins are expressed from the AAV rep region, Rep 78, Rep 68, Rep 52, and Rep 40, named according to their apparent molecular weight. The AAV cap region encodes at least three proteins, VP1, VP2, and VP3.

AAV is a helper-dependent virus requiring co-infection with a helper virus (*e.g.*, adenovirus, herpesvirus or vaccinia) in order to form AAV virions. In the absence of co-infection with a helper virus, AAV establishes a latent state in which the viral genome inserts into a host cell chromosome, but infectious virions are not produced. Subsequent infection by a helper virus “rescues” the integrated genome, allowing it to replicate and package its genome into infectious AAV virions. Although AAV can infect cells from different species, the helper virus must be of the same species as the host cell (*e.g.*, human AAV will replicate in canine cells co-infected with a canine adenovirus).

AAV has been engineered to deliver genes of interest by deleting the internal non-repeating portion of the AAV genome and inserting a heterologous gene between the ITRs. The heterologous gene may be functionally linked to a heterologous promoter (constitutive, cell-specific, or inducible) capable of driving gene expression in target cells. To produce infectious recombinant AAV (rAAV) containing a heterologous gene, a suitable producer cell line is transfected with a rAAV vector containing a heterologous gene. The producer cell is concurrently transfected with a second plasmid harboring the AAV rep and cap genes under the control of their respective endogenous promoters or heterologous promoters. Finally, the producer cell is infected with a helper virus.

Once these factors come together, the heterologous gene is replicated and packaged as though it were a wild-type AAV genome. When target cells are infected with

the resulting rAAV virions, the heterologous gene enters and is expressed in the target cells. Because the target cells lack the rep and cap genes and the adenovirus helper genes, the rAAV cannot further replicate, package or form wild-type AAV.

5 The use of helper virus, however, presents a number of problems. First, the use of adenovirus in a rAAV production system causes the host cells to produce both rAAV and infectious adenovirus. The contaminating infectious adenovirus can be inactivated by heat treatment (56.degree. C. for 1 hour). Heat treatment, however, results in approximately a 50% drop in the titer of functional rAAV virions. Second, varying
10 amounts of adenovirus proteins are present in these preparations. For example, approximately 50% or greater of the total protein obtained in such rAAV virion preparations is free adenovirus fiber protein. If not completely removed, these adenovirus proteins have the potential of eliciting an immune response from the patient. Third, AAV vector production methods which employ a helper virus require the use and manipulation
15 of large amounts of high titer infectious helper virus, which presents a number of health and safety concerns, particularly in regard to the use of a herpesvirus. Fourth, concomitant production of helper virus particles in rAAV virion producing cells diverts large amounts of host cellular resources away from rAAV virion production, potentially resulting in lower rAAV virion yields.

20 e. Other Viral Vectors

 The development and utility of viral vectors for gene delivery is constantly improving and evolving. Other viral vectors such as poxvirus; *e.g.*, vaccinia virus (Gnant
25 *et al.*, 1999; Gnant *et al.*, 1999), alpha virus; *e.g.*, sindbis virus, Semliki forest virus (Lundstrom, 1999), reovirus (Coffey *et al.*, 1998) and influenza A virus (Neumann *et al.*, 1999) are contemplated for use in the present invention and may be selected according to the requisite properties of the target system.

 In certain embodiments, vaccinia viral vectors are contemplated for use in the
30 present invention. Vaccinia virus is a particularly useful eukaryotic viral vector system for expressing heterologous genes. For example, when recombinant vaccinia virus is

properly engineered, the proteins are synthesized, processed and transported to the plasma membrane. Vaccinia viruses as gene delivery vectors have recently been demonstrated to transfer genes to human tumor cells, *e.g.*, EMAP-II (Gnant *et al.*, 1999), inner ear (Derby *et al.*, 1999), glioma cells, *e.g.*, p53 (Timiryasova *et al.*, 1999) and
5 various mammalian cells, *e.g.*, P-450 (U. S. Patent 5,506,138). The preparation, growth and manipulation of vaccinia viruses are described in U. S. Patent 5,849,304 and U. S. Patent 5,506,138 (each specifically incorporated herein by reference).

In other embodiments, sindbis viral vectors are contemplated for use in gene
10 delivery. Sindbis virus is a species of the alphavirus genus (Garoff and Li, 1998) which includes such important pathogens as Venezuelan, Western and Eastern equine encephalitis viruses (Sawai *et al.*, 1999; Mastrangelo *et al.*, 1999). *In vitro*, sindbis virus infects a variety of avian, mammalian, reptilian, and amphibian cells. The genome of sindbis virus consists of a single molecule of single-stranded RNA, 11,703 nucleotides in
15 length. The genomic RNA is infectious, is capped at the 5' terminus and polyadenylated at the 3' terminus, and serves as mRNA. Translation of a vaccinia virus 26S mRNA produces a polyprotein that is cleaved co- and post-translationally by a combination of viral and presumably host-encoded proteases to give the three virus structural proteins, a capsid protein (C) and the two envelope glycoproteins (E1 and PE2, precursors of the
20 virion E2).

Three features of sindbis virus suggest that it would be a useful vector for the expression of heterologous genes. First, its wide host range, both in nature and in the laboratory. Second, gene expression occurs in the cytoplasm of the host cell and is rapid
25 and efficient. Third, temperature-sensitive mutations in RNA synthesis are available that may be used to modulate the expression of heterologous coding sequences by simply shifting cultures to the non-permissive temperature at various time after infection. The growth and maintenance of sindbis virus is known in the art (U. S. Patent 5,217,879, specifically incorporated herein by reference).

30

f. Chimeric Viral Vectors

Chimeric or hybrid viral vectors are being developed for use in therapeutic gene delivery and are contemplated for use in the present invention. Chimeric poxviral/retroviral vectors (Holzer *et al.*, 1999), adenoviral/retroviral vectors (Feng *et al.*, 1997; Bilbao *et al.*, 1997; Caplen *et al.*, 1999) and adenoviral/adeno-associated viral vectors (Fisher *et al.*, 1996; U. S. Patent 5,871,982) have been described.

These "chimeric" viral gene transfer systems can exploit the favorable features of two or more parent viral species. For example, Wilson *et al.*, provide a chimeric vector construct which comprises a portion of an adenovirus, AAV 5' and 3' ITR sequences and a selected transgene, described below (U. S. Patent 5,871,983, specifically incorporate herein by reference).

The adenovirus/AAV chimeric virus uses adenovirus nucleic acid sequences as a shuttle to deliver a recombinant AAV/transgene genome to a target cell. The adenovirus nucleic acid sequences employed in the hybrid vector can range from a minimum sequence amount, which requires the use of a helper virus to produce the hybrid virus particle, to only selected deletions of adenovirus genes, which deleted gene products can be supplied in the hybrid viral production process by a selected packaging cell. At a minimum, the adenovirus nucleic acid sequences employed in the pAdA shuttle vector are adenovirus genomic sequences from which all viral genes are deleted and which contain only those adenovirus sequences required for packaging adenoviral genomic DNA into a preformed capsid head. More specifically, the adenovirus sequences employed are the cis-acting 5' and 3' inverted terminal repeat (ITR) sequences of an adenovirus (which function as origins of replication) and the native 5' packaging/enhancer domain, that contains sequences necessary for packaging linear Ad genomes and enhancer elements for the E1 promoter. The adenovirus sequences may be modified to contain desired deletions, substitutions, or mutations, provided that the desired function is not eliminated.

30

The AAV sequences useful in the above chimeric vector are the viral sequences from which the rep and cap polypeptide encoding sequences are deleted. More specifically, the AAV sequences employed are the cis-acting 5' and 3' inverted terminal repeat (ITR) sequences. These chimeras are characterized by high titer transgene
5 delivery to a host cell and the ability to stably integrate the transgene into the host cell chromosome (U. S. Patent 5,871,983, specifically incorporate herein by reference). In the hybrid vector construct, the AAV sequences are flanked by the selected adenovirus sequences discussed above. The 5' and 3' AAV ITR sequences themselves flank a selected transgene sequence and associated regulatory elements, described below. Thus,
10 the sequence formed by the transgene and flanking 5' and 3' AAV sequences may be inserted at any deletion site in the adenovirus sequences of the vector. For example, the AAV sequences are desirably inserted at the site of the deleted E1a/E1b genes of the adenovirus. Alternatively, the AAV sequences may be inserted at an E3 deletion, E2a deletion, and so on. If only the adenovirus 5' ITR/packaging sequences and 3' ITR
15 sequences are used in the hybrid virus, the AAV sequences are inserted between them.

The transgene sequence of the vector and recombinant virus can be a gene, a nucleic acid sequence or reverse transcript thereof, heterologous to the adenovirus sequence, which encodes a protein, polypeptide or peptide fragment of interest. The
20 transgene is operatively linked to regulatory components in a manner which permits transgene transcription. The composition of the transgene sequence will depend upon the use to which the resulting hybrid vector will be put. For example, one type of transgene sequence includes a therapeutic gene which expresses a desired gene product in a host cell. These therapeutic genes or nucleic acid sequences typically encode products for
25 administration and expression in a patient *in vivo* or *ex vivo* to replace or correct an inherited or non-inherited genetic defect or treat an epigenetic disorder or disease.

E. Antibodies Against *Chlamydia psittaci* Proteins.

In another aspect, the present invention provides antibody compositions that are immunoreactive with a *Chlamydia psittaci* polypeptide of the present invention, or any portion thereof.

5

An antibody can be a polyclonal or a monoclonal antibody. An antibody may also be monovalent or bivalent. A prototype antibody is an immunoglobulin composed by four polypeptide chains, two heavy and two light chains, held together by disulfide bonds. Each pair of heavy and light chains forms an antigen binding site, also defined as complementarity-determining region (CDR). Therefore, the prototype antibody has two CDRs, can bind two antigens, and because of this feature is defined bivalent. The prototype antibody can be split by a variety of biological or chemical means. Each half of the antibody can only bind one antigen and, therefore, is defined monovalent. Means for preparing and characterizing antibodies are well known in the art (see, e.g., Howell and Lane, 1988).

15

Peptides corresponding to one or more antigenic determinants of a *Chlamydia psittaci* polypeptide of the present invention also can be prepared. Such peptides should generally be at least five or six amino acid residues in length, will preferably be about 10, 15, 20, 25 or about 30 amino acid residues in length, and may contain up to about 35-50 residues or so. Synthetic peptides will generally be about 35 residues long, which is the approximate upper length limit of automated peptide synthesis machines, such as those available from Applied Biosystems (Foster City, CA). Longer peptides also may be prepared, e.g., by recombinant means.

25

The identification and preparation of epitopes from primary amino acid sequences on the basis of hydrophilicity is taught in U.S. Patent 4,554,101 (Hopp), incorporated herein by reference. Through the methods disclosed in Hopp, one of skill in the art would be able to identify epitopes from within an amino acid sequence such as a *Chlamydia psittaci* polypeptide sequence.

30

Numerous scientific publications have also been devoted to the prediction of secondary structure, and to the identification of epitopes, from analyses of amino acid sequences (Chou & Fasman, 1974a; Chou & Fasman, 1974b; Chou & Fasman, 1978a; Chou & Fasman, 1978b; Chou & Fasman, 1979). Any of these may be used, if desired, to supplement the teachings of Hopp in U.S. Patent 4,554,101.

Moreover, computer programs are currently available to assist with predicting antigenic portions and epitopic core regions of proteins. Examples include those programs based upon the Jameson-Wolf analysis (Jameson & Wolf, 1988; Wolf *et al.*, 1988), the program PEPLOT® (Brutlag *et al.*, 1990; Weinberger *et al.*, 1985), and other new programs for protein tertiary structure prediction (Fetrow & Bryant, 1993). Another commercially available software program capable of carrying out such analyses is MACVECTOR (IBI, New Haven, CT).

In further embodiments, major antigenic determinants of a *Chlamydia psittaci* polypeptide may be identified by an empirical approach in which portions of the gene encoding the polypeptide are expressed in a recombinant host, and the resulting proteins tested for their ability to elicit an immune response. For example, PCR can be used to prepare a range of peptides lacking successively longer fragments of the C-terminus of the protein. The immunoactivity of each of these peptides is determined to identify those fragments or domains of the polypeptide that are immunodominant. Further studies in which only a small number of amino acids are removed at each iteration then allows the location of the antigenic determinants of the polypeptide to be more precisely determined.

Another method for determining the major antigenic determinants of a polypeptide is the SPOTS system (Genosys Biotechnologies, Inc., The Woodlands, TX). In this method, overlapping peptides are synthesized on a cellulose membrane, which following synthesis and deprotection, is screened using a polyclonal or monoclonal antibody. The antigenic determinants of the peptides which are initially identified can be further localized by performing subsequent syntheses of smaller peptides with larger

overlaps, and by eventually replacing individual amino acids at each position along the immunoreactive peptide.

Once one or more such analyses are completed, polypeptides are prepared that contain at least the essential features of one or more antigenic determinants. The peptides are then employed in the generation of antisera against the polypeptide. Minigenes or gene fusions encoding these determinants also can be constructed and inserted into expression vectors by standard methods, for example, using PCR cloning methodology.

The use of such small peptides for antibody generation or vaccination typically requires conjugation of the peptide to an immunogenic carrier protein, such as hepatitis B surface antigen, keyhole limpet hemocyanin or bovine serum albumin. Methods for performing this conjugation are well known in the art.

1. *Anti-Chlamydia psittaci* Antibody Generation

The present invention provides monoclonal antibody compositions that are immunoreactive with a *Chlamydia psittaci* polypeptide. As detailed above, in addition to antibodies generated against a full length *Chlamydia psittaci* polypeptide, antibodies also may be generated in response to smaller constructs comprising epitopic core regions, including wild-type and mutant epitopes. In other embodiments of the invention, the use of anti-*Chlamydia psittaci* single chain antibodies, chimeric antibodies, diabodies and the like are contemplated.

As used herein, the term "antibody" is intended to refer broadly to any immunologic binding agent such as IgG, IgM, IgA, IgD and IgE. Generally, IgG and/or IgM are preferred because they are the most common antibodies in the physiological situation and because they are most easily made in a laboratory setting.

Monoclonal antibodies (mAbs) are recognized to have certain advantages, e.g., reproducibility and large-scale production, and their use is generally preferred.

However, “humanized” *Chlamydia psittaci* antibodies also are contemplated, as are chimeric antibodies from mouse, rat, goat or other species, fusion proteins, single chain antibodies, diabodies, bispecific antibodies, and other engineered antibodies and fragments thereof. As defined herein, a “humanized” antibody comprises constant regions from a human antibody gene and variable regions from a non-human antibody gene. A “chimeric antibody, comprises constant and variable regions from two genetically distinct individuals. An anti-*Chlamydia psittaci* humanized or chimeric antibody can be genetically engineered to comprise a *Chlamydia psittaci* antigen binding site of a given of molecular weight and biological lifetime, as long as the antibody retains its *Chlamydia psittaci* antigen binding site.

The term “antibody” is used to refer to any antibody-like molecule that has an antigen binding region, and includes antibody fragments such as Fab’, Fab, F(ab’)₂, single domain antibodies (DABs), Fv, scFv (single chain Fv), chimeras and the like. Methods and techniques of producing the above antibody-based constructs and fragments are well known in the art (U.S. Patent 5,889,157; U.S. Patent 5,821,333; U.S. Patent 5,888,773, each specifically incorporated herein by reference).

U.S. Patent 5,889,157 describes a humanized B3 scFv antibody preparation. The B3 scFv is encoded from a recombinant, fused DNA molecule, that comprises a DNA sequence encoding humanized Fv heavy and light chain regions of a B3 antibody and a DNA sequence that encodes an effector molecule. The effector molecule can be any agent having a particular biological activity which is to be directed to a particular target cell or molecule. Described in U.S. Patent 5,888,773, is the preparation of scFv antibodies produced in eukaryotic cells, wherein the scFv antibodies are secreted from the eukaryotic cells into the cell culture medium and retain their biological activity. It is contemplated that similar methods for preparing multi-functional anti-*Chlamydia psittaci* fusion proteins, as described above, may be utilized in the present invention.

Means for preparing and characterizing antibodies also are well known in the art (See, e.g., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988;

incorporated herein by reference). The methods for generating monoclonal antibodies (mAbs) generally begin along the same lines as those for preparing polyclonal antibodies. Briefly, a polyclonal antibody is prepared by immunizing an animal with an immunogenic *Chlamydia psittaci* polypeptide composition in accordance with the present invention and collecting antisera from that immunized animal.

A wide range of animal species can be used for the production of antisera. Typically the animal used for production of antisera is a rabbit, a mouse, a rat, a hamster, a guinea pig or a goat. Because of the relatively large blood volume of rabbits, a rabbit is a preferred choice for production of polyclonal antibodies.

As is well known in the art, a given composition may vary in its immunogenicity. It is often necessary therefore to boost the host immune system, as may be achieved by coupling a peptide or polypeptide immunogen to a carrier. Exemplary and preferred carriers are keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA). Other albumins such as ovalbumin, mouse serum albumin or rabbit serum albumin also can be used as carriers. Means for conjugating a polypeptide to a carrier protein are well known in the art and include glutaraldehyde, m-maleimidobenzoyl-N-hydroxysuccinimide ester, carbodiimide and bis-biazotized benzidine.

As also well known in the art, the immunogenicity of a particular immunogen composition can be enhanced by the use of non-specific stimulators of the immune response, known as adjuvants. Suitable molecule adjuvants include all acceptable immunostimulatory compounds, such as cytokines, toxins or synthetic compositions.

Adjuvants that may be used include IL-1, IL-2, IL-4, IL-7, IL-12, γ -interferon, GMCSF, BCG, aluminum hydroxide, MDP compounds, such as thur-MDP and nor-MDP, CGP (MTP-PE), lipid A, and monophosphoryl lipid A (MPL). RIBI, which contains three components extracted from bacteria, MPL, trehalose dimycolate (TDM) and cell wall skeleton (CWS) in a 2% squalene/Tween 80 emulsion also is contemplated. MHC antigens may even be used. Exemplary, often preferred adjuvants include

complete Freund's adjuvant (a non-specific stimulator of the immune response containing killed *Mycobacterium tuberculosis*), incomplete Freund's adjuvants and aluminum hydroxide adjuvant.

5 In addition to adjuvants, it may be desirable to coadminister biologic response modifiers (BRM), which have been shown to upregulate T cell immunity or downregulate suppressor cell activity. Such BRMs include, but are not limited to, Cimetidine (CIM; 1200 mg/d) (SmithKline Beecham, PA); low-dose Cyclophosphamide (CYP; 300 mg/m²) (Johnson/ Mead, NJ), cytokines such as γ -interferon, IL-2, or IL-12 or
10 genes encoding proteins involved in immune helper functions, such as B-7.

 The amount of immunogen composition used in the production of polyclonal antibodies varies upon the nature of the immunogen as well as the animal used for immunization. A variety of routes can be used to administer the immunogen
15 (subcutaneous, intramuscular, intradermal, intravenous and intraperitoneal). The production of polyclonal antibodies may be monitored by sampling blood of the immunized animal at various points following immunization.

 A second, booster injection, also may be given. The process of boosting and
20 titering is repeated until a suitable titer is achieved. When a desired level of immunogenicity is obtained, the immunized animal can be bled and the serum isolated and stored, and/or the animal can be used to generate mAbs.

 For production of rabbit polyclonal antibodies, the animal can be bled through an
25 ear vein or alternatively by cardiac puncture. The removed blood is allowed to coagulate and then centrifuged to separate serum components from whole cells and blood clots. The serum may be used as is for various applications or else the desired antibody fraction may be purified by well-known methods, such as affinity chromatography using another antibody, a peptide bound to a solid matrix, or by using, *e.g.*, protein A or protein G
30 chromatography.

mAbs may be readily prepared through use of well-known techniques, such as those exemplified in U.S. Patent 4,196,265, incorporated herein by reference. Typically, this technique involves immunizing a suitable animal with a selected immunogen composition, *e.g.*, a purified or partially purified *Chlamydia psittaci* polypeptide, peptide or domain, be it a wild-type or mutant composition. The immunizing composition is administered in a manner effective to stimulate antibody producing cells.

The methods for generating monoclonal antibodies (mAbs) generally begin along the same lines as those for preparing polyclonal antibodies. Rodents such as mice and rats are preferred animals, however, the use of rabbit, sheep or frog cells also is possible. The use of rats may provide certain advantages (Goding, 1986, pp. 60-61), but mice are preferred, with the BALB/c mouse being most preferred as this is most routinely used and generally gives a higher percentage of stable fusions.

The animals are injected with antigen, generally as described above. The antigen may be coupled to carrier molecules such as keyhole limpet hemocyanin if necessary. The antigen would typically be mixed with adjuvant, such as Freund's complete or incomplete adjuvant. Booster injections with the same antigen would occur at approximately two-week intervals, or the gene encoding the protein of interest can be directly injected.

Following immunization, somatic cells with the potential for producing antibodies, specifically B lymphocytes (B cells), are selected for use in the mAb generating protocol. These cells may be obtained from biopsied spleens, tonsils or lymph nodes, or from a peripheral blood sample. Spleen cells and peripheral blood cells are preferred, the former because they are a rich source of antibody-producing cells that are in the dividing plasmablast stage, and the latter because peripheral blood is easily accessible.

Often, a panel of animals will have been immunized and the spleen of an animal with the highest antibody titer will be removed and the spleen lymphocytes obtained by

homogenizing the spleen with a syringe. Typically, a spleen from an immunized mouse contains approximately 5×10^7 to 2×10^8 lymphocytes.

The antibody-producing B lymphocytes from the immunized animal are then
5 fused with cells of an immortal myeloma cell, generally one of the same species as the animal that was immunized. Myeloma cell lines suited for use in hybridoma-producing fusion procedures preferably are non-antibody-producing, have high fusion efficiency, and enzyme deficiencies that render them incapable of growing in certain selective media which support the growth of only the desired fused cells (hybridomas).

10 Any one of a number of myeloma cells may be used, as are known to those of skill in the art (Goding, pp. 65-66, 1986; Campbell, pp. 75-83, 1984). For example, where the immunized animal is a mouse, one may use P3-X63/Ag8, X63-Ag8.653, NS1/1.Ag 4 1, Sp210-Ag14, FO, NSO/U, MPC-11, MPC11-X45-GTG 1.7 and
15 S194/5XX0 Bul; for rats, one may use R210.RCY3, Y3-Ag 1.2.3, IR983F and 4B210; and U-266, GM1500-GRG2, LICR-LON-HMy2 and UC729-6 are all useful in connection with human cell fusions.

One preferred murine myeloma cell is the NS-1 myeloma cell line (also termed
20 P3-NS-1-Ag4-1), which is readily available from the NIGMS Human Genetic Mutant Cell Repository by requesting cell line repository number GM3573. Another mouse myeloma cell line that may be used is the 8-azaguanine-resistant mouse murine myeloma SP2/0 non-producer cell line.

25 Methods for generating hybrids of antibody-producing spleen or lymph node cells and myeloma cells usually comprise mixing somatic cells with myeloma cells in a 2:1 proportion, though the proportion may vary from about 20:1 to about 1:1, respectively, in the presence of an agent or agents (chemical or electrical) that promote the fusion of cell membranes. Fusion methods using Sendai virus have been described by Kohler and
30 Milstein (1975; 1976), and those using polyethylene glycol (PEG), such as 37% (v/v)

PEG, by Gefter *et al.* (1977). The use of electrically induced fusion methods also is appropriate (Goding pp. 71-74, 1986).

Fusion procedures usually produce viable hybrids at low frequencies, about
5 1×10^{-6} to 1×10^{-8} . However, this does not pose a problem, as the viable, fused hybrids are differentiated from the parental, unfused cells (particularly the unfused myeloma cells that would normally continue to divide indefinitely) by culturing in a selective medium. The selective medium is generally one that contains an agent that blocks the *de novo* synthesis of nucleotides in the tissue culture media. Exemplary and preferred agents are
10 aminopterin, methotrexate, and azaserine. HAT medium, a growth medium containing hypoxanthine, aminopterin and thymidine, is well known in the art as a medium for selection of hybrid cells. Aminopterin and methotrexate block *de novo* synthesis of both purines and pyrimidines, whereas azaserine blocks only purine synthesis. Where aminopterin or methotrexate is used, the media is supplemented with hypoxanthine and
15 thymidine as a source of nucleotides (HAT medium). Where azaserine is used, the media is supplemented with hypoxanthine.

The preferred selection medium is HAT. Only cells capable of operating nucleotide salvage pathways are able to survive in HAT medium. The myeloma cells are
20 defective in key enzymes of the salvage pathway, *e.g.*, hypoxanthine phosphoribosyl transferase (HPRT), and they cannot survive. The B cells can operate this pathway, but they have a limited life span in culture and generally die within about two weeks. Therefore, the only cells that can survive in the selective media are those hybrids formed from myeloma and B cells.

25

This culturing provides a population of hybridomas from which specific hybridomas are selected. Typically, selection of hybridomas is performed by culturing the cells by single-clone dilution in microtiter plates, followed by testing the individual clonal supernatants (after about two to three weeks) for the desired reactivity. The assay
30 should be sensitive, simple and rapid, such as radioimmunoassays, enzyme

immunoassays, cytotoxicity assays, plaque assays, dot immunobinding assays, and the like.

5 The selected hybridomas then would be serially diluted and cloned into individual antibody-producing cell lines, which clones can then be propagated indefinitely to provide mAbs. The cell lines may be exploited for mAb production in two basic ways. First, a sample of the hybridoma can be injected (often into the peritoneal cavity) into a histocompatible animal of the type that was used to provide the somatic and myeloma cells for the original fusion (*e.g.*, a syngeneic mouse). Optionally, the animals are primed
10 with a hydrocarbon, especially oils such as pristane (tetramethylpentadecane) prior to injection. The injected animal develops tumors secreting the specific monoclonal antibody produced by the fused cell hybrid. The body fluids of the animal, such as serum or ascites fluid, can then be tapped to provide mAbs in high concentration. Second, the individual cell lines could be cultured *in vitro*, where the mAbs are naturally secreted into
15 the culture medium from which they can be readily obtained in high concentrations.

mAbs produced by either means may be further purified, if desired, using filtration, centrifugation and various chromatographic methods such as HPLC or affinity chromatography. Fragments of the monoclonal antibodies of the invention can be
20 obtained from the monoclonal antibodies so produced by methods which include digestion with enzymes, such as pepsin or papain, and/or by cleavage of disulfide bonds by chemical reduction. Alternatively, monoclonal antibody fragments encompassed by the present invention can be synthesized using an automated peptide synthesizer.

25 It also is contemplated that a molecular cloning approach may be used to generate monoclonals. For this, combinatorial immunoglobulin phagemid libraries are prepared from RNA isolated from the spleen of the immunized animal, and phagemids expressing appropriate antibodies are selected by panning using cells expressing the antigen and control cells. The advantages of this approach over conventional hybridoma techniques
30 are that approximately 10^4 times as many antibodies can be produced and screened in a

single round, and that new specificities are generated by H and L chain combination which further increases the chance of finding appropriate antibodies.

Alternatively, monoclonal antibody fragments encompassed by the present invention can be synthesized using an automated peptide synthesizer, or by expression of full-length gene or of gene fragments in, for example, *E. coli*.

F. Pharmaceutical Compositions

Aqueous compositions of the present invention comprise an effective amount of a purified polynucleotide comprising a *Chlamydia psittaci* sequence and/or a purified protein, polypeptide, peptide, epitopic core region of a *Chlamydia psittaci* protein, and the like, dissolved and/or dispersed in a pharmaceutically acceptable carrier and/or aqueous medium. Aqueous compositions of gene therapy vectors expressing any of the foregoing are also contemplated.

The phrases "pharmaceutically and/or pharmacologically acceptable" refer to molecular entities and/or compositions that do not produce an adverse, allergic and/or other untoward reaction when administered to an animal.

As used herein, "pharmaceutically acceptable carrier" includes any and/or all solvents, dispersion media, coatings, antibacterial and/or antifungal agents, isotonic and/or absorption delaying agents and the like. The use of such media and/or agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media and/or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions. For animal and more particularly human administration, preparations should meet sterility, pyrogenicity, general safety and/or purity standards as required by FDA Office of Biologics standards.

The biological material should be extensively dialyzed to remove undesired small molecular weight molecules and/or lyophilized for more ready formulation into a desired

vehicle, where appropriate. The active compounds may generally be formulated for parenteral administration, e.g., formulated for injection via the intravenous, intramuscular, sub-cutaneous, intralesional, and/or even intraperitoneal routes, or formulated for oral or inhaled delivery. The preparation of an aqueous compositions that
5 contain an effective amount of purified *Chlamydia psittaci* polynucleotide or polypeptide agent as an active component and/or ingredient will be known to those of skill in the art in light of the present disclosure. Typically, such compositions can be prepared as injectables, either as liquid solutions and/or suspensions; solid forms suitable for using to prepare solutions and/or suspensions upon the addition of a liquid prior to injection can
10 also be prepared; and/or the preparations can also be emulsified.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions and/or dispersions; formulations including sesame oil, peanut oil and/or aqueous propylene glycol; and/or sterile powders for the extemporaneous preparation of
15 sterile injectable solutions and/or dispersions. In all cases the form must be sterile and/or must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and/or storage and/or must be preserved against the contaminating action of microorganisms, such as bacteria and/or fungi.

Solutions of the active compounds as free base and/or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and/or mixtures thereof and/or in oils. Under ordinary conditions of storage and/or use, these preparations contain a preservative to prevent the growth of
20 microorganisms.
25

A *Chlamydia psittaci* polynucleotide or polypeptide of the present invention can be formulated into a composition in a neutral and/or salt form. Pharmaceutically acceptable salts, include the acid addition salts (formed with the free amino groups of the
30 protein) and/or which are formed with inorganic acids such as, for example, hydrochloric and/or phosphoric acids, and/or such organic acids as acetic, oxalic, tartaric, mandelic,

and/or the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, and/or ferric hydroxides, and/or such organic bases as isopropylamine, trimethylamine, histidine, procaine and/or the like. In terms of using peptide therapeutics as active ingredients, the technology of U.S. Patents 4,608,251; 4,601,903; 4,599,231; 4,599,230; 4,596,792; and/or 4,578,770, each incorporated herein by reference, may be used.

The carrier can also be a solvent and/or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and/or liquid polyethylene glycol, and/or the like), suitable mixtures thereof, and/or vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and/or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and/or antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and/or the like. In many cases, it will be preferable to include isotonic agents, for example, sugars and/or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and/or gelatin.

Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and/or the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and/or freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. The preparation of more, and/or highly, concentrated solutions for direct injection is also contemplated, where the use of DMSO as solvent is envisioned to result in extremely

rapid penetration, delivering high concentrations of the active agents to a small tumor area.

Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and/or in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, but drug release capsules and/or the like can also be employed.

For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and/or the liquid diluent first rendered isotonic with sufficient saline and/or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and/or intraperitoneal administration. In this connection, sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage could be dissolved in 1 ml of isotonic NaCl solution and/or either added to 1000 ml of hypodermoclysis fluid and/or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and/or 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.

A *Chlamydia psittaci* polynucleotide or protein-derived peptides and/or agents may be formulated within a therapeutic mixture to comprise about 0.0001 to 1.0 milligrams, and/or about 0.001 to 0.1 milligrams, and/or about 0.1 to 1.0 and/or even about 10 milligrams per dose and/or so. Multiple doses can also be administered.

In addition to the compounds formulated for parenteral administration, such as intravenous and/or intramuscular injection, other pharmaceutically acceptable forms include, e.g., tablets and/or other solids for oral administration; liposomal formulations; time release capsules; and/or any other form currently used, including cremes.

One may also use nasal solutions and/or sprays, aerosols and/or inhalants in the present invention. Nasal solutions are usually aqueous solutions designed to be administered to the nasal passages in drops and/or sprays. Nasal solutions are prepared so that they are similar in many respects to nasal secretions, so that normal ciliary action is maintained. Thus, the aqueous nasal solutions usually are isotonic and/or slightly buffered to maintain a pH of 5.5 to 6.5. In addition, antimicrobial preservatives, similar to those used in ophthalmic preparations, and/or appropriate drug stabilizers, if required, may be included in the formulation. Various commercial nasal preparations are known and/or include, for example, antibiotics and/or antihistamines and/or are used for asthma prophylaxis.

Additional formulations which are suitable for other modes of administration include vaginal suppositories and/or pessaries. A rectal pessary and/or suppository may also be used. Suppositories are solid dosage forms of various weights and/or shapes, usually medicated, for insertion into the rectum, vagina and/or the urethra. After insertion, suppositories soften, melt and/or dissolve in the cavity fluids. In general, for suppositories, traditional binders and/or carriers may include, for example, polyalkylene glycols and/or triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably 1%-2%.

Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate and/or the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations and/or powders. In certain defined embodiments, oral pharmaceutical compositions will comprise an inert diluent and/or assimilable edible carrier, and/or they may be enclosed in hard and/or soft shell gelatin capsule, and/or they may be compressed into tablets, and/or they may be incorporated directly with the food of the diet. For oral therapeutic administration, the active compounds may be incorporated with excipients and/or used in the form of ingestible tablets, buccal tables, troches, capsules, elixirs, suspensions, syrups, wafers, and/or the like. Such compositions and/or preparations should contain at

least 0.1% of active compound. The percentage of the compositions and/or preparations may, of course, be varied and/or may conveniently be between about 2 to about 75% of the weight of the unit, and/or preferably between 25-60%. The amount of active compounds in such therapeutically useful compositions is such that a suitable dosage will
5 be obtained.

The tablets, troches, pills, capsules and/or the like may also contain the following: a binder, as gum tragacanth, acacia, cornstarch, and/or gelatin; excipients, such as dicalcium phosphate; a disintegrating agent, such as corn starch, potato starch, alginic
10 acid and/or the like; a lubricant, such as magnesium stearate; and/or a sweetening agent, such as sucrose, lactose and/or saccharin may be added and/or a flavoring agent, such as peppermint, oil of wintergreen, and/or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings and/or to otherwise modify the
15 physical form of the dosage unit. For instance, tablets, pills, and/or capsules may be coated with shellac, sugar and/or both. A syrup or elixir may contain the active compounds sucrose as a sweetening agent methyl and/or propylparabens as preservatives, a dye and/or flavoring, such as cherry and/or orange flavor.

20 G. Kits

Therapeutic kits of the present invention are kits comprising a *Chlamydia psittaci* polynucleotide or polypeptide. Such kits will generally contain, in suitable container means, a pharmaceutically acceptable formulation of a *Chlamydia psittaci* polynucleotide or polypeptide or vector expressing any of the foregoing in a pharmaceutically acceptable
25 formulation. The kit may have a single container means, and/or it may have distinct container means for each compound.

When the components of the kit are provided in one and/or more liquid solutions, the liquid solution is an aqueous solution, with a sterile aqueous solution being
30 particularly preferred. The *Chlamydia psittaci* polynucleotide or polypeptide compositions may also be formulated into a syringeable composition. In which case, the

container means may itself be a syringe, pipette, and/or other such like apparatus, from which the formulation may be applied to an infected area of the body, injected into an animal, and/or even applied to and/or mixed with the other components of the kit.

5 However, the components of the kit may be provided as dried powder(s). When reagents and/or components are provided as a dry powder, the powder can be reconstituted by the addition of a suitable solvent. It is envisioned that the solvent may also be provided in another container means.

10 The container means will generally include at least one vial, test tube, flask, bottle, syringe and/or other container means, into which the *Chlamydia psittaci* polynucleotide or polypeptide formulation are placed, preferably, suitably allocated. The kits may also comprise a second container means for containing a sterile, pharmaceutically acceptable buffer and/or other diluent.

15 The kits of the present invention will also typically include a means for containing the vials in close confinement for commercial sale, such as, *e.g.*, injection and/or blow-molded plastic containers into which the desired vials are retained.

20 Irrespective of the number and/or type of containers, the kits of the invention may also comprise, and/or be packaged with, an instrument for assisting with the injection/administration and/or placement of the ultimate *Chlamydia psittaci* polynucleotide or polypeptide within the body of an animal. Such an instrument may be a syringe, pipette, forceps, and/or any such medically approved delivery vehicle.

25

H. Examples

30 The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the

present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

5

Example 1

Exemplary ELI Protocol

The following sections outline general methodology that one might use to prepare, screen and utilize ELI according to the present invention. Of course the following methods are merely general guidelines and should not limit one of skill in the art from modifying the present invention to accomplish a desired goal using ELI.

1. Library Construction

The present invention provides expression library constructs of genus *Chlamydia psittaci*. An expression library of *C. psittaci* can be produced by first physically shearing the genomic DNA of *C. psittaci* (e.g., *C. psittaci* strain B577) and size-selecting fragments of 300-800 base pairs. The protocol used by the present inventors to produce a *C. psittaci* library is similar to that described in Sykes and Johnston (1999). Adaptors were added and the DNA fragments ligated into a genetic immunization vector (FIG. 2) designed to link fragments to the mouse ubiquitin gene. However, the fragments can be blunt-end cloned.

This vector is known to enhance MHC class I-restricted immune responses (Sykes and Johnston, 1999), while sterilizing immunity against *Chlamydia* is thought to be MHC class II-dependent (Morrison *et al.*, 1995). However, any genetic immunization procedure, by the mechanism of intracellular expression of the inserted genes, will target towards class I antigen presentation. Nevertheless, both MHC class I- and class II-restricted immune responses to the expressed antigens are well documented (Barry *et al.*, 1995; Sykes and Johnston, 1999). The inventors observed, for instance, pronounced delayed-type hypersensitivity responses, mediated by MHC II-restricted CD4⁺ Th1 cells, against protective *C. psittaci* B577 antigens, which were expressed from the ubiquitin fusion vector. In addition to the fact that MHC II-restricted immunity is generated by the

ubiquitin fusion vector, MHC I-restricted immunity appears to mediate protection in the early phase of chlamydial infection (Morrison et al., 1995; Rottenberg et al., 1999). This duality of the cellular immune response generated by the ubiquitin fusion vector might explain the efficacy of this vector for genetic immunization against intracellular bacteria.

5

A library of approximately 82,000 individual members was created and tested as 27 sub-libraries each with 2,400-3,400 plasmid clones. The average insert frequency was approximately 67% and the average insert size was 660 base pairs. Nitrocellulose replica filters were made of each original colony plating of a sub-library pool for subsequent retrieval of positive clones. This generated a library with approximately six-fold expression-equivalent redundancy. One expression equivalent is defined as the number of in-frame fragments necessary to completely represent all authentic open reading frames. Since the genome size of *C. psittaci* is approximately 1×10^6 base pairs and only one-sixth of the actual open-reading frames will be cloned in the right orientation and frame, it requires at least six genomic equivalents to encode one expression equivalent. Each sub-library was propagated on plates and harvested to prepare DNA. DNA representing each sub-library was used for genetic immunization of mice in the following section.

10

15

20

2. Vaccination and Challenge

For the first round of testing, outbred, 6-week old, female NIH-Swiss Webster mice were inoculated with the purified DNA of each sub-library using both intramuscular (i.m.) and epidermal injection. The epidermal injection was effected with a gene gun (Sanford et al., 1991). Each mouse was given 50 μ g DNA i.m. and 5 μ g DNA by gene gun. It has been argued that the gene gun immunization favors a Th2 and the i.m. injection a Th1 type response (Feltquate et al., 1997), therefore both types of injection were given to each group. In the first round of testing, the prime inoculation was followed by a boost 9 weeks later, before intranasal challenge with 3×10^6 inclusion forming units (IFU) of *C. psittaci* strain B577 13 weeks after prime inoculation. The animals were sacrificed 12 days after the challenge, and lungs were weighed.

25

30

3. Library Deconvolution

The basic scheme for handling the reduction of the libraries is depicted in FIG. 3. Fourteen groups out of the first round looked promising, so the individual clones from these groups were picked and grown in 96 well microtiter plates. This gave
5 approximately 40,000 wells in microtiter plates, therefore about 40,000 clones. The second round was reduced using a two dimensional array format. As depicted in FIG. 3, the DNA was prepared from colonies pooled from rows and columns of the array. The rationale was that if a row and column conferred protection, the colonies at the intersection would be responsible. This scheme is premised on largely additive effects of
10 the protective clones. This 24x24 array yielded pools of ~1,700 clones with each intercession having ~96 clones. Currently the inventors deconvolute the second round with a 3-dimesional array.

Since the lung weight was highly variable in the outbred NIH-Swiss mice with
15 variable MHC background, the inventors decided to use inbred BALB/c mice in subsequent rounds. The 48 DNA pools for round two were i.m. injected into BALB/c mice at 50 µg DNA/animal, and the animals were boosted at seven weeks by both gene gun inoculation and i.m. injection. The mice were given a higher *C. psittaci* challenge, 1.6×10^6 IFU *C. psittaci* B577, at approximately 12 weeks, again to further differentiate
20 the groups. Animals were sacrificed and results evaluated as in round one.

In the fourth round, the animals received two boosts rather than one, and the challenge inoculum was increased to 3×10^6 IFU *C. psittaci* B577 to increase the selectivity of protection scoring. Furthermore, because too much DNA may lead to a
25 decrease in cellular immune response, the amount of each individual clone was reduced by half, with the difference made up with pUC118 DNA, so each mouse received a total 50 µg DNA for i.m. immunization, but only 25 µg of the specific clone. The inventors also decreased the gene gun DNA in the same manner: 1.25 µg/ear of the specific clone and 1.25 µg pUC118. Mice were boosted i.m. at both four and nine weeks after prime
30 inoculation, and were challenged. The results of this final round are depicted in FIG. 5.

4. Analysis of Sequences

The clones conferring protection were re-sequenced and then compared by BLAST search to Genbank and particularly to the recently completed *C. pneumoniae* (Kalman et al., 1999) genome sequences (FIG. 6). Of the 14 single genes identified in this study, ten are internal fragments and three contain the C-terminus of the protein. Of the five most protective clones, one was from a putative outer membrane protein and one was from a cell surface protein. The other three were from cytosolic proteins.

Four of the 14 clones have sequence similarity to a class of proteins known as putative outer membrane proteins (POMPs) in *Chlamydia psittaci* and *Chlamydia pneumoniae*. Many of the "putative" outer membrane proteins are known to be localized to the outer membrane and to be highly immunogenic (Longbottom et al., 1996; Tan et al., 1990).

5. Mixing Experiment

The two dimensional approach used to find protective gene fragments assumes that the protection is due to a single highly protective gene within a pool. To verify that such genes would be found, 25 ng (i.e. 1/2000) of either of the two most protective genes was added to a pool that scored negative (pool 6 round 1). As depicted in FIG. 7, spiking with either clone converted the negative library to a positive.

Example 2

Materials and Methods

Library construction. *C. psittaci* strain B577 (ATCC VR-656) was grown in BGMK cells and elementary bodies (EB) were purified by renograff gradient centrifugation as described (Huang et al., 1999). Genomic DNA was isolated from EB by proteinase K and RNase digestion followed by cetyl-trimethyl ammonium bromide (Kaltenbock et al., 1997).

Genomic DNA was physically sheared using a nebulizer (Glas Col, Terra Haute, IN), then size fractionated on a 1.5% TBE agarose gel. Agarose with fragments between

300-700 base pairs was excised and the DNA was electroeluted. Adaptors (top strand 5': GATCTGGATCCCGAT (SEQ ID NO.2) ATCGGGCTCCA (SEQ ID NO.3) onto the fragments, then the fragments were cloned into pCMVi-UBs at the Bgl II site (See FIG. 6 and Sykes and Johnston, 1999 for more details). The ligations were transformed into DH 5 alpha electrocompetent cells and plated onto 150 mm diameter YT-Ampicillin (75 µg/mL final concentration) plates. The resulting plates had between 2400-3400 individual clones per plate. After the plates were incubated overnight at 37°C, the colonies from were lifted using nitrocellulose filters soaked in L-Broth with 8% DMSO, and these filters were stored at -80 °C. The original agar plates were then incubated at 37 °C for an additional six hours. Ten mL of L Broth was added to each plate, the E. coli was scraped into 150 mL of L-Broth and grown at 37 °C for 30 minutes. Ampicillin was then added to a final concentration of 50 µg/mL, and the cultures were grown overnight at 37°C. Cells were pelleted and the DNA was purified using Qiagen tip 500 columns.

Inoculation of DNA. Round One: DNA from the pools was injected into 6-week old female NIH-Swiss mice. All mice received 50 µg total DNA by i.m. injections, evenly distributed between the quadriceps and tibialis anterior muscles. Eighteen of the groups also received gene gun inoculations (wand), with 2.5 µg DNA inoculated into each ear. The animals were boosted once at nine weeks in the same manner as the primary inoculation – all mice received i.m. injections, but only the same 18 groups received gene gun injections -- then intranasally challenged with 5.5×10^5 IFU of *C. psittaci* strain B577 at 13 weeks. The mice were sacrificed 11 days after the challenge, and lungs were weighed.

Round Two: Nitrocellulose filters from the positive pools were placed on L-Broth Bio-Assay plates supplemented with 75 µg/mL ampicillin and 2% agar. The filters were incubated on the plates for approximately 15 minutes, then the nitrocellulose was discarded. The colonies were grown at 30°C for 12 hours. The majority of the colonies were picked into 96 well microtiter plates containing HYT media (1.6% Bacto-tryptone, 1.0% Bacto-yeast extract, 85.5 mM NaCl, 36 mM K₂HPO₄, 13.2 mM KH₂PO₄, 1.7 mM Sodium citrate, 0.4 mM MgSO₄, 6.8 mM ammonium sulfate, 4.4 % wt/vol glycerol)

supplemented with 75 µg/mL ampicillin, using a Hybaid colony picker; the plates were then visually inspected and the remainder of the colonies were hand-picked. The microtiter plates were designated by their original pool number and by the order in which they were picked. Hence, plate 5.10 was from original pool 5 and was the tenth plate
5 picked. The colonies were subdivided into groups as is indicated in FIG. 2. All of the microtiter plates comprising a pool were stamped onto on L-Broth Bio-Assay plates supplemented with 75 µg/mL ampicillin and were grown overnight at 37°C. The cells from these plates were harvested by adding L-Broth to the plates and scraping off the cells. The cells were pelleted by centrifugation then resuspended in Qiagen buffer P1.
10 The remainder of the DNA prep proceeded according to manufacture's instructions.

These 48 DNA pools were i.m. injected into 6-week old BALB/c mice at 50 µg DNA/animal. For the initial inoculation, the mice did not receive gene gun inoculations. At seven weeks, the mice were boosted with 50 µg DNA/animal. In addition to the i.m.
15 injections, the first 31 groups received gene gun (Rumsey-Loomis) inoculations at 2.5 µg DNA/ear; however, the gene gun failed at group 32, and the last 17 groups received only i.m. injections. The mice were given a higher challenge, 1.6×10^6 IFU *C. psittaci* B577, at 12 weeks. Animals were sacrificed as in round one.

20 Round Three: Colonies from the microtiter plates that were judged to be positive were arrayed as in FIG. 2. For each pool, new microtiter plates with HYT media supplemented with 75 µg/mL ampicillin were constructed from all of the colonies which comprise the. Colonies were grown and DNA prepared as in round two.

25 The mice received both gene gun (wand) and i.m. inoculations at the dosage indicated above. At six weeks, the mice were boosted with 50 µg DNA/animal, but only by i.m. injections. The challenge schedule was the same as in Round Two.

30 Round Four: *E. coli* from wells at either full by full protection or full by partial protection was streaked out onto YT-plates supplemented with 75 µg/mL ampicillin. Six colonies from each of the plates were tested by PCR colony screening, using the primers

FS-UB 5': CCGCACCCCTCTCTGATTAC (SEQ ID No: 4) CTGGAGTGGCAACTTCC.
(SEQ ID NO. 5) Colonies with different sizes, hence different inserts, were sequenced
using ABI Big Dye terminator and the FS-UB primer. Samples were purified on G-50
spin columns, and run on an ABI 377 Sequencer. The generated sequences were
5 analyzed for open reading frames using a program designed by Simon Raynor, Ph.D.

Example 3

Vaccination and Challenge

It was established that the weight increase of the infected lung over the lung
10 weight of naïve, uninfected controls (~ 120 mg) correlated strongly with disease
intensity. Maximum disease in this model resulted in approximately 250% lung weight
increase, while further lung weight increases were lethal. The lung disease on day 12
after inoculation was characterized by areas of gross lung tissue consolidation and the
presence of mononuclear interstitial infiltrates in consolidated tissue. Chlamydial
15 inclusions were observed by immunohistochemistry in many macrophages, but rarely in
other cells. Controls for complete protection were established by low level intranasal
infection of naïve mice with 3×10^4 IFU of *C. psittaci* strain B577 4 weeks prior to
challenge. These mice were completely protected from disease after challenge infection
and had lung weight increases of 10-30% compared to naïve animals. Lungs of
20 completely protected mice did not show gross lung lesions, and pathohistological
examination revealed no interstitial infiltrates, but prominent peribronchiolar
lymphocytic cuffs, interpreted as sign of protective immune stimulation. The chlamydial
lung burden on day 11 after challenge was typically $1-3 \times 10^6$ IFU per 100mg lung tissue
in protected, and $2-6 \times 10^6$ IFU per 100 mg lung in diseased animals. Since the lowest
25 chlamydial burden was, however, not consistently associated with lowest disease, the
inventors used the disease-dependent parameter lung weight rather than chlamydial
burden as readout for evaluation of protection. The lung weights were transformed to
relative protection scores in a linear equation that assumed the high average lung weight
of the severely ill, naïve, challenged mice as 0 and that of fully protected controls as 1
30 (FIG. 4).

Example 4

Deconvolution of the Libraries

Since the lung weight was highly variable in the outbred NIH-Swiss mice with variable MHC background, the inventors decided to use inbred BALB/c mice in subsequent rounds. The 48 DNA pools for round two were i.m. injected into BALB/c mice at 50 µg DNA/animal, and the animals were boosted at seven weeks by both gene gun inoculation and i.m. injection. The mice were given a higher *C. psittaci* challenge, 1.6×10^6 IFU *C. psittaci* B577, at approximately 12 weeks, again to further differentiate the groups. Animals were sacrificed and results evaluated as in round one.

The results of the Round two challenge are depicted in FIG. 4. Of the 48 groups from round two, 15 were judged to be positive, giving a total of 3936 wells. These wells were again arrayed as in round two, but the array had 112 colonies per column and 156 per row with 4-5 colonies per intersection (See FIG. 3). The mice received both gene gun and i.m. injections at the dosage indicated above. At six weeks, the mice were boosted. Both the challenge and the sacrifice were performed as in Round two.

The positive 46 colonies from the intersection wells from Round three were sequenced, and those clones with open reading frames greater than 50 amino acids long were prepared individually and shot into mice as single genes and as a pool. Fourteen clones met these criteria. The disease scoring on each pool in rounds 1-3 are depicted in FIG. 4.

In the fourth round, the animals received two boosts rather than one, and the challenge inoculum was increased to 3×10^6 IFU *C. psittaci* B577 to increase the selectivity of protection scoring. Furthermore, because too much DNA may lead to a decrease in cellular immune response, the amount of each individual clone was reduced by half but made up the difference with pUC118 DNA, and each mouse received a total 50 µg DNA for i.m. immunization, but only 25 µg of the specific clone. The inventors also decreased the gene gun DNA in the same manner: 1.25 µg/ear of the specific clone

and 1.25 µg pUC118. Mice were boosted i.m. at both four and nine weeks after prime inoculation, and were challenged. The results of this final round are depicted in FIG. 5.

Example 5

Comparison of clones

Based on the hypothesis that sequences from genes conferring a high level of protection might be selected more than once in the ELI process, the clones were compared against each other for overlaps. Interestingly, one of the clones, CP4 #10, did overlap with another gene, CP4 #11. The gene from which these two clones arise had been partially sequenced (Longbottom et al., 1998).

Two of the genes, CP4 #5 and CP4 #9, had an overlapping region, but they were fused to ubiquitin in opposite orientations. CP4 #5, is composed of two different *C. psittaci* DNA fragments, fused in opposite orientations. The first gene is fused to ubiquitin in the correct orientation and the correct reading frame. Interestingly, the second gene, which is in the opposite orientation to the ubiquitin gene, has an overlapping sequence to CP4 #5. It is doubtful that the protein from the second gene is produced in the mouse.

Example 6

Analysis of Sequences

The clones conferring protection were re-sequenced and then compared by BLAST search to Genbank and particularly to the recently completed *C. pneumoniae* (Kalman et al., 1999) genome sequences (FIG. 6). The full-length *Chlamydia psittaci* genes were next isolated and sequences. Upon analysis, all nucleic acid sequences, except #4, #10, #11, and #12, were previously undisclosed in any context. Further, only portions of the sequences encoding #10 and #11 were previously disclosed.

Since most protective genes would not have been predicted by any bioinformatics or information-based approach, it is likely that one will need to apply an unbiased, global approach, such as ELI to define vaccine candidates.

Table 2, lists a comparison of the *Chlamydia psittaci* genes with homologues from *Chlamydia trachomatis* and *Chlamydia pneumoniae*.

Table 2

| | <i>C. psittaci</i> | <i>C. trachomatis</i> | Identity/ Similarity | <i>C. pneumoniae</i> | Identity/ Similarity |
|---------|--------------------|--|-------------------------|--|-------------------------|
| CP4 #1 | | DNA Pol III Gamma and Tau | 62/73 | DNA Pol III Gamma and Tau | 66/76 |
| CP4 #2 | | Glu-tRNA Gln Amido- transferase (C subunit) | 49/70 | Glu-tRNA Gln Amido- transferase (C subunit) | 48/63 |
| CP4 #3 | | Glu-tRNA Gln Amido- transferase (A subunit) | 71/85 | Glu-tRNA Gln Amido- transferase (A subunit) | 71/84 |
| CP4 #4 | OMP 90A | Outer Membrane Protein 5 | 30/45 | Outer Membrane Protein G Fami | 40/54 |
| CP4 #5 | | Transglycolase/transpeptidase | 67/80 | Outer Membrane Protein G/I Fa | 28/46 |
| CP4 #6 | | Protein Translocase | 80/89 | Transglycolase/transpeptidase | 67/77 |
| CP4 #7 | | | | Protein Translocase | 84/92 |
| CP4 #8 | | Oligopeptidase | 60/75 | Outer Membrane Lipoprotein | 60/79 |
| CP4 #9 | | Hypothetical protein | 62/76 | Oligopeptidase | 61/74 |
| CP4 #10 | | Outer Membrane Protein 4 | 27/42 | Hypothetical protein | 62/77 |
| CP4 #11 | | Outer Membrane Protein 4 | 27/42 | Outer Membrane Protein G fami | 33/51 |
| CP4 #12 | OMP 98 kDa | Outer Membrane Protein 5 | 30/43 | Outer Membrane Protein G famil | 33/51 |
| CP4 #13 | | Protein Translocase | 80/89 | Outer membrane Protein G famil | 44/58 |
| CP4 #14 | | Succinate Dehydrogenase | 60/76 | Protein Translocase | 84/92 |
| | | | | Succinate Dehydrogenase | 61/77 |

Table 3 lists all of the cloned fragments, their corresponding full length nucleotide sequences, and the amino acid sequences encoded by both the fragments and the full length sequences. Table 2 further describes the fragments.

5

TABLE 3—SEQUENCE LISTING INDEX

| <u>SEQ ID NO</u> | <u>CP4 NO</u> | <u>Description</u> |
|------------------|---------------|--|
| SEQ ID NO:6 | CP4 #1 | (fragment) homolog to <i>C. pneumoniae</i> DNA Pol III Gamma and Tau subunits (dnaX2 gene) |
| SEQ ID NO:7 | CP4 #1 | Polypeptide translation corresponding to SEQ ID NO. 6, homolog to <i>C. pneumoniae</i> DNA Pol III Gamma and Tau subunits (dnaX2 gene) |
| SEQ ID NO:8 | CP4 #1 | (full length) homolog to <i>C. pneumoniae</i> DNA Pol III Gamma and Tau subunits (dnaX2 gene) |
| SEQ ID NO:9 | CP4 #1 | Polypeptide translation corresponding to SEQ ID NO. 8, homolog to <i>C. pneumoniae</i> DNA Pol III Gamma and Tau subunits (dnaX2 gene) |
| SEQ ID NO:10 | CP4 #2 | (fragment) homolog to <i>C. pneumoniae</i> Glu-tRNA Gln Amido-transferase (C subunit) (gatC gene) |
| SEQ ID NO:11 | CP4 #2 | Polypeptide translation corresponding to SEQ ID NO. 10, homolog to <i>C. pneumoniae</i> Glu-tRNA Gln Amido-transferase (C subunit) (gatC gene) |
| SEQ ID NO:12 | CP4 #2 | (full length) homolog to <i>C. pneumoniae</i> Glu-tRNA Gln Amido-transferase (C subunit) (gatC gene) |
| SEQ ID NO:13 | CP4 #2 | Polypeptide translation corresponding to SEQ ID NO. 12, homolog to <i>C. pneumoniae</i> Glu-tRNA Gln Amido-transferase (C subunit) (gatC gene) |
| SEQ ID NO:14 | CP4 #3 | (fragment) homolog to <i>C. pneumoniae</i> Glu-tRNA Gln Amido-transferase (A subunit) (gatA gene) |
| SEQ ID NO:15 | CP4 #3 | Polypeptide translation corresponding to SEQ ID NO. 14, homolog to <i>C. pneumoniae</i> Glu-tRNA Gln Amido-transferase (A subunit) (gatA gene) |

| | | |
|--------------|--------|--|
| SEQ ID NO:16 | CP4 #3 | (full length) homolog to <i>C. pneumoniae</i> Glu-tRNA Gln Amido-transferase (A subunit) (gatA gene) |
| SEQ ID NO:17 | CP4 #3 | Polypeptide translation corresponding to SEQ ID NO. 16, homolog to <i>C. pneumoniae</i> Glu-tRNA Gln Amido-transferase (A subunit) (gatA gene) |
| SEQ ID NO:18 | CP4 #3 | (full length) homolog to <i>C. pneumoniae</i> Glu-tRNA Gln Amido-transferase (B subunit) (gatB gene) |
| SEQ ID NO:19 | CP4 #3 | Polypeptide translation corresponding to SEQ ID NO. 18, homolog to <i>C. pneumoniae</i> Glu-Trna Gln Amido-transferase (B subunit) (gatB gene) |
| SEQ ID NO:20 | CP4 #4 | (fragment) <i>C. psittaci</i> 90 kDa outer membrane protein (OMP90A gene) (Previously sequenced by Longbottom, et al), homolog to <i>Chlamydia pneumoniae</i> Outer Membrane Protein G/I (pmp 9) and Outer Membrane Protein G (pmp 5) |
| SEQ ID NO:21 | CP4 #4 | Polypeptide translation corresponding to SEQ ID NO. 20, <i>C. psittaci</i> 90 kDa outer membrane protein (OMP90A gene), homolog to <i>Chlamydia pneumoniae</i> Outer Membrane Protein G/I (pmp 9) and Outer Membrane Protein G (pmp 5) |
| SEQ ID NO:22 | CP4 #4 | (full length) <i>C. psittaci</i> 90 kDa outer membrane protein (OMP90A gene) (Previously sequenced by Longbottom, et al), homolog to <i>Chlamydia pneumoniae</i> Outer Membrane Protein G/I (pmp 9) and Outer Membrane Protein G (pmp 5) |
| SEQ ID NO:23 | CP4 #4 | Polypeptide translation corresponding to SEQ ID NO. 22, <i>C. psittaci</i> 90 kDa outer membrane protein (OMP90A gene), homolog to <i>Chlamydia pneumoniae</i> Outer Membrane Protein G/I (pmp 9) and Outer Membrane Protein G (pmp 5) |
| SEQ ID NO:24 | CP4 #5 | (fragment) homolog to <i>C. pneumoniae</i> transglycolase/transpeptidase (pbp3 gene) |
| SEQ ID NO:25 | CP4 #5 | Polypeptide translation corresponding to SEQ ID NO. 24, homolog to <i>C. pneumoniae</i> transglycolase/transpeptidase (pbp3 gene) |

| | | |
|--------------|-------------|--|
| SEQ ID NO:26 | CP4 #5 | (full length) homolog to <i>C. pneumoniae</i> transglycolase/transpeptidase (pbp3 gene) |
| SEQ ID NO:27 | CP4 #5 | Polypeptide translation corresponding to SEQ ID NO. 26, homolog to <i>C. pneumoniae</i> transglycolase/transpeptidase (pbp3 gene) |
| SEQ ID NO:28 | CP4 #6 | (fragment) homolog to <i>C. pneumoniae</i> Protein Translocase (secA2 gene) |
| SEQ ID NO:29 | CP4 #6 | Polypeptide translation corresponding to SEQ ID NO. 28, homolog to <i>C. pneumoniae</i> Protein Translocase (secA2 gene) |
| SEQ ID NO:30 | CP4 #13 | (fragment) homolog to <i>C. pneumoniae</i> Protein Translocase (secA2 gene) |
| SEQ ID NO:31 | CP4 #13 | Polypeptide translation corresponding to SEQ ID NO. 30, homolog to <i>C. pneumoniae</i> Protein Translocase (secA2 gene) |
| SEQ ID NO:32 | CP4 #6 & 13 | (full length) homolog to <i>C. pneumoniae</i> Protein Translocase (secA2 gene) |
| SEQ ID NO:33 | CP4 #6 & 13 | Polypeptide translation corresponding to SEQ ID NO. 32, homolog to <i>C. pneumoniae</i> Protein Translocase (secA2 gene) |
| SEQ ID NO:34 | CP4 #7 | (fragment) homolog to <i>C. pneumoniae</i> Outer Membrane Lipoprotein (Cpn 0278) |
| SEQ ID NO:35 | CP4 #7 | Polypeptide translation corresponding to SEQ ID NO. 34, homolog to <i>C. pneumoniae</i> Outer Membrane Lipoprotein (Cpn 0278 gene) |
| SEQ ID NO:36 | CP4 #7 | (full length) homolog to <i>C. pneumoniae</i> Outer Membrane Lipoprotein (Cpn 0278) |
| SEQ ID NO:37 | CP4 #7 | Polypeptide translation corresponding to SEQ ID NO. 36, homolog to <i>C. pneumoniae</i> Outer Membrane Lipoprotein (Cpn 0278 gene) |
| SEQ ID NO:38 | CP4 #8 | (fragment) homolog to <i>C. pneumoniae</i> Oligopeptidase (pepF gene) |

| | | |
|--------------|---------|---|
| SEQ ID NO:39 | CP4 #8 | Polypeptide translation corresponding to SEQ ID NO. 38, homolog to <i>C. pneumoniae</i> Oligopeptidase (pepF gene) |
| SEQ ID NO:40 | CP4 #8 | (full length) homolog to <i>C. pneumoniae</i> Oligopeptidase (pepF gene) |
| SEQ ID NO:41 | CP4 #8 | Polypeptide translation corresponding to SEQ ID NO. 40, homolog to <i>C. pneumoniae</i> Oligopeptidase (pepF gene) |
| SEQ ID NO:42 | CP4 #9 | (fragment) homolog to <i>C. pneumoniae</i> gene of unknown function, co-translationally coupled to Yop N Flagellar-Type ATPase (Cpn 0708 gene) |
| SEQ ID NO:43 | CP4 #9 | Polypeptide translation corresponding to SEQ ID NO. 42, homolog to <i>C. pneumoniae</i> gene of unknown function, co-translationally coupled to Yop N Flagellar-Type ATPase (Cpn 0708 gene) |
| SEQ ID NO:44 | CP4 #9 | (full length) homolog to <i>C. pneumoniae</i> gene of unknown function, co-translationally coupled to Yop N Flagellar-Type ATPase (Cpn 0708 gene) |
| SEQ ID NO:45 | CP4 #9 | Polypeptide translation corresponding to SEQ ID NO. 44, homolog to <i>C. pneumoniae</i> gene of unknown function, co-translationally coupled to Yop N Flagellar-Type ATPase (Cpn 0708 gene) |
| SEQ ID NO:46 | CP4 #9 | (full length) homolog to <i>C. pneumoniae</i> Yop N Flagellar-Type ATPase (yscN gene) |
| SEQ ID NO:47 | CP4 #9 | Polypeptide translation corresponding to SEQ ID NO. 46, homolog to <i>C. pneumoniae</i> Yop N Flagellar-Type ATPase (yscN gene) |
| SEQ ID NO:48 | CP4 #10 | (fragment) homolog to <i>C. pneumoniae</i> outer membrane protein G (pmp 2 gene) (Nucleotides 1-423 were previously sequenced by Longbottom <i>et al.</i>) |
| SEQ ID NO:49 | CP4 #10 | Polypeptide translation corresponding to SEQ ID NO. 48, homolog to <i>C. pneumoniae</i> outer membrane protein G (pmp 2 gene) |

| | | |
|--------------|--------------|--|
| SEQ ID NO:50 | CP4 #11 | (fragment) homolog to <i>C. pneumoniae</i> outer membrane protein G (pmp 2 gene) (Nucleotides 1-301 were previously sequenced by Longbottom <i>et al.</i>) |
| SEQ ID NO:51 | CP4 #11 | Polypeptide translation corresponding to SEQ ID NO. 50, homolog to <i>C. pneumoniae</i> outer membrane protein G (pmp 2 gene) |
| SEQ ID NO:52 | CP4 #10 & 11 | (full length) homolog to <i>C. pneumoniae</i> outer membrane protein G (pmp 2 gene). This gene immediately follows the OMP90A gene on <i>C. psittaci</i> , and nucleotides 1-502 were published by Longbottom <i>et al.</i> , although they did not report this as a gene. |
| SEQ ID NO:53 | CP4 #10 & 11 | Polypeptide translation corresponding to SEQ ID NO. 52, homolog to <i>C. pneumoniae</i> outer membrane protein G (pmp 2 gene). |
| SEQ ID NO:54 | CP4 #12 | (fragment) <i>C. psittaci</i> 98 kDa outer membrane protein (POMP gene) (Previously sequenced by Longbottom, et al) |
| SEQ ID NO:55 | CP4 #12 | Polypeptide translation corresponding to SEQ ID NO. 54, <i>C. psittaci</i> 98 kDa outer membrane protein (POMP gene) |
| SEQ ID NO:56 | CP4 #12 | (full length) <i>C. psittaci</i> 98 kDa outer membrane protein (POMP gene) (Previously sequenced by Longbottom <i>et al.</i>) |
| SEQ ID NO:57 | CP4 #12 | Polypeptide translation corresponding to SEQ ID NO. 56, <i>C. psittaci</i> 98 kDa outer membrane protein (POMP gene) |
| SEQ ID NO:58 | CP4 #14 | (fragment) homolog to <i>C. pneumoniae</i> Succinate Dehydrogenase (sdhC) |
| SEQ ID NO:59 | CP4 #14 | Polypeptide translation corresponding to SEQ ID NO. 58, homolog to <i>C. pneumoniae</i> Succinate Dehydrogenase (sdhC gene) |
| SEQ ID NO:60 | CP4 #14 | (full length) homolog to <i>C. pneumoniae</i> Succinate Dehydrogenase (sdhC) |

SEQ ID NO:61 CP4 #14 Polypeptide translation corresponding to SEQ ID
NO. 60, homolog to *C. pneumoniae* Succinate
Dehydrogenase (sdhC gene)

Of the 14 single genes identified in this study, ten are internal fragments and three contain the C-terminus of the protein. Of the five most protective clones (CP4 #1-5), one was from a putative outer membrane protein (CP4 #4) and one was from a cell surface
5 protein (CP4 #5). The other three were from cytosolic proteins, with CP4 #2 and CP4 #3 deriving independently from genes encoding a particular amidotransferase complex.

Four of the 14 clones have sequence similarity to a class of proteins known as putative outer membrane proteins (POMPs) in *Chlamydia psittaci* and *Chlamydia pneumoniae* (CP4 #4, CP4 #10, CP4 #11 and CP4 #12). Many of the “putative” outer
10 membrane proteins are known to be localized to the outer membrane and to be highly immunogenic (Longbottom et al., 1996; Tan et al., 1990). The clone designated CP4 #4 is an in-frame fragment of POMP90A (Longbottom et al., 1998) and CP4 #12 is an in-frame fragment of a 98 kDa POMP which has been completely sequenced (Accession
15 U72499). The clones CP4 #10 and CP4 #11 immediately follow CP4 #4 in the genome and have sequence similarity to POMPs in *C. psittaci*, *C. trachomatis* and *C. pneumoniae*. As stated earlier, the clone CP4 #10 overlaps the CP4 #11 clone. Of these clones only CP4 #4 confers significant protection in isolation so clearly the criteria of being an outer membrane protein is not sufficient to predict a protective vaccine.

20

Example 7

Mixing Experiment

The two dimensional approach used to find protective gene fragments assumes that the protection is due to a single highly protective gene within a pool. To verify that
25 such genes would be found, 25 ng (i.e. 1/2000) of either CP4 #4 or CP4 #11 was added to a pool that scored negative (pool 6 round 1). As depicted in FIG. 7, spiking with either clone converted the negative library to a positive. Of note is that CP4 #11 did not confer protection when tested individually, however, it does protect in combination.

The fact that a CP4 #4 positive library confers protection validates the sensitivity of the system. The fact that a CP4 #11 positive library protects implies that CP4 #11 can be a useful component of a vaccine, but that it may depend upon having other antigens present. A likely explanation is that CP4 #11 is a good vaccine antigen, but requires immunological help.

Example 8

Vaccination in Cattle

An important question is whether the genes identified in this manner in a mouse model are clinically relevant. Of course, this concern is not peculiar to genetic vaccines or ELI, but any system that uses models to identify vaccine candidates. In this case the clinically relevant situation is protection of cattle. In a preliminary experiment, the inventors evaluated the pool of 14 individual clones in the original host in a fertility challenge model. All fourteen clones were used as the individual test data on each clone in mice was not available by the time it was necessary to initiate the cow trial.

TABLE 4.

C. psittaci Vaccine in Cows

| | Percent Pregnant | Pregnant | Not Pregnant |
|-----------------------------------|---------------------|----------|-----------------|
| Not Challenged | 75 | 3 | 1 |
| Challenged, Not Vaccinated | 0 | 0 | 4 |
| EB Vaccine | 25 | 1 | 3 |
| Genetic Vaccine (14 gene pool) | 33 | 2 | 4 |

C. psittaci is normally introduced by the fecal-oral and respiratory routes in cattle, and disseminates to other tissues including reproductive organs. *C. psittaci* infection of

the uterine mucosa reduces fertility, the basis of the economic interest in a *C. psittaci* vaccine. Four groups of heifers were used. One group was the naïve unchallenged control, another the naïve, challenged control, a third received the same pool of fourteen gene fragments that were tested in mice, and the fourth group was vaccinated with an experimental, inactivated vaccine of elementary bodies (EB) and also challenged. This EB vaccine had shown great promise in field trials but is too expensive to produce. After a prime and one boost, the heifers were estrus synchronized by prostaglandin injection, were in heat 2-3 days later, and were artificially inseminated, simultaneously receiving an intracervical chlamydial challenge of 3×10^7 inclusion forming units. The heifers were palpated for pregnancy at six weeks after insemination. This challenge was very high in order to maximize the difference between positive and negative control animals. This was necessary because only a small number of cows could be justified for this high-risk experiment.

Although the animal numbers are small, the results are quite encouraging. As is seen in Table 4, three out of four animals became pregnant in the positive control (non-challenged) group, 0/4 in the negative control (non-vaccinated, challenged) group, 2/6 in the genetic immunization group, and 1/4 in the elementary body vaccine group. The genetic vaccine of the pooled genes performed at least as well as the EB vaccine. Also relative to the inventor's interest in therapeutic vaccines, these cows were not sterile with respect to *C. psittaci* at the time of the prime inoculation. The vaccination was in the face of previous exposure and low level *C. psittaci* infection; as determined by the high titers of preinoculation antichlamydial antibodies, and occasional positivity of *Chlamydia omp1* PCRs from vaginal scrapings.

The next phase in developing a cow vaccine will be to experimentally verify the effectiveness of particular groups of the protective genes and then convert the codon usage of the *C. psittaci* genes to that of a mammal. This should increase the expression of the antigen in cows and increase the effectiveness of the vaccine. The inventors will test different combinations of those genes which have been found to be individually

protective, as well as combinations with CP4 #11. Both the original fragments and their full-length versions can be tested, both as nucleic acid segments and proteins. Once the combinations have been verified in mice or other small mammals, those combinations showing the most promise will be tested in cows. After immunization, the cows will be challenged with *C. psittaci*, either by direct challenge at insemination or infection by herd-mates. Direct challenge at insemination is a very severe and unnatural form of challenge. Therefore, even if protection is not demonstrated in the wake of such challenge, this does not necessarily mean that no protection has been conferred upon the cows.

All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

Example 9

Fertility at 42 days post breeding in heifers vaccinated with the pool of the 5 best mouse-protective genes of *Chlamydia psittaci*.

Because it is known that bacterial genes are not expressed efficiently in mammalian cells, the five most protective genes were chemically resynthesized to give an optimal mammalian codon bias. In addition, the full-length genes corresponding to the fragments isolated in the screen were used.

One group of five heifers was vaccinated with this pool. Another group of six heifers was vaccinated with an Alum-Quil A based vaccine containing per dose 100 µg each of the affinity-purified protein fragments expressed in *E. coli* from these genes. The control group of twelve heifers was vaccinated with a plasmid expressing an unrelated bacterial gene. Six weeks after the initial immunization all groups received booster vaccinations. Eight weeks later all heifers, including a cohort of 27 non-vaccinated heifers, were estrus-synchronized by prostaglandin injection. After coming into heat two to three days later, the non-vaccinated cohort heifers were infected with an intrauterine chlamydial inoculum of 10^8 IFUs *C. psittaci* B577. The function of this group was to shed chlamydiae, and thus to challenge through natural infection routes the vaccinated animals at the time of breeding. Eleven days later, the vaccinated animals were re-synchronized, and inseminated at estrus. The heifers were rectally palpated for pregnancy determination at six weeks after insemination.

The Genetic Vaccine group was vaccinated with DNA comprised of the pool of 5 full length, mammalianized genes, the Protein Vaccine group with the 5 full-length proteins, and the control group with DNA of an unrelated gene from *Salmonella typhimurium*. During the 3-week period prior to *C. psittaci* infection, heifers of all groups, including the non-vaccinated challenge cohort, shed low levels of *C. psittaci* (0.5 ± 0.2 genomes/swab) as determined by qPCR of weekly collected vaginal cytobrush swabs. To challenge the vaccinated animals via natural transmission at the time of breeding, a cohort of 27 non-vaccinated animals was intracervically infected with *C. psittaci*. Eleven days later, all vaccinated groups were estrus-synchronized and inseminated. During the 4 weeks following the infection, the infected cohort animals shed high levels of chlamydiae (3826 ± 2052 genomes per swab), and then returned to low baseline shedding (24.2 ± 10.9 genomes per swab) for the remaining 5-week observation period. All vaccinated heifers were exposed to the natural challenge infection, as evident in their 7-fold increased post-breeding shedding of chlamydiae (3.6 ± 1.2 genomes/swab; $p < 0.05$) compared to pre-breeding shedding of all heifers. No difference in chlamydial shedding before or after breeding was found between the *C. psittaci* vaccinated and the control vaccinated groups.

TABLE 5. Fertility in cows vaccinated with a pool of the 5 best mouse-protective *Chlamydia psittaci* genes.

| Group | Percent Pregnant | Pregnant | Not Pregnant |
|-----------------|------------------|----------|--------------|
| Control Group | 50 | 6 | 6 |
| Genetic Vaccine | 80 | 4 | 1 |
| Protein Vaccine | 83 | 5 | 1 |

As is seen in Table 5, six out of twelve animals (50 % fertility) became pregnant in the control group, 4/5 or (80 % fertility in the genetic vaccine group, and five out of six (83% fertility) in the protein vaccine group. Thus, 9/11 animals in both vaccine groups were pregnant. The genetic vaccine of the pooled genes performed as well as the protein vaccine. These fertility data correspond very well with typical data of bovine herds with and without fertility problems. When both vaccine groups combined are compared to the controls, the 1-tailed Fisher's exact test indicates with a $p = 0.122$ that vaccination is effective to improve *Chlamydia*-induced reduction of fertility. The odds ratio for improvement of fertility by vaccination is 4.5 (0.67-30.23, 95% confidence interval). These data are important in view of the fact that all heifers in the experiment had been previously exposed to chlamydiae and experienced low-level herd infection with *C. psittaci*, as determined by positive *C. psittaci* B577 MOMP-peptide ELISA and sporadic detection by quantitative PCR of low levels of *C. psittaci* in pre-challenge vaginal cytobrush swabs.

REFERENCES

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein
5 by reference.

U. S. Patent No. 5,670,488

U. S. Patent No. 5,770,414

U.S. Patent No. 5,824,544

10 U.S. Patent No. 5,830,725

U.S. Patent No. 5,851,826

U.S. Patent No. 5,858,744

U.S. Patent No. 5,879,934

U.S. Patent No. 5,888,502

15 U.S. Patent No. 5,932,210

U.S. Patent No. 5,955,331

Amado and Chen, "Lentiviral vectors—the promise of gene therapy within reach?"
Science, 285(5428):674-676, 1999.

20 Amado, Mitsuyasu, Zack, "Gene therapy for the treatment of AIDS: animal models and
human clinical experience," *Front Biosci.*, 4:D468-475, 1999.

Babiuk, L. A. "Broadening the approaches to developing more effective vaccines,"
Vaccine 17, 1587-95 1999.

Bangham *et al.*, *J. Mol. Biol.*, 13:238, 1965.

25 Barry, M. A., Lai, W. C., and Johnston, S. A. Protection against mycoplasma infection
using expression-library immunization. *Nature* 377, 632-5 1995.

Batra, Guttridge, Brenner, Dubinett, Baldwin, Boucher, "IkappaBalpha gene transfer is
cytotoxic to squamous-cell lung cancer cells and sensitizes them to tumor necrosis
factor-alpha-mediated cell death," *Am. J. Respir. Cell Mol. Biol.*, 21(2):238-245,
30 1999.

- Bett, Prevec, Graham, "Packaging capacity and stability of human adenovirus type 5 vectors," *J. Virol.*, 67(10):5911-5921, 1993.
- Blackwell, Miller, Douglas, Li, Peters, Carroll, Peters, Strong, Curiel, "Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma,"
5 *Arch. Otolaryngol Head Neck Surg.*, 125(8):856-863, 1999.
- Brayton, K. A., Vogel, S. W., and Allsopp, B. A. Expression library immunization to identify protective antigens from *Cowdria ruminantium*. *Ann N Y Acad Sci* 849, 369-71, 1998.
- Campbell, L. A., C.-C., K., and Grayston, J. T. *Chlamydia pneumoniae* and
10 cardiovascular disease. *Emerging Infectious Disease* 4, 571-579, 1998.
- Carrio, Romagosa, Mercade, Mazo, Nadal, Gomez-Foix, Fillat, "Enhanced pancreatic tumor regression by a combination of adenovirus and retrovirus-mediated delivery of the herpes simplex virus thymidine kinase gene," *Gene Ther.*, 6(4):547-553, 1999.
- 15 Case, Price, Jordan, Yu, Wang, Bauer, Haas, Xu, Stripecke, Naldini, Kohn, Crooks, "Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors," *Proc. Natl. Acad. Sci. USA*, 96(6):2988-2993, 1999.
- Chillon, Bosch, Zabner, Law, Armentano, Welsh, Davidson, "Group D adenoviruses
20 infect primary central nervous system cells more efficiently than those from group C," *J. Virol.*, 73(3):2537-2540, 1999.
- Clay, Custer, Spiess, Nishimura, "Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy fo cancer," *Pathol. Oncol. Res.*, 5(1):3-15, 1999.
- 25 Danesh, J., Collins, R., and Peto, R. Chronic infections and coronary heart disease: is there a link? [see comments]. *Lancet* 350, 430-6, 1997.
- Deamer and Uster, "Liposome Preparation: Methods and Mechanisms," *LIPOSOMES*, M. Ostro ed., 1983.
- Derby, Sena-esteves, Breakefield, Corey, "Gene transfer into the mammalian inner ear
30 using HSV-1 and vaccinia virus vectors," *Hear Res.*, 134(1-2):1-8, 1999.

- Dongji, Z., Xi, Y., Caixia, S., and Brunham, R. C. The immune responses following intramuscular DNA immunization with the MOMP gene of *Chlamydia trachomatis*. In *Chlamydial Infections: Proceedings of the 9th International Symposium on Human Chlamydial Infection.*, e. a. R. Stephens, ed. (Napa, California: University of California Press, Berkeley, USA.), pp. 442-445, 1998.
- 5 Dorai, Perlman, Walsh, Shabsigh, Goluboff, Olsson, Buttyan, "A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells," *Int. J. Cancer*, 82(6):846-852, 1999.
- Ellis, R. W. (1999). New technologies for making vaccines. *Vaccine 17*, 1596-604.
- 10 Engel and Kohn, "Stem cell directed gene therapy," *Front Biosci.*, 4:26-33, 1999.
- Feldman, Tahlil, Steg, "Adenovirus-mediated arterial gene therapy for restenosis: problems and perspectives," *Semin Interv. Cardiol.*, 1(3):203-208, 1996.
- Feltquate, D. M., Heaney, S., Webster, R. G., and Robinson, H. L. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA
- 15 immunization. *J Immunol 158*, 2278-84, 1997.
- Fujiwara and Tanaka, "Molecular surgery for human colorectal cancer with tumor suppressor p53 gene transfer," *Nippon Geka gakkai Zasshi*, 99(7):463-468, 1998.
- Garrido, Carnicero, Lim, Schimmang, "Differential effects on the survival of neuronal and non-neuronal cells after infection by herpes simplex virus type 1 mutants," *J.*
- 20 *Neurovirol.*, 5(30)280-288, 1999.
- Ghosh and Bachhawat, "Targeting of liposomes to hepatocytes," *In: Wu G. Wu C ed., Liver diseases, targeted diagnosis and therapy using specific receptors and ligands*, New York: Marel Dekker, pp. 87-104, 1991.
- Graham and Prevec, "Methods for construction of adenovirus vectors," *Mol. Biotechnol.*,
- 25 3(3):207-220, 1995.
- Grayston, J. T., Woolridge, R. L., and Wang, S.-P. Trachoma vaccine studies on Taiwan. *Ann. NY Acad. Sci.* 98, 352-362, 1962.
- Gregoriadis, *DRUG CARRIERS IN BIOLOGY AND MEDICINE*, G. Gregoriadis (ed.), pp. 287-341, 1979.

- Haecker, Stedman, Balice-Gordon, Smith, Greelish, Mitchell, Wells, Sweeney, Wilson,
"In vivo expression of full-length human dystrophin from adenoviral vectors
deleted of all viral genes," *Hum. Gene Ther.*, 7(15):1907-1914, 1996.
- Hermens and Vergaagen, "Viral vectors, tools for gene transfer in the nervous system,"
5 *Prog. Neurobiol.*, 55(4):399-432, 1998.
- Howard, Kalthoff, Fong, "Ablation of tumor cells *in vivo* by direct injection of HSV-
thymidine kinase retroviral vector and ganciclovir therapy," *Ann. N.Y. Acad. Sci.*,
880-352-365, 1999.
- Huang, J., Wang, M.-D., Lenz, S. D., Gao, D., and Kaltenboeck, B. Interleukin-12
10 administered during *Chlamydia psittaci* lung infection in mice confers immediate
and long-term protection and reduces MIP-2 level and neutrophil infiltration in
lung tissue. *J. Immunol.* 162, 2217-2226, 1999.
- Ilan, Saito, Thummala, Chowdhury, "Adenovirus-mediated gene therapy of liver
diseases," *Semin Liver Dis.*, 19(1):49-59, 1999.
- 15 Irie, Anderegg, Kashani-Sabet, Ohkawa, Suzuki, Halks-Miller, Curiel, Scanlon,
"Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in
experimental bladder cancer," *Antisense Nucleic Acid Drug Dev.*, 9(4):341-349,
1999.
- Johnston, Gasmi, Lim, Elder, Yee, Jolly, Campbell, Davidson, Sauter, "Minimum
20 requirements for efficient transduction of dividing and nondividing cells by
feline immunodeficiency virus vectors," *J. Virol.*, 73(6):4991-5000, 1999.
- Kalman, S., Mitchell, W., Marathe, R., Lammel, C., Fan, J., Hyman, R. W., Olinger, L.,
Grimwood, J., Davis, R. W., and Stephens, R. S. Comparative genomes of
Chlamydia pneumoniae and *C. trachomatis*. *Nature Genetics* 21, 385-389, 1999.
- 25 Kaltenboeck, B., Schmeer, N., and Schneider, R. Evidence for numerous omp1 alleles of
porcine *Chlamydia trachomatis* and novel chlamydial species obtained by PCR. *J*
Clin Microbiol 35, 1835-41, 1997.
- Kaltenboeck, B., Huang, J., Wang, M.-D., Lenz, S. D., and Gao, D. Genetically
determined vigorous innate immunity is associated with protection against
30 primary chlamydial lung infection in mice, but with profound disease
exacerbation in reinfection. In *Chlamydial Infections: Proceedings of the 9th*

- International Symposium on Human Chlamydial Infection, e. a. R. Stephens, ed. (Napa, California: University of California Press), 1998.
- Kaltenboeck, B., Kousoulas, K. G., and Storz, J. Structures of and allelic diversity and relationships among the major outer membrane protein (ompA) genes of the four
5 chlamydial species. *J Bacteriol* 175, 487-502, 1993.
- Kaneda *et al.*, "Increased expression of DNA cointroduced with nuclear protein in adult rat liver," *Science*, 243:375-378, 1989.
- Kato *et al.*, "Expression of hepatitis B virus surface antigen in adult rat liver," *J. Biol. Chem.*, 266:3361-3364, 1991.
- 10 Kaufman, Jia, Tan, Chen, Gabelt, Booth, Tufaro, Cynader, "A perspective of gene therapy in the glaucomas," *Surv. Ophthalmol.*, 43(1S):91-97, 1999.
- Kay, "Hepatic gene therapy for haemophilia B.," *Haemophilia*, 4(4):389-392, 1998.
- Klimatcheva, Rosenblatt, Planelles, "Lentiviral vectors and gene therapy," *Front Biosci.*, 4:D481-496, 1999.
- 15 Lachmann and Efstathiou, "Use of herpes simplex virus type 1 for transgene expression within the nervous system," *Clin. Sci.*, 96(6):533-541, 1999.
- Leibowitz, Beattie, Kafri, Cirulli, Lopez, Hayek, Levine, "Gene transfer to human pancreatic endocrine cells using viral vectors," 48(4):745-753, 1999.
- Lesch, "Gene transfer to the brain: emerging therapeutic strategy in psychiatry," *Biol.*
20 *Psychiatry*, 45(3):247-253, 1999.
- Longbottom, D., Russell, M., Dunbar, S. M., Jones, G. E., and Herring, A. J. Molecular cloning and characterization of the genes coding for the highly immunogenic cluster of 90-kilodalton envelope proteins from the *Chlamydia psittaci* subtype that causes abortion in sheep. *Infect Immun* 66, 1317-24, 1998.
- 25 Longbottom, D., Russell, M., Jones, G. E., Lainson, A., and Herring, A. J. Identification of a multigene family coding for the 90 kDa proteins of the ovine abortion subtype of *Chlamydia psittaci*. *FEMS Microbiology Letters* 142, 277-281, 1996.
- Marienfeld, Haack, Thalheimer, Schneider-Rasp, Brackmann, Poller, "Autoreplication of the vector genome in recombinant adenoviral vectors with different E1 region
30 deletions and transgenes, *Gene Ther.*, 6(6):1101-1113, 1999.

- Miller, Miller, Garcia, Lynch, "Use of retroviral vectors for gene transfer and expression," *Methods Enzymol.*, 217:581-599, 1993.
- Miyake, Suzuki, Matsuoka, Tohyama, Shimada, "Stable integration of human immunodeficiency virus-based retroviral vectors into the chromosomes of nondividing cells," *Hum. Gene Ther.*, 9(4):467-475, 1998.
- Miyatake, Tani, Feigenbaum, Sundaresan, Toda, Narumi, Kikuchi, Hashimoto, Hangai, Martuza, Rabkin, "Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus *in vivo*," *Gene Ther.*, 6(4):564,572, 1999.
- Moldawer, Edwards, Josephs, Minter, Copeland, MacKay, "Application of gene therapy to acute inflammatory diseases," *Shock*, 12(2):83-101, 1999.
- Morrison, Onions, Nicolson, "Complete DNA sequence of canine adenovirus type 1," *J. Gen. Virol.*, 78(Pt4):873-878, 1997.
- Morrison, R. P., Feilzer, K., and Tumas, D. B. Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in *Chlamydia trachomatis* genital tract infection. *Infect. Immun.* 63, 4661-4668, 1995.
- Morrison, R. P., J., B. R., Lyng, K., and Caldwell, H. D. *Chlamydia* disease pathogenesis. The 57-kDa chlamydial hypersensitivity antigen is a stress response protein. *J Exp Med* 170, 1271, 1989.
- Morrison, R. P., Lyng, K., and Caldwell, H. Chlamydial disease pathogenesis: ocular hypersensitivity elicited by a genus-specific 57-kD protein. *J. Exp. Med.* 169, 663-675, 1989.
- Muhlestein, J. B. Bacterial infections and atherosclerosis. *J. Invest. Med.* 46, 396-402, 1998.
- Nicolau *et al.*, "Liposomes as carriers for *in vivo* gene transfer and expression," *Methods Enzymol.*, 149:157-176, 1987.
- Pal, S., Barnhart, K. M., Wei, Q., Abai, A. M., Peterson, E. M., and de la Maza, L. M. Vaccination of mice with DNA plasmids coding for the *Chlamydia trachomatis* major outer membrane protein elicits an immune response but fails to protect against a genital challenge. *Vaccine* 17, 459-65, 1999.

- Petrof, "Respiratory muscles as a target for adenovirus-mediated gene therapy," *Eur. Respir. J.*, 11(2):492-497, 1998.
- Piedrafita, D., Xu, D., Hunter, D., Harrison, R. A., and Liew, F. Y. Protective immune response induced by vaccination with an expression genomic library of *Leishmania major*. *Journal of Immunology* 163, 1467-1472, 1999.
- Quinn Does *Chlamydia pneumoniae* cause coronary heart disease? *Current Opinions in Infectious Diseases* 11, 301-307, 1998.
- Rabinovitch, Suarez-Pinzon, Strynadka, Ju, Edelstein, Brownlee, Korbitt, Rajotte, "Transfection of human pancreatic islets with an anti-apoptotic gene (bcl-2) protects beta-cells from cytokine-induced destruction," *Diabetes*, 48(6):1223-1229, 1999.
- Reddy, Idamakanti, Zakhartchouk, Baxi, Lee, Pyne, Babiuk, Tikoo, "Nucleotide sequence, genome organization, and transcription map of bovine adenovirus type 3," *J. Virol.*, 72(2):1394-1402, 1998.
- Robbins, Tahara, Ghivizzani, "Viral vectors for gene therapy," *Trends Biotech.*, 16(1):35-40, 1998
- Rottenberg, M. E., Gigliotti Rothfuchs, A. C., Gigliotti, D., Svanholm, C., Bandtholtz, L., and Wigzell, H. Role of innate and adaptive immunity in the outcome of primary infection with *Chlamydia pneumoniae*, as analyzed in genetically modified mice. *J. Immunol.*, 2829-2836, 1999.
- Sanford, J. C., Devit, M. J., Russel, J. A., Smith, F. D., Harpending, P. R., Roy, M. K., and Johnston, S. A. An improved, helium-driven biolistic device. *Technique* 3, 3-16, 1991.
- Schachter, J. Overview of human diseases. In *Microbiology of Chlamydia*, A. L. Barron, ed. (Boca Raton, FL: CRC Press, Inc.), pp. 153-165, 1988.
- Smith, "Adenovirus-mediated gene transfer to treat neurologic disease," *Arch. Neurol.*, 55(8):1061-1064, 1998.
- Stamm, W. E. *Chlamydia trachomatis* infections: progress and problems. *J. Inf. Dis.* 179 Suppl 2, S380-383, 1999.
- Stewart, Lassam, Quirt, Bailey, Rotstein, Krajden, Dessureault, Gallinger, Cappe, Wan, Addison, Moen, Gauldie, Graham, "Adenovector-mediated gene delivery of

- interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial," *Gene Ther.*, 6(3):350-363, 1999.
- Storz, J. Antigenic structures and interrelations of PL agents associated with polyarthritis, enzootic abortion, intrauterine and latent intestinal infections. J. Comp. Pathol. 76, 351, 1966.
- Storz, J., and Kaltenboeck, B. Disease diversity of chlamydial infections. In Rickettsial and chlamydial diseases of domestic animals, Z. Woldehiwet and M. Ristic, eds. (Oxford, UK: Pergamon Press), pp. 363-392, 1993.
- Sykes, K. F., and Johnston, S. A. Genetically-live vaccines mimic the antigenicity but not pathogenicity of live viruses. *DNA Cell. Biol.* 18, 521-531, 1999.
- Szoka and Papahadjopoulos, *Proc. Nat'l Acad. Sci. U.S.A.* 75:4194-98, 1978.
- Takahashi, Miyoshi, Verma, Gage, "Rescue from photoreceptor degeneration in the rd mouse by human immunodeficiency virus vector-mediated gene transfer," *J. Virol.*, 73(9):7812-7816, 1999.
- Tan, T. W., Herring, A. J., Anderson, I. E., and Jones, G. E. Protection of sheep against *Chlamydia psittaci* infection with a subcellular vaccine containing the major outer membrane protein. *Infect Immun* 58, 3101-8, 1990.
- Tang, D. C., DeVit, M., and Johnston, S. A. Genetic immunization is a simple method for eliciting an immune response. *Nature* 356, 152-4, 1992.
- Vanderkwaak, Wang, Gomez-Navarro, Rancourt, Dmitriev, Krasnykh, Barnes, Siegal, Alvarez, Curiel, "An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches," *Gynecol. Oncol.*, 74(2):227-234, 1999.
- Vanrompay, D., Cox, E., Vandenbussche, F., Volckaert, G., and Goddeeris, B. Protection against *Chlamydia psittaci* challenge by gene gun-based DNA immunizations. *Vaccine* 17, 2628-2635, 1999.
- Wang, R., Doolan, D. L., Charoenvit, Y., Hedstrom, R. C., Gardner, M. J., Hobart, P., Tine, J., Sedegah, M., Fallarme, V., Sacci jr., J. B., Kaur, M., Klinman, D. M., Hoffman, S. L., and Weiss, W. R. Simultaneous induction of multiple antigen-specific cytotoxic T lymphocytes in nonhuman primates by immunization with a

mixture of four Plasmodium falciparum DNA plasmids. *Infect. Immun.* 66, 4193-4202, 1998.

Weihl, Macdonald, Stoodley, Luders, Lin, "Gene therapy for cerebrovascular disease," *Neurosurgery*, 44(2):239-252, 1999.

5 White, Renda, Nam, Klimatcheva, Zhu, Fisk, Halterman, Rimel, Federoff, Pandya, Rosenblatt, Planelles, "Lentivirus vectors using human and simian immunodeficiency virus elements," *J. Virol.*, 73(4):2832-2840, 1999.

Wilson, "Adenoviruses as gene-delivery vehicles," *N. Engl. J. Med.*, 334(18):1185-1187, 1996.

10 Wong *et al.*, "Appearance of β -lactamase activity in animal cells upon liposome mediated gene transfer," *Gene*, 10:87-94, 1980.

Wu, "Recent advances in gene therapy of GI and liver diseases," 39(5):297-300, 1998.

Yeung, Bockhold, Tufaro, "Efficient infection of mature skeletal muscle with herpes simplex virus vectors by using dextran sulfate as a co-receptor," *Gene Ther.*,
15 6(9):1536-1544, 1999.

Yoon, Carroll, Chiocca, Tanabe, "Influence of p53 on herpes simplex virus type 1 vectors for cancer gene therapy," *J. Gastrointest. Surg.*, 3(10):34-48, 1999.

Zheng, Graham, Prevec, "Transcription units of E1a, E1b and pIX regions of bovine adenovirus type 3," *J. Gen. Virol.*, 80(Pt7):1735-1742, 1999.

WHAT IS CLAIMED IS:

1. An isolated polynucleotide comprising a region having a sequence of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:58, or SEQ ID NO:60, or fragment thereof.
2. An isolated polynucleotide comprising a region having a sequence having at least 17 contiguous nucleotides in common with at least one of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:58, or SEQ ID NO:60, or its complement.
3. The isolated polynucleotide of claim 2, further defined as comprising a sequence having least 50 contiguous nucleotides in common with at least one of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:58, or SEQ ID NO:60, or its complement.
4. The isolated polynucleotide of claim 3, further defined as comprising a sequence having all nucleotides in common with at least one of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:58, or SEQ ID NO:60, or its complement.

5. A polypeptide having a sequence of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:59, SEQ ID NO:61 or fragment thereof.

6. The polypeptide of claim 5, further defined as a recombinant polypeptide.

7. A method of producing a polypeptide having a sequence of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:59, SEQ ID NO:61 or fragment thereof, comprising:

- a) obtaining a polynucleotide comprising a region encoding the sequence;
and
- b) expressing the polynucleotide to obtain the polypeptide.

8. The method of claim 7, wherein the polynucleotide has a region having a sequence of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:58, or SEQ ID NO:60, or fragment thereof

9. An antibody directed against an antigen having sequence of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID

NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, or SEQ ID NO:61, or antigenic fragment thereof.

10. The antibody of claim 9, further defined as a monoclonal antibody.

11. A vaccine for the immunization of an animal against *Chlamydia psittaci* comprising:

- (a) a pharmaceutically acceptable carrier, and
- (b) at least one polynucleotide having a *Chlamydia psittaci* sequence.

12. The vaccine of claim 11, further defined as a vaccine for the immunization of a bovine.

13. The vaccine of claim 11, wherein the at least one polynucleotide has a sequence isolated from a *Chlamydia psittaci* genomic DNA expression library

14. The vaccine of claim 11, wherein the at least one polynucleotide has a sequence of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, or SEQ ID NO:60, or fragment thereof.

15. The vaccine of claim 14, wherein the at least one polynucleotide has a sequence of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, or SEQ ID NO:26, or fragment thereof.

16. The vaccine of claim 14, wherein the at least one polynucleotide has a sequence of SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, SEQ ID NO:20, or SEQ ID NO:24.

17. The vaccine of claim 11, wherein the polynucleotide is comprised in a genetic immunization vector.

5 18. The vaccine of claim 17, wherein the vector comprises a gene encoding a mouse ubiquitin fusion polypeptide.

19. The vaccine of claim 17, wherein the vector comprises a promoter operable in eukaryotic cells.

10 20. The vaccine of claim 19, wherein the promoter is a CMV promoter.

21. The vaccine of claim 11, wherein the polynucleotide is cloned into a viral expression vector.

15 22. The vaccine of claim 21, wherein the viral expression vector is selected from the group consisting of adenovirus, adeno-associated virus, retrovirus and herpes-simplex virus.

20 23. The vaccine of claim 11, comprising a polynucleotide encoding aN antigen having a sequence of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, or SEQ ID NO:61, or antigenic fragment thereof.

25 24. The vaccine of claim 11, comprising at least a first polynucleotide having a *Chlamydia psittaci* sequence and a second polynucleotide having a *Chlamydia psittaci*

30

sequence, wherein the first polynucleotide and the second polynucleotide have different *Chlamydia psittaci* sequences.

25. The vaccine of claim 24, wherein the first polynucleotide has a sequence of SEQ ID NO:50.

26. A vaccine for the immunization of an animal against *Chlamydia psittaci* comprising:

- (a) a pharmaceutically acceptable carrier; and
- (b) at least one *Chlamydia psittaci* antigen.

27. The vaccine of claim 26, further defined as a vaccine for the immunization of a bovine.

28. The vaccine of claim 26, wherein the at least one *Chlamydia psittaci* antigen has a sequence of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, or SEQ ID NO:61, or antigenic fragment thereof.

29. The vaccine of claim 26, wherein the at least one *Chlamydia psittaci* antigen has a sequence of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, or SEQ ID NO:27, or an antigenic fragment thereof.

30. The vaccine of claim 26, wherein the at least one *Chlamydia psittaci* antigen has a sequence of SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:21, or SEQ ID NO:25.

31. A method of immunizing a bovine comprising providing to the bovine at least one *Chlamydia psittaci* antigen, or antigenic fragment thereof, in an amount effective to induce an immune response.

5

32. The method of claim 31, wherein the at least one *Chlamydia psittaci* antigen has a sequence of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, or SEQ ID NO:61, or an antigenic fragment thereof.

10

15

33. The method of claim 31, wherein the provision of the at least one *Chlamydia psittaci* antigen comprises:

- (a) preparing a cloned expression library from fragmented genomic DNA, cDNA or sequenced genes of *Chlamydia psittaci*;
- (b) administering at least one clone of the library in a pharmaceutically acceptable carrier into the bovine; and
- (c) expressing at least one *Chlamydia psittaci* antigen in the bovine.

20

34. The method of claim 33, wherein the expression library comprises at least one or more polynucleotide having a sequence of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, or SEQ ID NO:60, or fragment thereof.

30

35. The method of claim 34, wherein the expression library is cloned in a genetic immunization vector of SEQ ID NO:1.

36. The method of claim 35, wherein the vector comprises a gene encoding a mouse ubiquitin fusion polypeptide designed to link the expression library polynucleotides to the ubiquitin gene.

37. The method of claim 36, wherein the vector comprises a promoter operable in eukaryotic cells.

38. The method of claim 37, wherein the promoter is a CMV promoter.

39. The method of claim 34, wherein the polynucleotide is administered by a intramuscular injection or epidermal injection.

40. The method of claim 34, wherein the polynucleotide is administered by intravenous, subcutaneous, intralesional, intraperitoneal, oral or inhaled routes of administration.

41. The method of claim 39, wherein a second intramuscular injection and epidermal injection are administered at least about three weeks after the first injection.

42. The method of claim 34, wherein the polynucleotide is cloned into a viral expression vector.

43. The method of claim 31, wherein the provision of the *Chlamydia psittaci* antigen(s) comprises:

- (a) preparing a pharmaceutical composition comprising at least one polynucleotide having a sequence of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24,

SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32,
 SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40,
 SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48,
 SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56,
 SEQ ID NO: 58, or SEQ ID NO:60, or fragment thereof;

- (b) administering one or more clones of the library in a pharmaceutically acceptable carrier into the bovine; and
- (c) expressing one or more *Chlamydia psittaci* antigens in the bovine.

44. The method of claim 43, wherein the one or more polynucleotides is in one or more expression vectors.

45. The method of claim 44, wherein the one or more polynucleotides is cloned in a genetic immunization vector of SEQ ID NO:1.

46. The method of claim 31, wherein the provision of the *Chlamydia* antigen(s) comprises:

- (a) preparing a pharmaceutical composition of at least one *Chlamydia* antigen having a sequence of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, or SEQ ID NO:61, or an antigenic fragment thereof; and
- (b) administering the at least one antigen or fragment into the bovine.

47. The method of claim 46, wherein the antigen(s) is administered by a first intramuscular injection, intravenous injection, parenteral injection, epidermal injection, inhalation or oral route.

48. The method of claim 47, wherein a second intramuscular injection, intravenous injection, parenteral injection or epidermal injection is administered at least about three weeks after the first injection.

5

49. A method of assaying for the presence of *Chlamydia psittaci* infection in an animal comprising:

- (a) obtaining an antibody directed against a *Chlamydia psittaci* antigen;
- (b) obtaining a sample from the animal;
- (c) admixing the antibody with the sample; and
- (d) assaying the sample for antigen-antibody binding,

10

wherein the antigen-antibody binding indicates *Chlamydia psittaci* infection in the animal.

15

50. The method of claim 49, wherein the animal is a bovine.

51. The method of claim 49, wherein the antibody directed against the antigen is further defined as a monoclonal antibody.

20

52. The method of claim 49, wherein assaying the sample for antigen-antibody binding is by precipitin reaction, radioimmunoassay, ELISA, Western blot or immunofluorescence.

25

53. A kit for assaying a *Chlamydia psittaci* infection comprising, in a suitable container:

- (a) a pharmaceutically acceptable carrier; and
- (b) an antibody directed against a *Chlamydia psittaci* antigen.

30

54. A method of assaying for the presence of a *Chlamydia psittaci* infection in a bovine comprising:

- 5 (a) obtaining an oligonucleotide probe comprising a sequence comprised within SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO: 58, or SEQ ID NO:60, or a complement thereof; and
- 10 (b) employing the probe in a PCR detection protocol.




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6

Chlamydia psittaci Addition Experiments




FIG. 7

SEQUENCE LISTING

<110> JOHNSTON, STEPHEN A.
STEMKE-HALE, KATHERINE
SYKES, KATHRYN F.
KALTENBOECK, BERNHARD

<120> METHODS AND COMPOSITIONS FOR VACCINATION COMPRISING
NUCLEIC ACID AND/OR POLYPEPTIDE SEQUENCES OF
CHLAMYDIA PSITTACI

<130> UTSD:659

<140> UNKNOWN

<141> 2000-12-15

<160> 61

<170> PatentIn Ver. 2.1

<210> 1

<211> 127

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Primer

<400> 1

ctgcacctgg tccttcgcct gagaggtgca gatcttggat cctaagtaag taagcttgca 60
tgcctgcagg tcgactctag gtgactaata tctagaggat cgatcccggg tggcatccct 120
gtgaccc 127

<210> 2

<211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Primer

<400> 2

gatctggatc ccgat 15

<210> 3

<211> 11

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Primer

<400> 3

atcgggctcc a

11

<210> 4

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Primer

<400> 4

ccgcaccctc tctgattac

19

<210> 5

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Primer

<400> 5

ctggagtggc aacttcc

17

<210> 6

<211> 449

<212> DNA

<213> Chlamydia psittaci
e

<400> 6

| | | | | | | |
|-------------|-------------|------------|------------|------------|------------|-----|
| gaatgtattc | gcacgcaaaa | atacgctgaa | gctttgcttc | ctgtcacgac | agcgatcaat | 60 |
| tctggagtcg | cgcctatcac | cttcctccat | gacctcactg | ttttttatcg | cgatgtactg | 120 |
| ctaaacaaag | atcagggaaa | ttctcctcta | tcggccatcg | ccatgcacta | ttccagtga | 180 |
| tgtttattag | aatcattga | tttccttgg | gaagcggcca | aacatctaca | acaaactatt | 240 |
| tttgaaaaaa | cattttttaga | aacagtcata | atccatctta | ttcggatatg | ccaacgtccc | 300 |
| tcttttagaaa | ctctgttttc | tcaactgaaa | acatccacgt | ttgatacagt | gagaaacgta | 360 |
| ccccagcagc | aagaaccctc | gaaaccgagt | atacaacctg | aaaaacacta | tcaagatcag | 420 |
| agttttcttaa | cttcaccttc | tcccacgcc | | | | 449 |

<210> 7

<211> 149

<212> PRT

<213> Chlamydia psittaci

<400> 7

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Glu | Cys | Ile | Arg | Thr | Gln | Lys | Tyr | Ala | Glu | Ala | Leu | Leu | Pro | Val | Thr |
| 1 | | | | | 5 | | | | 10 | | | | | 15 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Thr | Ala | Ile | Asn | Ser | Gly | Val | Ala | Pro | Ile | Thr | Phe | Leu | His | Asp | Leu |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|

| | | |
|---|-----|-----|
| 20 | 25 | 30 |
| Thr Val Phe Tyr Arg Asp Val Leu Leu Asn Lys Asp Gln Gly Asn Ser | | |
| 35 | 40 | 45 |
| Pro Leu Ser Ala Ile Ala Met His Tyr Ser Ser Glu Cys Leu Leu Glu | | |
| 50 | 55 | 60 |
| Ile Ile Asp Phe Leu Gly Glu Ala Ala Lys His Leu Gln Gln Thr Ile | | |
| 65 | 70 | 75 |
| Phe Glu Lys Thr Phe Leu Glu Thr Val Ile Ile His Leu Ile Arg Ile | | |
| 85 | 90 | 95 |
| Cys Gln Arg Pro Ser Leu Glu Thr Leu Phe Ser Gln Leu Lys Thr Ser | | |
| 100 | 105 | 110 |
| Thr Phe Asp Thr Val Arg Asn Val Pro Gln Gln Gln Glu Pro Ser Lys | | |
| 115 | 120 | 125 |
| Pro Ser Ile Gln Pro Glu Lys His Tyr Gln Asp Gln Ser Phe Leu Thr | | |
| 130 | 135 | 140 |
| Ser Pro Ser Pro Thr | | |
| 145 | | |

<210> 8

<211> 1332

<212> DNA

<213> Chlamydia psittaci

<400> 8

| | | | | | | |
|-------------|-------------|------------|-------------|------------|-------------|------|
| atgacatcag | caacatacca | agtttcttct | agaaaatacc | gccctcaaac | atttgccgaa | 60 |
| atgctggggc | aagatgccgt | ggtcactggt | ttaaaaaatg | ctttgcagtt | tcaacgtgtc | 120 |
| gcgcatgcgt | atttattttc | agggattcgc | ggaacaggaa | aaacaacttt | agcaagaatc | 180 |
| tttgcaaaag | ccttaaactg | taaagagctg | actcctgaac | atgaaccatg | caaccagtgt | 240 |
| tgtgtttgta | aagaaatctc | ttcaggaacc | tccttagacg | tgatcgaaat | cgatggtgcc | 300 |
| tcgcaccgag | gtattgaaga | tatccgtcaa | atcaatgaaa | ccgtgctctt | tactcctgcc | 360 |
| aaatcacat | ataaaatcta | tatcatagat | gaagtccata | tgctgactaa | ggaggcgttt | 420 |
| aattccttac | tcaaaacttt | agaagagcct | ccgagccatg | taaaattctt | cttagcgact | 480 |
| acagaaaatt | ataaaaatacc | cagcaccatt | ttaagtcggt | gtcaaaaaat | gcacctaaag | 540 |
| agaattcctg | agacaatgat | tgtagataag | ctagcatcca | tatctcaagc | aggtgggata | 600 |
| gaaacctctc | gagaagctct | tcttcctatt | gctagagcag | cacagggaag | cttacgcgat | 660 |
| gctgaatctc | tttatgatta | tgtcataggg | ttattcccta | catctttatc | cccagagttg | 720 |
| gttgacagacg | cattaggttt | attatctcaa | gacaccttag | ctacattatc | agaatgtatt | 780 |
| cgcacgcaaa | aatacgctga | agctttgctt | cctgtcacga | cagcgatcaa | ttctggagtc | 840 |
| gcgcctatca | ccttcctcca | tgacctcact | gtttttttatc | gcgatgtact | gctaaacaaa | 900 |
| gatcagggaa | attctcctct | atcggccatc | gccatgcact | attccagtga | atgtttatta | 960 |
| gaaatcattg | atttccttgg | tgaagcggcc | aaacatctac | aacaaactat | ttttgaaaaa | 1020 |
| acatttttag | aaacagtcac | catccatctt | attcggatat | gccaacgtcc | ctcttttagaa | 1080 |
| actctgtttt | ctcaactgaa | aacatccacg | tttgatacag | tgagaaacgt | accccagcag | 1140 |
| caagaaccct | cgaaaccgag | tatacaacct | gaaaaaact | atcaagatca | gagttttctta | 1200 |
| acttcacctt | ctcccacgcc | aaaagttcag | catcaaaaag | aagcttcccc | ttcttttagtg | 1260 |
| ggatcagcta | ctatagatac | gctttttaca | tttgctgttg | ttgagttttc | cggaatttta | 1320 |
| accaaggagt | aa | | | | | 1332 |

<210> 9

<211> 443

<212> PRT

<213> Chlamydia psittaci

<400> 9

```

Met Thr Ser Ala Thr Tyr Gln Val Ser Ser Arg Lys Tyr Arg Pro Gln
 1          5          10          15

Thr Phe Ala Glu Met Leu Gly Gln Asp Ala Val Val Thr Val Leu Lys
          20          25          30

Asn Ala Leu Gln Phe Gln Arg Val Ala His Ala Tyr Leu Phe Ser Gly
          35          40          45

Ile Arg Gly Thr Gly Lys Thr Thr Leu Ala Arg Ile Phe Ala Lys Ala
          50          55          60

Leu Asn Cys Lys Glu Leu Thr Pro Glu His Glu Pro Cys Asn Gln Cys
          65          70          75          80

Cys Val Cys Lys Glu Ile Ser Ser Gly Thr Ser Leu Asp Val Ile Glu
          85          90          95

Ile Asp Gly Ala Ser His Arg Gly Ile Glu Asp Ile Arg Gln Ile Asn
          100          105          110

Glu Thr Val Leu Phe Thr Pro Ala Lys Ser Gln Tyr Lys Ile Tyr Ile
          115          120          125

Ile Asp Glu Val His Met Leu Thr Lys Glu Ala Phe Asn Ser Leu Leu
          130          135          140

Lys Thr Leu Glu Glu Pro Pro Ser His Val Lys Phe Phe Leu Ala Thr
          145          150          155          160

Thr Glu Asn Tyr Lys Ile Pro Ser Thr Ile Leu Ser Arg Cys Gln Lys
          165          170          175

Met His Leu Lys Arg Ile Pro Glu Thr Met Ile Val Asp Lys Leu Ala
          180          185          190

Ser Ile Ser Gln Ala Gly Gly Ile Glu Thr Ser Arg Glu Ala Leu Leu
          195          200          205

Pro Ile Ala Arg Ala Ala Gln Gly Ser Leu Arg Asp Ala Glu Ser Leu
          210          215          220

Tyr Asp Tyr Val Ile Gly Leu Phe Pro Thr Ser Leu Ser Pro Glu Leu
          225          230          235          240

Val Ala Asp Ala Leu Gly Leu Leu Ser Gln Asp Thr Leu Ala Thr Leu
          245          250          255

Ser Glu Cys Ile Arg Thr Gln Lys Tyr Ala Glu Ala Leu Leu Pro Val
          260          265          270

```

Thr Thr Ala Ile Asn Ser Gly Val Ala Pro Ile Thr Phe Leu His Asp
 275 280 285
 Leu Thr Val Phe Tyr Arg Asp Val Leu Leu Asn Lys Asp Gln Gly Asn
 290 295 300
 Ser Pro Leu Ser Ala Ile Ala Met His Tyr Ser Ser Glu Cys Leu Leu
 305 310 315 320
 Glu Ile Ile Asp Phe Leu Gly Glu Ala Ala Lys His Leu Gln Gln Thr
 325 330 335
 Ile Phe Glu Lys Thr Phe Leu Glu Thr Val Ile Ile His Leu Ile Arg
 340 345 350
 Ile Cys Gln Arg Pro Ser Leu Glu Thr Leu Phe Ser Gln Leu Lys Thr
 355 360 365
 Ser Thr Phe Asp Thr Val Arg Asn Val Pro Gln Gln Gln Glu Pro Ser
 370 375 380
 Lys Pro Ser Ile Gln Pro Glu Lys His Tyr Gln Asp Gln Ser Phe Leu
 385 390 395 400
 Thr Ser Pro Ser Pro Thr Pro Lys Val Gln His Gln Lys Glu Ala Ser
 405 410 415
 Pro Ser Leu Val Gly Ser Ala Thr Ile Asp Thr Leu Leu Gln Phe Ala
 420 425 430
 Val Val Glu Phe Ser Gly Ile Leu Thr Lys Glu
 435 440

<210> 10
 <211> 123
 <212> DNA
 <213> Chlamydia psittaci

<400> 10
 gagtttatttc aagagtatga aagttcttta aatgaagtca ttaaaactat ggcagcatcc 60
 atcgctatgg atgtaaccga cgtgggttatt gaggttggtt tatcccatgt gatcagtc 120
 gaa 123

<210> 11
 <211> 41
 <212> PRT
 <213> Chlamydia psittaci

<400> 11
 Glu Phe Ile Gln Glu Tyr Glu Ser Ser Leu Asn Glu Val Ile Lys Thr
 1 5 10 15
 Met Ala Ala Ser Ile Ala Met Asp Val Thr Asp Val Val Ile Glu Val
 20 25 30

Gly Leu Ser His Val Ile Ser Pro Glu
 35 40

<210> 12

<211> 303

<212> DNA

<213> Chlamydia psittaci

<400> 12

atgacacaac cctatgtaac tagagaagac attatacttc tggcgaagag ttcagctctg 60
 gaattaagcg aagagtttat tcaagagtat gaaagttctt taaatgaagt cattaact 120
 atggcagcat ccatcgctat ggatgtaacc gacgtgggta ttgaggttg tttatcccat 180
 gtgatcagtc ccgaagattt acgagaagat atcgttgccct caagtttctc tcgtgaggag 240
 tttctaacta atgtccctga atccttaggg ggattagtaa aagtaccac agtcattaag 300
 tag 303

<210> 13

<211> 100

<212> PRT

<213> Chlamydia psittaci

<400> 13

Met Thr Gln Pro Tyr Val Thr Arg Glu Asp Ile Ile Leu Leu Ala Lys
 1 5 10 15

Ser Ser Ala Leu Glu Leu Ser Glu Glu Phe Ile Gln Glu Tyr Glu Ser
 20 25 30

Ser Leu Asn Glu Val Ile Lys Thr Met Ala Ala Ser Ile Ala Met Asp
 35 40 45

Val Thr Asp Val Val Ile Glu Val Gly Leu Ser His Val Ile Ser Pro
 50 55 60

Glu Asp Leu Arg Glu Asp Ile Val Ala Ser Ser Phe Ser Arg Glu Glu
 65 70 75 80

Phe Leu Thr Asn Val Pro Glu Ser Leu Gly Gly Leu Val Lys Val Pro
 85 90 95

Thr Val Ile Lys
 100

<210> 14

<211> 514

<212> DNA

<213> Chlamydia psittaci

<400> 14

gaaaagtgtg atgtgattgc gatgcctgta tgctcatgcc cagcattcgc cgatggcgaa 60
 atccttgatc ctacctctct atatctccag gatattctata ccgtggctat gaatttagcc 120
 tacctcccag ctatcgccgt tccttcaggg ttttctcgag aagggtgcc tctaggattc 180
 caggtgattg gacaaaaggg taaagatcaa caggtgtgcc aggtaggcta tagcttccaa 240

```

gaacattcag gaattaagaa tttataccct aaaggatgta acaaacttgt tgatggagag 300
gtgaaataat gagcgacgtt tatgctgatt gggaatccgt cataggtctt gaagtccacg 360
tagaattaaa cacaaaatct aaattgttca gttgtgcacg caaccgtttt ggagacgaac 420
ctaatacaaa catctctcct gtatgcaccg gcatgccggg gtcactgcca gtactgaata 480
aagaagcagt gagaaaggct gttttatttg gttg 514

```

<210> 15

<211> 102

<212> PRT

<213> Chlamydia psittaci

<400> 15

```

Glu Lys Cys Asp Val Ile Ala Met Pro Val Cys Ser Cys Pro Ala Phe
  1                      5                      10                      15

```

```

Ala Asp Gly Glu Ile Leu Asp Pro Thr Ser Leu Tyr Leu Gln Asp Ile
          20                      25                      30

```

```

Tyr Thr Val Ala Met Asn Leu Ala Tyr Leu Pro Ala Ile Ala Val Pro
          35                      40                      45

```

```

Ser Gly Phe Ser Arg Glu Gly Leu Pro Leu Gly Phe Gln Val Ile Gly
          50                      55                      60

```

```

Gln Lys Gly Lys Asp Gln Gln Val Cys Gln Val Gly Tyr Ser Phe Gln
          65                      70                      75                      80

```

```

Glu His Ser Gly Ile Lys Asn Leu Tyr Pro Lys Gly Cys Asn Lys Leu
          85                      90                      95

```

```

Val Asp Gly Glu Val Lys
          100

```

<210> 16

<211> 1476

<212> DNA

<213> Chlamydia psittaci

<400> 16

```

atgtatcaga agagtgcctt agagttaaga aatgccgtag tgagtggaga gtcttcagct 60
acagcaatag caaagtatth ttataataga ataaaaacag aagacaatca gataggagct 120
tttctttctc tttgtgaaga aagagcttat gagaaagcag ctatcataga tgcgaaagtg 180
gcgcgaggag aacctttggg gaaactcgca ggtgtcccca tcgggataaa agataatatt 240
catattcggg gtttgcgcac cacttgtgct tctaaaatgt tagaaaatta tatagcgcct 300
tttgatgcta cagtcgtcga acggatagaa gctgaagatg gggatcatttt aggcaaactc 360
aatatggatg agtttgctat gggatcgaca acgcagtatt ctgctttcca tcctacgaaa 420
aatccttggg gtttatcctg tgtgccagga ggatccttcag ggggatccgc cgccgcagtt 480
tctgcaagat tttgtcctat agcgttaggt tcggataaccg gtggatctat acgtcagcca 540
gcagcatttt gtggagtgtt ggggtttaag ccctcctatg gagccgtctc ccgttacggt 600
ttagtcgctt ttgggtcttc attagatcag ataggccctt taacaacagt tgtcgaagat 660
gtcgccttag ctatggatgt attcgcaggt aaggatgata gagatgcaac ttctcagaag 720
ttttttacag gatctttcca agaggccttg tcttttagacg ttccgagttt gatcggcggtg 780
cctatgggat ttttagacgg tttacgtgat gatgttaaag agaatttctt tgcctcttta 840
agtatttttg aacgtcaggg tagccgcatt gttgaagtgg atcttaacat cttagatcac 900
gctgtctctg tttactacat tgctgccttct gcagaagccg caacaaatct tgcaagatth 960

```

```

gatgggtattc gttacggcta tcgttctcca gaagcgcata gtatagaaga tatttatacg 1020
atctcccgcg tacaaggctt cggtaaggaa gtcatgcgta ggattctttt aggtaactat 1080
gtgttatcca ctgagcgcca aaatgtctat tataagaaag gctccgcaat tcgagcaaaa 1140
atcattcaag cttttcaaaa agcttatgaa aagtgtgatg tgattgcgat gcctgtatgc 1200
tcatgccag cattcgccga tggcgaaatc cttgatccta cctctctata tctccaggat 1260
atctataccg tggctatgaa tttagcctac ctcccagcta tcgccgttcc ttcagggttt 1320
tctcgagaag ggctgcctct aggattccag gtgattggac aaaagggtaa agatcaacag 1380
gtgtgccagg taggctatag cttccaagaa cattcaggaa ttaagaattt ataccctaaa 1440
ggatgtaaca aacttggtga tggagaggtg aaataa 1476

```

<210> 17

<211> 491

<212> PRT

<213> Chlamydia psittaci

<400> 17

```

Met Tyr Gln Lys Ser Ala Leu Glu Leu Arg Asn Ala Val Val Ser Gly
  1          5          10          15
Glu Ser Ser Ala Thr Ala Ile Ala Lys Tyr Phe Tyr Asn Arg Ile Lys
          20          25          30
Thr Glu Asp Asn Gln Ile Gly Ala Phe Leu Ser Leu Cys Glu Glu Arg
          35          40          45
Ala Tyr Glu Lys Ala Ala Ile Ile Asp Ala Lys Val Ala Arg Gly Glu
          50          55          60
Pro Leu Gly Lys Leu Ala Gly Val Pro Ile Gly Ile Lys Asp Asn Ile
          65          70          75          80
His Ile Arg Gly Leu Arg Thr Thr Cys Ala Ser Lys Met Leu Glu Asn
          85          90          95
Tyr Ile Ala Pro Phe Asp Ala Thr Val Val Glu Arg Ile Glu Ala Glu
          100          105          110
Asp Gly Val Ile Leu Gly Lys Leu Asn Met Asp Glu Phe Ala Met Gly
          115          120          125
Ser Thr Thr Gln Tyr Ser Ala Phe His Pro Thr Lys Asn Pro Trp Gly
          130          135          140
Leu Ser Cys Val Pro Gly Gly Ser Ser Gly Gly Ser Ala Ala Ala Val
          145          150          155          160
Ser Ala Arg Phe Cys Pro Ile Ala Leu Gly Ser Asp Thr Gly Gly Ser
          165          170          175
Ile Arg Gln Pro Ala Ala Phe Cys Gly Val Val Gly Phe Lys Pro Ser
          180          185          190
Tyr Gly Ala Val Ser Arg Tyr Gly Leu Val Ala Phe Gly Ser Ser Leu
          195          200          205
Asp Gln Ile Gly Pro Leu Thr Thr Val Val Glu Asp Val Ala Leu Ala

```

| 210 | 215 | 220 |
|--|-----|-----|
| Met Asp Val Phe Ala Gly Lys Asp Asp Arg Asp Ala Thr Ser Gln Lys 225 230 235 240 | | |
| Phe Phe Thr Gly Ser Phe Gln Glu Ala Leu Ser Leu Asp Val Pro Ser 245 250 255 | | |
| Leu Ile Gly Val Pro Met Gly Phe Leu Asp Gly Leu Arg Asp Asp Val 260 265 270 | | |
| Lys Glu Asn Phe Phe Ala Ser Leu Ser Ile Leu Glu Arg Gln Gly Ser 275 280 285 | | |
| Arg Ile Val Glu Val Asp Leu Asn Ile Leu Asp His Ala Val Ser Val 290 295 300 | | |
| Tyr Tyr Ile Val Ala Ser Ala Glu Ala Ala Thr Asn Leu Ala Arg Phe 305 310 315 320 | | |
| Asp Gly Ile Arg Tyr Gly Tyr Arg Ser Pro Glu Ala His Ser Ile Glu 325 330 335 | | |
| Asp Ile Tyr Thr Ile Ser Arg Val Gln Gly Phe Gly Lys Glu Val Met 340 345 350 | | |
| Arg Arg Ile Leu Leu Gly Asn Tyr Val Leu Ser Thr Glu Arg Gln Asn 355 360 365 | | |
| Val Tyr Tyr Lys Lys Gly Ser Ala Ile Arg Ala Lys Ile Ile Gln Ala 370 375 380 | | |
| Phe Gln Lys Ala Tyr Glu Lys Cys Asp Val Ile Ala Met Pro Val Cys 385 390 395 400 | | |
| Ser Cys Pro Ala Phe Ala Asp Gly Glu Ile Leu Asp Pro Thr Ser Leu 405 410 415 | | |
| Tyr Leu Gln Asp Ile Tyr Thr Val Ala Met Asn Leu Ala Tyr Leu Pro 420 425 430 | | |
| Ala Ile Ala Val Pro Ser Gly Phe Ser Arg Glu Gly Leu Pro Leu Gly 435 440 445 | | |
| Phe Gln Val Ile Gly Gln Lys Gly Lys Asp Gln Gln Val Cys Gln Val 450 455 460 | | |
| Gly Tyr Ser Phe Gln Glu His Ser Gly Ile Lys Asn Leu Tyr Pro Lys 465 470 475 480 | | |
| Gly Cys Asn Lys Leu Val Asp Gly Glu Val Lys 485 490 | | |

<210> 18
 <211> 1464
 <212> DNA

<213> Chlamydia psittaci

<400> 18

```

atgagcgcgacg tttatgctga ttgggaatcc gtcataggtc ttgaagtcca cgtagaatta 60
aacacaaaat ctaaattggt cagttgtgca cgcaaccggt ttggagacga acctaataca 120
aacatctctc ctgtatgcac cggcatgccg gggtcactgc cagtactgaa taaagaagca 180
gtgagaaagg ctgtttttatt tggttgtgct gttgaaggcg aagtagcttt gctcagccgt 240
tttgatagaa agtcctatth ttatcccgat agcccaagga attttcaa at tacc caattc 300
gaacatccta ttgtgcgagg aggacatata aaagctatcg ttcacgggtga ggaacgtcat 360
tttgaactgg ctcaagcgca tatcgaagat gatgccggta tgctaaaaca tttcggagaa 420
tttgctggag tagattataa ccgcgctggg gtacctttta tagagattgt gtctaagccg 480
tgcatgtttt gtgctgatga tgctgttgct tatgccacag ctttgggtatc cttattagac 540
tacataggca tttctgactg taatatggaa gaaggctcgg tacgctttga tgtaaacata 600
tccgtacgtc ctaaaggtag cgaagaacta cgcaataaag tagaaattaa aaatatgaac 660
tccttttgct ttatggccca agctctagaa gccgagcggt gtcgtcagat cgatgcatat 720
ttagacaatc caaatgcaga ccccaaaaact gttattccag gagcgacata ccgttgggat 780
cctgaaaaga aaaaaacagt gttgatgcgt cttaaaggaac gagctgaaga ttacaagtat 840
ttcatagagc ctgatctccc agtattgcaa ttaacagaag catatattga tgaaattcgt 900
catacgcttc ccgagctccc tttcaacaaa taccaaaggt atttgcacga atatgctctt 960
gccgaagaca tcgctgccat ttttaattagc gataagcata gtgcgcactt ctttgaatta 1020
gccgctcagg aatgtaaaaa ctacagagcc ctttctaatt ggttaactgt tgagtttgcc 1080
ggacgttgta aactcaaggg taagaatctc gctttctcag gtatcctgcc cagtagtgta 1140
gctcagcttg tgaattttat tgatcaaggc gtgattaccg gaaagatcgc taaggatatc 1200
gcagacatga tgatggaatc tcctgaaaag agtcctgaga ctatcctcaa agaaaatcct 1260
gaaatgttgc ccatgacaga tgaaagtgcg ttgggtggcg tcatttccga ggtgattacc 1320
gcaaatccgc agtctgtcgt agactacaaa agtggtgaaga ccaaggcggt aggattttta 1380
gttgggcaaa ttatgaaacg taccagggc aaggccctc caaatagggt aaatgaactt 1440
ttgcttgtgg aattaagtaa ataa 1464

```

<210> 19

<211> 487

<212> PRT

<213> Chlamydia psittaci

<400> 19

```

Met Ser Asp Val Tyr Ala Asp Trp Glu Ser Val Ile Gly Leu Glu Val
 1              5              10              15

His Val Glu Leu Asn Thr Lys Ser Lys Leu Phe Ser Cys Ala Arg Asn
      20              25              30

Arg Phe Gly Asp Glu Pro Asn Thr Asn Ile Ser Pro Val Cys Thr Gly
      35              40              45

Met Pro Gly Ser Leu Pro Val Leu Asn Lys Glu Ala Val Arg Lys Ala
      50              55              60

Val Leu Phe Gly Cys Ala Val Glu Gly Glu Val Ala Leu Leu Ser Arg
      65              70              75              80

Phe Asp Arg Lys Ser Tyr Phe Tyr Pro Asp Ser Pro Arg Asn Phe Gln
      85              90              95

Ile Thr Gln Phe Glu His Pro Ile Val Arg Gly Gly His Ile Lys Ala
      100              105              110

```

| | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Val | His | Gly | Glu | Glu | Arg | His | Phe | Glu | Leu | Ala | Gln | Ala | His | Ile | 115 | 120 | 125 |
| Glu | Asp | Asp | Ala | Gly | Met | Leu | Lys | His | Phe | Gly | Glu | Phe | Ala | Gly | Val | 130 | 135 | 140 |
| Asp | Tyr | Asn | Arg | Ala | Gly | Val | Pro | Leu | Ile | Glu | Ile | Val | Ser | Lys | Pro | 145 | 150 | 155 |
| Cys | Met | Phe | Cys | Ala | Asp | Asp | Ala | Val | Ala | Tyr | Ala | Thr | Ala | Leu | Val | 165 | 170 | 175 |
| Ser | Leu | Leu | Asp | Tyr | Ile | Gly | Ile | Ser | Asp | Cys | Asn | Met | Glu | Glu | Gly | 180 | 185 | 190 |
| Ser | Val | Arg | Phe | Asp | Val | Asn | Ile | Ser | Val | Arg | Pro | Lys | Gly | Ser | Glu | 195 | 200 | 205 |
| Glu | Leu | Arg | Asn | Lys | Val | Glu | Ile | Lys | Asn | Met | Asn | Ser | Phe | Ala | Phe | 210 | 215 | 220 |
| Met | Ala | Gln | Ala | Leu | Glu | Ala | Glu | Arg | Cys | Arg | Gln | Ile | Asp | Ala | Tyr | 225 | 230 | 235 |
| Leu | Asp | Asn | Pro | Asn | Ala | Asp | Pro | Lys | Thr | Val | Ile | Pro | Gly | Ala | Thr | 245 | 250 | 255 |
| Tyr | Arg | Trp | Asp | Pro | Glu | Lys | Lys | Lys | Thr | Val | Leu | Met | Arg | Leu | Lys | 260 | 265 | 270 |
| Glu | Arg | Ala | Glu | Asp | Tyr | Lys | Tyr | Phe | Ile | Glu | Pro | Asp | Leu | Pro | Val | 275 | 280 | 285 |
| Leu | Gln | Leu | Thr | Glu | Ala | Tyr | Ile | Asp | Glu | Ile | Arg | His | Thr | Leu | Pro | 290 | 295 | 300 |
| Glu | Leu | Pro | Phe | Asn | Lys | Tyr | Gln | Arg | Tyr | Leu | His | Glu | Tyr | Ala | Leu | 305 | 310 | 315 |
| Ala | Glu | Asp | Ile | Ala | Ala | Ile | Leu | Ile | Ser | Asp | Lys | His | Ser | Ala | His | 325 | 330 | 335 |
| Phe | Phe | Glu | Leu | Ala | Ala | Gln | Glu | Cys | Lys | Asn | Tyr | Arg | Ala | Leu | Ser | 340 | 345 | 350 |
| Asn | Trp | Leu | Thr | Val | Glu | Phe | Ala | Gly | Arg | Cys | Lys | Leu | Lys | Gly | Lys | 355 | 360 | 365 |
| Asn | Leu | Ala | Phe | Ser | Gly | Ile | Leu | Pro | Ser | Ser | Val | Ala | Gln | Leu | Val | 370 | 375 | 380 |
| Asn | Phe | Ile | Asp | Gln | Gly | Val | Ile | Thr | Gly | Lys | Ile | Ala | Lys | Asp | Ile | 385 | 390 | 395 |
| Ala | Asp | Met | Met | Met | Glu | Ser | Pro | Glu | Lys | Ser | Pro | Glu | Thr | Ile | Leu | 405 | 410 | 415 |

Lys Glu Asn Pro Glu Met Leu Pro Met Thr Asp Glu Ser Ala Leu Val
 420 425 430
 Ala Ile Ile Ser Glu Val Ile Thr Ala Asn Pro Gln Ser Val Val Asp
 435 440 445
 Tyr Lys Ser Gly Lys Thr Lys Ala Leu Gly Phe Leu Val Gly Gln Ile
 450 455 460
 Met Lys Arg Thr Gln Gly Lys Ala Pro Pro Asn Arg Val Asn Glu Leu
 465 470 475 480
 Leu Leu Val Glu Leu Ser Lys
 485

<210> 20
 <211> 379
 <212> DNA
 <213> Chlamydia psittaci

<400> 20
 tatttagtgt cgaaaaacaa cgccaacatt tacgcagggt ctctctatta tcagcatatc 60
 tcctattgga gcgcttggca gaatctgcta caaaacacta tcggtgcaga agctccgtta 120
 gtccttaacg cacagttaac ttattgtcat gcttcaaacg acatgaaaac caacatgacg 180
 actacttacg ctctctgtaa aacaacgtat gcagaaatca aggggtgattg gggtaacgat 240
 tgtttcggag tcgagcttgg tgcaactgtg cctatccaaa cagaatcttc tctcctattc 300
 gatatgtact cacctttcct gaagtttcaa cttgtgcata cgcaccaaga tgactttaag 360
 gaaaacaata gcgatcagg 379

<210> 21
 <211> 126
 <212> PRT
 <213> Chlamydia psittaci

<400> 21
 Tyr Leu Val Ser Lys Asn Asn Ala Asn Ile Tyr Ala Gly Ser Leu Tyr
 1 5 10 15
 Tyr Gln His Ile Ser Tyr Trp Ser Ala Trp Gln Asn Leu Leu Gln Asn
 20 25 30
 Thr Ile Gly Ala Glu Ala Pro Leu Val Leu Asn Ala Gln Leu Thr Tyr
 35 40 45
 Cys His Ala Ser Asn Asp Met Lys Thr Asn Met Thr Thr Thr Tyr Ala
 50 55 60
 Pro Arg Lys Thr Thr Tyr Ala Glu Ile Lys Gly Asp Trp Gly Asn Asp
 65 70 75 80
 Cys Phe Gly Val Glu Leu Gly Ala Thr Val Pro Ile Gln Thr Glu Ser
 85 90 95
 Ser Leu Leu Phe Asp Met Tyr Ser Pro Phe Leu Lys Phe Gln Leu Val
 100 105 110

His Thr His Gln Asp Asp Phe Lys Glu Asn Asn Ser Asp Gln
 115 120 125

<210> 22

<211> 2520

<212> DNA

<213> Chlamydia psittaci

<400> 22

```

atgaaacatc cagtctactg gttcttaata tctctgagcc tatttgcctc gaattctttg 60
agcttcgcta acgacgctca aacagcctta actccctccg atagctataa tggaaatgtg 120
acctctgagg agttccagggt aaaagaaact tcatcaggaa caacgtatac ttgtgaaggc 180
aatgtgtgta tctcctttgc agggaaagat tcagggtctaa agaaaagttg tttctcagct 240
actgataacc ttaccttcct aggaaacggg tatactcttt gctttgataa tattactact 300
acagctagta accccggagc cattaatgtt caagggtcaag gaaaaacctt aggcattctca 360
ggattttctt tattttcatg tgcttattgt cctccaggca caactgggtta cggagctata 420
cagactaaag gcaacacaac tttaaaagat aactctagtc ttgtcttcca taaaaactgc 480
tcaacagcag aaggtggggc tatccagtgt aaaggaagca gtgatgctga attaaaaata 540
gaaaataatc agaactctgg tttctcagaa aactcctcca cttcaaaagg cggggctatt 600
tatgctgata aactcaccat tgtctcagggt gggcctacat tattttctaa caactctgta 660
tccaacgggt catcccttaa aggcggagct attagcataa aagattcaag tggatgaatgt 720
agcctaaccg ctgatctcgg agatattacc ttcgatggga acaaaatcat caaaactagt 780
ggtggaagtt ctacagtaac aagaaattcc atagatctcg gcacaggga atttacaaag 840
ctacgtgcta aagacggctt cggaattttc ttctatgacc ctattactgg gggaggatct 900
gatgaactaa acattaataa aaaagaaact gttgattata caggaaagat cgtcttctca 960
ggtgaaaaat tatccgatga agaaaaagca cgagcggaaa acctagcttc tactttcaac 1020
caacccatca cattatcagc aggatctctt gtacttaaag atggtgtatc tgtaaccgca 1080
aaacaagtaa cgcaggaagc gggatctacc gttgtcatgg atctaggga cacattacag 1140
acgccttctt caggtggaga aaccatcacc ctaactaatc tagatattaa catcgccctc 1200
ttgggggggg ggggggggtac ctctcctgct aaactcgcaa caaatacagc aagtcaagct 1260
ataactatta acgctgtcaa tctagtcgat gctgatggca atgcttatga agatcctatt 1320
cttgctacgt ctaaaccctt cacagcaata gtagctacaa ctaacgctag tacagtcaca 1380
cagcctacag ataactaac aaattatgtc cctcctactc attacggtta ccaaggaaat 1440
tggaacagtaa cttgggacac cgaaacagct acaaaaacag ccactctaac ttgggaacaa 1500
actggctact cccctaacc agaacgtcaa ggacctttag tcccgaatac tctttggggg 1560
gcattctctg acctcagagc tatacaaaac ttaatggata ttagcgtcaa tggcgctgac 1620
taccatagag gtttttgggt atccgggtcta gctaacttct tacacaaaag tggctctgat 1680
actaaacgca agttccgtca caatagcgcc ggatacgctt taggcgtcta cgcaaaaact 1740
ccttctgatg atattttcag tgcgggtttc tgccaactct tcggaaagga caaagactat 1800
ttagtgctga aaaacaacgc caacatttac gcagggttct tctattatca gcataatctc 1860
tattggagcg cttggcagaa tctgctacaa aacactatcg gtgcagaagc tccgttagtc 1920
cttaacgcac agttaactta ttgtcatgct tcaaacgaca tgaaaaccaa catgacgact 1980
acttacgctc ctcgtaaaac aacgtatgca gaaatcaagg gtgattgggg taacgattgt 2040
ttcggagtcg agcttgggtgc aactgtgcct atccaaacag aatcttctct cctattcgat 2100
atgtactcac ctttcctgaa gtttcaactt gtgcatacgc accaagatga ctttaaggaa 2160
aacaatagcg atcagggaag atacttcgaa agcagcaatc tcaccaacct ttctctgcct 2220
atcggcatca agtttgagag atttgctaac aacgatacag cttcttatca tgtcactgct 2280
gcttattctc ctgatatcgt aagaagtaac cctgactgta ctacttctct gttagtaagc 2340
cccgactctg ctgtctgggt aacgaaagcc aacaaccttg cgcgaagcgc cttcatgcta 2400
caagcaggaa actacttgct ttttaagtcac aacatagaaa tcttcagcca gttcgggttt 2460
gagctcaggg gatcttcacg aacctataac gtagatctcg gatcgaagat ccagttctaa 2520

```

<210> 23

<211> 839

<213> Chlamydia psittaci

Met Lys His Pro Val Tyr Trp Phe Leu Ile Ser Ser Ser Leu Phe Ala
1 5 10 15

Ser Asn Ser Leu Ser Phe Ala Asn Asp Ala Gln Thr Ala Leu Thr Pro
20 25 30

Ser Asp Ser Tyr Asn Gly Asn Val Thr Ser Glu Glu Phe Gln Val Lys
35 40 45

Glu Thr Ser Ser Gly Thr Thr Tyr Thr Cys Glu Gly Asn Val Cys Ile
50 55 60

Ser Phe Ala Gly Lys Asp Ser Gly Leu Lys Lys Ser Cys Phe Ser Ala
65 70 75 80

Thr Asp Asn Leu Thr Phe Leu Gly Asn Gly Tyr Thr Leu Cys Phe Asp
85 90 95

Asn Ile Thr Thr Thr Ala Ser Asn Pro Gly Ala Ile Asn Val Gln Gly
100 105 110

Gln Gly Lys Thr Leu Gly Ile Ser Gly Phe Ser Leu Phe Ser Cys Ala
115 120 125

Tyr Cys Pro Pro Gly Thr Thr Gly Tyr Gly Ala Ile Gln Thr Lys Gly
130 135 140

Asn Thr Thr Leu Lys Asp Asn Ser Ser Leu Val Phe His Lys Asn Cys
145 150 155 160

Ser Thr Ala Glu Gly Gly Ala Ile Gln Cys Lys Gly Ser Ser Asp Ala
165 170 175

Glu Leu Lys Ile Glu Asn Asn Gln Asn Leu Val Phe Ser Glu Asn Ser
180 185 190

Ser Thr Ser Lys Gly Gly Ala Ile Tyr Ala Asp Lys Leu Thr Ile Val
195 200 205

Ser Gly Gly Pro Thr Leu Phe Ser Asn Asn Ser Val Ser Asn Gly Ser
210 215 220

Ser Pro Lys Gly Gly Ala Ile Ser Ile Lys Asp Ser Ser Gly Glu Cys
225 230 235 240

Ser Leu Thr Ala Asp Leu Gly Asp Ile Thr Phe Asp Gly Asn Lys Ile
245 250 255

Ile Lys Thr Ser Gly Gly Ser Ser Thr Val Thr Arg Asn Ser Ile Asp
260 265 270

Leu Gly Thr Gly Lys Phe Thr Lys Leu Arg Ala Lys Asp Gly Phe Gly
275 280 285

| | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ile | Phe | Phe | Tyr | Asp | Pro | Ile | Thr | Gly | Gly | Gly | Ser | Asp | Glu | Leu | Asn | 290 | 295 | 300 |
| Ile | Asn | Lys | Lys | Glu | Thr | Val | Asp | Tyr | Thr | Gly | Lys | Ile | Val | Phe | Ser | 305 | 310 | 315 |
| Gly | Glu | Lys | Leu | Ser | Asp | Glu | Glu | Lys | Ala | Arg | Ala | Glu | Asn | Leu | Ala | 325 | 330 | 335 |
| Ser | Thr | Phe | Asn | Gln | Pro | Ile | Thr | Leu | Ser | Ala | Gly | Ser | Leu | Val | Leu | 340 | 345 | 350 |
| Lys | Asp | Gly | Val | Ser | Val | Thr | Ala | Lys | Gln | Val | Thr | Gln | Glu | Ala | Gly | 355 | 360 | 365 |
| Ser | Thr | Val | Val | Met | Asp | Leu | Gly | Thr | Thr | Leu | Gln | Thr | Pro | Ser | Ser | 370 | 375 | 380 |
| Gly | Gly | Glu | Thr | Ile | Thr | Leu | Thr | Asn | Leu | Asp | Ile | Asn | Ile | Ala | Ser | 385 | 390 | 395 |
| Leu | Gly | Gly | Gly | Gly | Gly | Thr | Ser | Pro | Ala | Lys | Leu | Ala | Thr | Asn | Thr | 405 | 410 | 415 |
| Ala | Ser | Gln | Ala | Ile | Thr | Ile | Asn | Ala | Val | Asn | Leu | Val | Asp | Ala | Asp | 420 | 425 | 430 |
| Gly | Asn | Ala | Tyr | Glu | Asp | Pro | Ile | Leu | Ala | Thr | Ser | Lys | Pro | Phe | Thr | 435 | 440 | 445 |
| Ala | Ile | Val | Ala | Thr | Thr | Asn | Ala | Ser | Thr | Val | Thr | Gln | Pro | Thr | Asp | 450 | 455 | 460 |
| Asn | Leu | Thr | Asn | Tyr | Val | Pro | Pro | Thr | His | Tyr | Gly | Tyr | Gln | Gly | Asn | 465 | 470 | 475 |
| Trp | Thr | Val | Thr | Trp | Asp | Thr | Glu | Thr | Ala | Thr | Lys | Thr | Ala | Thr | Leu | 485 | 490 | 495 |
| Thr | Trp | Glu | Gln | Thr | Gly | Tyr | Ser | Pro | Asn | Pro | Glu | Arg | Gln | Gly | Pro | 500 | 505 | 510 |
| Leu | Val | Pro | Asn | Thr | Leu | Trp | Gly | Ala | Phe | Ser | Asp | Leu | Arg | Ala | Ile | 515 | 520 | 525 |
| Gln | Asn | Leu | Met | Asp | Ile | Ser | Val | Asn | Gly | Ala | Asp | Tyr | His | Arg | Gly | 530 | 535 | 540 |
| Phe | Trp | Val | Ser | Gly | Leu | Ala | Asn | Phe | Leu | His | Lys | Ser | Gly | Ser | Asp | 545 | 550 | 555 |
| Thr | Lys | Arg | Lys | Phe | Arg | His | Asn | Ser | Ala | Gly | Tyr | Ala | Leu | Gly | Val | 565 | 570 | 575 |
| Tyr | Ala | Lys | Thr | Pro | Ser | Asp | Asp | Ile | Phe | Ser | Ala | Ala | Phe | Cys | Gln | 580 | 585 | 590 |

Leu Phe Gly Lys Asp Lys Asp Tyr Leu Val Ser Lys Asn Asn Ala Asn
 595 600 605
 Ile Tyr Ala Gly Ser Leu Tyr Tyr Gln His Ile Ser Tyr Trp Ser Ala
 610 615 620
 Trp Gln Asn Leu Leu Gln Asn Thr Ile Gly Ala Glu Ala Pro Leu Val
 625 630 635 640
 Leu Asn Ala Gln Leu Thr Tyr Cys His Ala Ser Asn Asp Met Lys Thr
 645 650 655
 Asn Met Thr Thr Thr Tyr Ala Pro Arg Lys Thr Thr Tyr Ala Glu Ile
 660 665 670
 Lys Gly Asp Trp Gly Asn Asp Cys Phe Gly Val Glu Leu Gly Ala Thr
 675 680 685
 Val Pro Ile Gln Thr Glu Ser Ser Leu Leu Phe Asp Met Tyr Ser Pro
 690 695 700
 Phe Leu Lys Phe Gln Leu Val His Thr His Gln Asp Asp Phe Lys Glu
 705 710 715 720
 Asn Asn Ser Asp Gln Gly Arg Tyr Phe Glu Ser Ser Asn Leu Thr Asn
 725 730 735
 Leu Ser Leu Pro Ile Gly Ile Lys Phe Glu Arg Phe Ala Asn Asn Asp
 740 745 750
 Thr Ala Ser Tyr His Val Thr Ala Ala Tyr Ser Pro Asp Ile Val Arg
 755 760 765
 Ser Asn Pro Asp Cys Thr Thr Ser Leu Leu Val Ser Pro Asp Ser Ala
 770 775 780
 Val Trp Val Thr Lys Ala Asn Asn Leu Ala Arg Ser Ala Phe Met Leu
 785 790 795 800
 Gln Ala Gly Asn Tyr Leu Ser Leu Ser His Asn Ile Glu Ile Phe Ser
 805 810 815
 Gln Phe Gly Phe Glu Leu Arg Gly Ser Ser Arg Thr Tyr Asn Val Asp
 820 825 830
 Leu Gly Ser Lys Ile Gln Phe
 835

<210> 24

<211> 1039

<212> DNA

<213> Chlamydia psittaci

<400> 24

aaacgttttc atattaatgg ggttcctgaa tggcttttat ctacgcctta ttctcttgct 60

```

atgggggtata atatcttggc tacggggagtg cagatgggta aagcctatgc cattcttgcc 120
aacggtgggtt atgatgtgcg ccctaccttg ataaaaaaaa tagtcactac ttctggaaaa 180
gagtacgtgt tgcattcctca agttcgtgga gaaagaattc tttctcagga cattgtggat 240
gaggtattga aagctacgcg ttttactacc tatcctggag gaacgggatt tcgggctgcg 300
cctaaaaagc attccagtgc agggaaaaca ggaacaacag aaaagctagt tcatggaaag 360
tatgataagc atcggcataat ttcttcattt ataggtatca cgccgatata cccttcggca 420
gggggggagtg ttccttttggc catgcttgtc tctatcagtt atacgaccga caacggtagt 480
caagtgtacg tcgttcaatt gcgacatgag ggtatcgaaa tctgtcgtca attcgtccat 540
gttaacctaa ttgtgtggtc attatcgctt tctttatact acttaccgta gttcctacgg 600
atactagcaa aaagttctgc tctttgcgtt gctctttgaa cagcactactg tactttttaa 660
aagtctgcta aattttcccg ttctccattc ctatctgaga agtagagaag ggctctattt 720
aacacttctt ctccagaaga cacccaattg accatcttac gggcaacgga ctctgtttct 780
tcttcttttt tggtttgtaa gttttgttgc gtatgctcag ctatatcatt cagatcacca 840
ttgattaaat caatgatcac actgacagct tcaaaatggt cttgcatag tttattttga 900
tcttggttga gagtggattg tgcattccat aaacgctctt ttagattgtt tatttgctct 960
ttcagctctt ccgaatctaa cgctcttcc agttcaggat cgataatgtt agagtttctg 1020
tcttgcatac tcgccatag 1039

```

<210> 25

<211> 196

<212> PRT

<213> Chlamydia psittaci

<400> 25

```

Lys Arg Phe His Ile Asn Gly Val Pro Glu Trp Ser Leu Ser Thr Pro
  1             5             10             15

```

```

Tyr Ser Leu Ala Met Gly Tyr Asn Ile Leu Ala Thr Gly Val Gln Met
          20             25             30

```

```

Val Lys Ala Tyr Ala Ile Leu Ala Asn Gly Gly Tyr Asp Val Arg Pro
          35             40             45

```

```

Thr Leu Ile Lys Lys Ile Val Thr Thr Ser Gly Lys Glu Tyr Val Leu
  50             55             60

```

```

His Pro Gln Val Arg Gly Glu Arg Ile Leu Ser Gln Asp Ile Val Asp
  65             70             75             80

```

```

Glu Val Leu Lys Ala Thr Arg Phe Thr Thr Tyr Pro Gly Gly Thr Gly
          85             90             95

```

```

Phe Arg Ala Ala Pro Lys Lys His Ser Ser Ala Gly Lys Thr Gly Thr
          100            105            110

```

```

Thr Glu Lys Leu Val His Gly Lys Tyr Asp Lys His Arg His Ile Ser
          115            120            125

```

```

Ser Phe Ile Gly Ile Thr Pro Ile Tyr Pro Ser Ala Gly Gly Ser Val
          130            135            140

```

```

Pro Leu Val Met Leu Val Ser Ile Ser Tyr Thr Thr Asp Asn Gly Ser
          145            150            155            160

```

```

Gln Val Tyr Val Val Gln Leu Arg His Glu Gly Ile Glu Ile Cys Arg
          165            170            175

```

Gln Phe Val His Val Asn Leu Ile Val Trp Ser Leu Ser Leu Ser Leu
 180 185 190

Tyr Tyr Leu Pro
 195

<210> 26

<211> 1950

<212> DNA

<213> Chlamydia psittaci

<400> 26

```

atgaatcacc gtaaatgctt aaccatgatt acctatggag ttctgctctc ctattctttc 60
ctgatcatac ggtattataa aattcagatt tgtgaggaga aacgttgggc agcagaagct 120
ttaggacaac atgaatttcg agtaaaggac ctttttcgta gggggacggt tttttctcag 180
atgaatttac gtaagggaga ttcagagcaa cgacaagctc tggccgtgga cattacgaaa 240
tttcatcttt gtttagatgc tgtagctggt cctgaagaac accgtgatgt gattgctaag 300
aaagttttta gtctcattgg agaaggatgat tatgacaaac tccgtgcgga gtttgataaa 360
aaatctcgcct atcgaaagtt atttcttttg ttagatcgtg cggatcatga ccgcatcctg 420
tcttggtggc ggggggtacgc agcaaaatct aaaataccct cgaatgcttt gtttttcatg 480
accgactatc aaagatctta tccctttggc aaacttttag gccagttct acatactctg 540
agagaagtca aggatgagaa aacaggcaaa gctttcccta caggagggtt agaagcctat 600
tttaaccacg tccttgaagg agagccagga gaacggaaat tcctacgttc tcctttaaat 660
cgttttagatc tagataaagt cacaagatt cctagggatg gttcggatat ttatctcaca 720
gtcaatccct gtatacagac tatagcggaa gaggaattag aaaaaggggt aaaggaagcc 780
aaagctaaag gtgggctgtc aatttttaatg aatgcttata caggcgagat tcttgcttta 840
gcacagtatc ctttctttta tccttcggaa tacaaggaat ttttcaatga taaggaaaaa 900
atagagcaca caaaagtaac atcagtcagt gatgtgtttg aaccggctc tatcatgaaa 960
cctctgactc tggctatagc gttgctggcc aacgaagaga tggtgaaaag atcaggaaaag 1020
cccttatttg atcctaataga acctatagat gtaaccgcga ggattttccc aggaagaaaag 1080
caatttccgc ttaaggatat ctcatcgaat cggcgtttaa atatgtacat ggcgattcaa 1140
aagtcttcga acgtttatgt agcgcaactt gctgatctta tagtgcaaca tctagggaac 1200
cactgggatg aagacaagtt attgttatta ggatttggtg aaaagacggg gatagaattg 1260
ccaggggaag cgtcaggatt ggtaccttca cctaaacggt ttcataattaa tggggttcct 1320
gaatggtctt tatctacgcc ttattctctt gctatggggt ataatatctt ggctacggga 1380
gtgcagatgg ttaaagccta tgccattctt gccaacggtg gttatgatgt gcgccctacc 1440
ttgataaaaa aaatagtcac tacttctgga aaagagtacg tgttgcatcc tcaagttcgt 1500
ggagaaagaa ttctttctca ggacattgtg gatgaggat tgaaagctac gcgttttact 1560
acctatcctg gaggaacggg atttcgggct gcgcctaaaa agcattccag tgcagggaaa 1620
acaggaacaa cagaaaagct agttcatgga aagtatgata agcatcggca tatttcttca 1680
tttataggta tcacgccgat atacccttcg gcagggggga gtgttccttt ggtcatgctt 1740
gtctctatag atgatcctga tcattgtgtt cgcgaggatg gaacaaagaa ctatatggga 1800
ggccgatgtg ccgccctgt atttggcaga gttgcggatc gtgttttatc ttatctagga 1860
gttcccgaag ataaagaaaa atacagttat cagagtgagg tggctgctat gaaagctttg 1920
tatgaggaat ggaatcggtc ggggaaataa 1950

```

<210> 27

<211> 649

<212> PRT

<213> Chlamydia psittaci

<400> 27

Met Asn His Arg Lys Cys Leu Thr Met Ile Thr Tyr Gly Val Leu Leu
 1 5 10 15

Ser Tyr Ser Phe Leu Ile Ile Arg Tyr Tyr Lys Ile Gln Ile Cys Glu
 20 25 30
 Glu Lys Arg Trp Ala Ala Glu Ala Leu Gly Gln His Glu Phe Arg Val
 35 40 45
 Lys Asp Pro Phe Arg Arg Gly Thr Phe Phe Ser Gln Met Asn Leu Arg
 50 55 60
 Lys Gly Asp Ser Glu Gln Arg Gln Ala Leu Ala Val Asp Ile Thr Lys
 65 70 75 80
 Phe His Leu Cys Leu Asp Ala Val Ala Val Pro Glu Glu His Arg Asp
 85 90 95
 Val Ile Ala Lys Lys Val Phe Ser Leu Ile Gly Glu Gly Asp Tyr Asp
 100 105 110
 Lys Leu Arg Ala Glu Phe Asp Lys Lys Ser Arg Tyr Arg Lys Leu Phe
 115 120 125
 Leu Trp Leu Asp Arg Ala Asp His Asp Arg Ile Leu Ser Trp Trp Arg
 130 135 140
 Gly Tyr Ala Ala Lys Ser Lys Ile Pro Ser Asn Ala Leu Phe Phe Met
 145 150 155 160
 Thr Asp Tyr Gln Arg Ser Tyr Pro Phe Gly Lys Leu Leu Gly Gln Val
 165 170 175
 Leu His Thr Leu Arg Glu Val Lys Asp Glu Lys Thr Gly Lys Ala Phe
 180 185 190
 Pro Thr Gly Gly Leu Glu Ala Tyr Phe Asn His Val Leu Glu Gly Glu
 195 200 205
 Pro Gly Glu Arg Lys Phe Leu Arg Ser Pro Leu Asn Arg Leu Asp Leu
 210 215 220
 Asp Lys Val Thr Lys Ile Pro Arg Asp Gly Ser Asp Ile Tyr Leu Thr
 225 230 235 240
 Val Asn Pro Cys Ile Gln Thr Ile Ala Glu Glu Glu Leu Glu Lys Gly
 245 250 255
 Val Lys Glu Ala Lys Ala Lys Gly Gly Arg Leu Ile Leu Met Asn Ala
 260 265 270
 Tyr Thr Gly Glu Ile Leu Ala Leu Ala Gln Tyr Pro Phe Phe Asn Pro
 275 280 285
 Ser Glu Tyr Lys Glu Phe Phe Asn Asp Lys Glu Lys Ile Glu His Thr
 290 295 300
 Lys Val Thr Ser Val Ser Asp Val Phe Glu Pro Gly Ser Ile Met Lys
 305 310 315 320

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Pro | Leu | Thr | Leu | Ala | Ile | Ala | Leu | Leu | Ala | Asn | Glu | Glu | Met | Val | Lys |
| | | | | 325 | | | | | 330 | | | | | 335 | |
| Arg | Ser | Gly | Lys | Pro | Leu | Phe | Asp | Pro | Asn | Glu | Pro | Ile | Asp | Val | Thr |
| | | | 340 | | | | | 345 | | | | | 350 | | |
| Arg | Arg | Ile | Phe | Pro | Gly | Arg | Lys | Gln | Phe | Pro | Leu | Lys | Asp | Ile | Ser |
| | | 355 | | | | | 360 | | | | | 365 | | | |
| Ser | Asn | Arg | Arg | Leu | Asn | Met | Tyr | Met | Ala | Ile | Gln | Lys | Ser | Ser | Asn |
| | 370 | | | | | 375 | | | | | 380 | | | | |
| Val | Tyr | Val | Ala | Gln | Leu | Ala | Asp | Leu | Ile | Val | Gln | His | Leu | Gly | Asn |
| 385 | | | | | 390 | | | | | 395 | | | | | 400 |
| His | Trp | Tyr | Glu | Asp | Lys | Leu | Leu | Leu | Leu | Gly | Phe | Gly | Lys | Lys | Thr |
| | | | | 405 | | | | | 410 | | | | | 415 | |
| Gly | Ile | Glu | Leu | Pro | Gly | Glu | Ala | Ser | Gly | Leu | Val | Pro | Ser | Pro | Lys |
| | | | 420 | | | | | 425 | | | | | 430 | | |
| Arg | Phe | His | Ile | Asn | Gly | Val | Pro | Glu | Trp | Ser | Leu | Ser | Thr | Pro | Tyr |
| | | 435 | | | | | 440 | | | | | 445 | | | |
| Ser | Leu | Ala | Met | Gly | Tyr | Asn | Ile | Leu | Ala | Thr | Gly | Val | Gln | Met | Val |
| | 450 | | | | | 455 | | | | | 460 | | | | |
| Lys | Ala | Tyr | Ala | Ile | Leu | Ala | Asn | Gly | Gly | Tyr | Asp | Val | Arg | Pro | Thr |
| 465 | | | | | 470 | | | | | 475 | | | | | 480 |
| Leu | Ile | Lys | Lys | Ile | Val | Thr | Thr | Ser | Gly | Lys | Glu | Tyr | Val | Leu | His |
| | | | | 485 | | | | | 490 | | | | | 495 | |
| Pro | Gln | Val | Arg | Gly | Glu | Arg | Ile | Leu | Ser | Gln | Asp | Ile | Val | Asp | Glu |
| | | | 500 | | | | | 505 | | | | | 510 | | |
| Val | Leu | Lys | Ala | Thr | Arg | Phe | Thr | Thr | Tyr | Pro | Gly | Gly | Thr | Gly | Phe |
| | | 515 | | | | | 520 | | | | | 525 | | | |
| Arg | Ala | Ala | Pro | Lys | Lys | His | Ser | Ser | Ala | Gly | Lys | Thr | Gly | Thr | Thr |
| | 530 | | | | | 535 | | | | | 540 | | | | |
| Glu | Lys | Leu | Val | His | Gly | Lys | Tyr | Asp | Lys | His | Arg | His | Ile | Ser | Ser |
| 545 | | | | | 550 | | | | | 555 | | | | | 560 |
| Phe | Ile | Gly | Ile | Thr | Pro | Ile | Tyr | Pro | Ser | Ala | Gly | Gly | Ser | Val | Pro |
| | | | | 565 | | | | | 570 | | | | | 575 | |
| Leu | Val | Met | Leu | Val | Ser | Ile | Asp | Asp | Pro | Asp | His | Cys | Val | Arg | Glu |
| | | | 580 | | | | | 585 | | | | | 590 | | |
| Asp | Gly | Thr | Lys | Asn | Tyr | Met | Gly | Gly | Arg | Cys | Ala | Ala | Pro | Val | Phe |
| | | 595 | | | | | 600 | | | | | 605 | | | |
| Gly | Arg | Val | Ala | Asp | Arg | Val | Leu | Ser | Tyr | Leu | Gly | Val | Pro | Glu | Asp |
| | 610 | | | | | 615 | | | | | 620 | | | | |

Lys Glu Lys Tyr Ser Tyr Gln Ser Glu Val Ala Ala Met Lys Ala Leu
 625 630 635 640

Tyr Glu Glu Trp Asn Arg Ser Gly Lys
 645

<210> 28

<211> 960

<212> DNA

<213> Chlamydia psittaci

<400> 28

```

atgttcaata agctcattga aacagcacag aaacgggtgg aagcaagaaa ctatactatt 60
cgaaagcata ctcttgagta tgacgatggt atgaataggc aaaggcagac gatctatgct 120
tttcgtaatg acgttatccg ctctgaagat atctttgggt tagctaagga agcaatatct 180
catgttgcat taatgatcgc ttcgttgata gtgagccgtg atcatcctac agggaattct 240
cttcctaggc tggaagaatg gatgaactat tctttcccac tgcaattgaa tattgaagaa 300
ttgaaaagat tgaagtctat agatgccatt gccgaacggg ttgctgatga tctcatagaa 360
gttttccaga ataagtttgc ttctatgggt caggaaatta ccgaagcagc cggagaaaaa 420
gtcgatgcta atgggtgtctg taaagatggt attcgctcgg tcatgattat gcataatcgat 480
gagcagtggg aaattcatct tgtagatatg gattttattac gtagtgaagt aggtttacgt 540
actgtcggtc agaaagaccc tcttatcgaa tttaaacaatg agtcgttctt actattcgaa 600
agtcttattc gcgatattcg tattgctatt gtaaagcatt tgttccggtt agagttgacg 660
atgactagag aacagcggcc tcaaaatgtc gtgcctgttg ttgccacatc tttccaaaat 720
aatgaaaatt tcggtccttt ggaactcaca gttatcagtg attctgacga tgaataaaaa 780
gagctttagg gctgggctag cttccagcct tttcccttac gttattgatt tatagtttta 840
aataaatacg gaccactcag accaggattg tgtgtcgtgg tggcgtatcc aaaatgttct 900
gtgattatcc tcaatcagaa attgtacatg atgatcgaga ttgcgtgttg tcatgcaa 960

```

<210> 29

<211> 258

<212> PRT

<213> Chlamydia psittaci

<400> 29

Met Phe Asn Lys Leu Ile Glu Thr Ala Gln Lys Arg Val Glu Ala Arg
 1 5 10 15

Asn Tyr Thr Ile Arg Lys His Thr Leu Glu Tyr Asp Asp Val Met Asn
 20 25 30

Arg Gln Arg Gln Thr Ile Tyr Ala Phe Arg Asn Asp Val Ile Arg Ser
 35 40 45

Glu Asp Ile Phe Gly Leu Ala Lys Glu Ala Ile Ser His Val Ala Leu
 50 55 60

Met Ile Ala Ser Leu Ile Val Ser Arg Asp His Pro Thr Gly Asn Ser
 65 70 75 80

Leu Pro Arg Leu Glu Glu Trp Met Asn Tyr Ser Phe Pro Leu Gln Leu
 85 90 95

Asn Ile Glu Glu Leu Lys Arg Leu Lys Ser Ile Asp Ala Ile Ala Glu

| 100 | | | | | 105 | | | | | 110 | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Val | Ala | Asp | Asp | Leu | Ile | Glu | Val | Phe | Gln | Asn | Lys | Phe | Ala | Ser |
| | | 115 | | | | | 120 | | | | | 125 | | | |
| Met | Val | Gln | Glu | Ile | Thr | Glu | Ala | Ala | Gly | Glu | Lys | Val | Asp | Ala | Asn |
| | | 130 | | | | 135 | | | | | 140 | | | | |
| Gly | Val | Cys | Lys | Asp | Val | Ile | Arg | Ser | Val | Met | Ile | Met | His | Ile | Asp |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 |
| Glu | Gln | Trp | Lys | Ile | His | Leu | Val | Asp | Met | Asp | Leu | Leu | Arg | Ser | Glu |
| | | | | 165 | | | | | 170 | | | | | 175 | |
| Val | Gly | Leu | Arg | Thr | Val | Gly | Gln | Lys | Asp | Pro | Leu | Ile | Glu | Phe | Lys |
| | | | 180 | | | | | 185 | | | | | 190 | | |
| His | Glu | Ser | Phe | Leu | Leu | Phe | Glu | Ser | Leu | Ile | Arg | Asp | Ile | Arg | Ile |
| | | 195 | | | | | 200 | | | | | 205 | | | |
| Ala | Ile | Val | Lys | His | Leu | Phe | Arg | Leu | Glu | Leu | Thr | Met | Thr | Arg | Glu |
| | 210 | | | | | 215 | | | | | 220 | | | | |
| Gln | Arg | Pro | Gln | Asn | Val | Val | Pro | Val | Val | Ala | Thr | Ser | Phe | Gln | Asn |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 |
| Asn | Glu | Asn | Phe | Gly | Pro | Leu | Glu | Leu | Thr | Val | Ile | Ser | Asp | Ser | Asp |
| | | | | 245 | | | | | 250 | | | | | 255 | |

Asp Glu

<210> 30

<211> 697

<212> DNA

<213> Chlamydia psittaci

<400> 30

```

gggttttgatt atctcagaga taattctatt gcaacttctg tggatgagca ggtgggacgt 60
gggtttttatt ttgctattat cgatgaagtc gactcgattt taattgatga agccagaact 120
cctttaatta tttctgggtcc tggggaaaaa cataatcctg tgtatttcga actcaaagat 180
aaagtggctg acctcgttca gttacaaagg gagttatgta accagtttagc tcttgaagct 240
agacggggac tagaattggtt cttggatatg gatatttcttc ctaaggataa aaaagttatc 300
gaagctatct ccgaattttg ccgtagctta tggttagtta gtaagggaat gccttttaa 360
cgtgtttttgc gtagagtgcg cgaacaccca gatttgcgag ccatgataga taaatgggat 420
acttattatc atgctgagca aaataaagaa gagagtatag agaagctatc tcagctgtat 480
atcattgttg atgaacataa taacgatttt gaattgacag atcgtggcat gcaacaatgg 540
gtggataagg ctggagggttc tgctgaagat tttgtcatga tggacatggg gcatgaatat 600
gctcttatag atggtgacga taccttatca ccgacagaga aaatcaatag aaaaatagct 660
atttccgaag aagatacgag gagaaaagct cgagctc 697

```

<210> 31

<211> 232

<212> PRT

<213> Chlamydia psittaci

<400> 31

Gly Phe Asp Tyr Leu Arg Asp Asn Ser Ile Ala Thr Ser Val Asp Glu
 1 5 10 15
 Gln Val Gly Arg Gly Phe Tyr Phe Ala Ile Ile Asp Glu Val Asp Ser
 20 25 30
 Ile Leu Ile Asp Glu Ala Arg Thr Pro Leu Ile Ile Ser Gly Pro Gly
 35 40 45
 Glu Lys His Asn Pro Val Tyr Phe Glu Leu Lys Asp Lys Val Ala Asp
 50 55 60
 Leu Val Gln Leu Gln Arg Glu Leu Cys Asn Gln Leu Ala Leu Glu Ala
 65 70 75 80
 Arg Arg Gly Leu Glu Leu Phe Leu Asp Met Asp Ile Leu Pro Lys Asp
 85 90 95
 Lys Lys Val Ile Glu Ala Ile Ser Glu Phe Cys Arg Ser Leu Trp Leu
 100 105 110
 Val Ser Lys Gly Met Pro Leu Asn Arg Val Leu Arg Arg Val Arg Glu
 115 120 125
 His Pro Asp Leu Arg Ala Met Ile Asp Lys Trp Asp Thr Tyr Tyr His
 130 135 140
 Ala Glu Gln Asn Lys Glu Glu Ser Ile Glu Lys Leu Ser Gln Leu Tyr
 145 150 155 160
 Ile Ile Val Asp Glu His Asn Asn Asp Phe Glu Leu Thr Asp Arg Gly
 165 170 175
 Met Gln Gln Trp Val Asp Lys Ala Gly Gly Ser Ala Glu Asp Phe Val
 180 185 190
 Met Met Asp Met Gly His Glu Tyr Ala Leu Ile Asp Gly Asp Asp Thr
 195 200 205
 Leu Ser Pro Thr Glu Lys Ile Asn Arg Lys Ile Ala Ile Ser Glu Glu
 210 215 220
 Asp Thr Arg Arg Lys Ala Arg Ala
 225 230

<210> 32

<211> 2910

<212> DNA

<213> Chlamydia psittaci

<400> 32

atgttagatt ttcttaaagc tttcttttggga tcttctcaag agcgcacctt aaaaaaattt 60
 caaaaacttg tggataaggt caacctctat gatgagatgc tagctccttt gtctgatgag 120
 gagttacgta ataaaacagc agagttaaaa aagcggtatc aggacggcga atccttagat 180

```

gatatgcttc ccgaggctta tgccgtagtg aaaaatgtat gcaggcgttt aacaggaaact 240
cctgtagaag tgtcgggtta tcatcaaaat tgggacatgg ttccctatga tgtgcagggtt 300
ctcggtgcta tagctatgca taagggcttt ataaccgaga tgcagacagg agaggggaaa 360
actctcaccg ctgttatgcc tctatattta aatgcattga caggcaagcc tgtgcatttta 420
gtcacagtga atgattatct cgctcaaagg gattgtgagt gggtcggctc tatattgcgt 480
tggttagggtt taactaccgg agtattgata tcaggatcgc ctttagaaaa aagaaaagac 540
atztatcggtt gtgacgttgt ctacgggtaca gcatcagagt tcgggtttga ttatctcaga 600
gataattcta ttgcaacttc tgtggatgag cagggtgggac gtgggtttta ttttgctatt 660
atcgatgaag tcgactcgat ttttaattgat gaagccagaa ctcctttaat tatttctggt 720
cctggggaaa aacataatcc tgtgtatthc gaactcaaag ataaagtggc tgacctcggt 780
cagttacaaa gggagttatg taaccagtta gctcttgaag ctagacgggg actagaattg 840
ttcttgata tggaattctt tcctaaggat aaaaaagtta tcgaagctat ctccgaattt 900
tgccgtagct tatggttagt tagtaaggga atgcctthaa atcgtgtttt gcgtagagtg 960
cgcgaaacacc cagatttgcg agccatgata gataaatggg atacttatta tcatgctgag 1020
caaaataaag aagagagtat agagaagcta tctcagctgt atatcattgt tgatgaacat 1080
aataacgatt ttgaattgac agatcgtggc atgcaacaat ggggtggataa ggctggaggt 1140
tctgctgaag attttgtcat gatggacatg gggcatgaat atgctcttat agatggtgac 1200
gataccttat caccgacaga gaaaatcaat agaaaaatag ctatttccga agaagatacg 1260
aggagaaaag ctcgagctca tggcttgcg caactattaa gagcgcatct tcttatggaa 1320
cgcgatgtgg attatatgtt tcgtaatgat caaattgtca tcattgacga acatacgggc 1380
cgcccgcaac caggctcgctg tttttccgaa ggactgcatc aagccataga agcaaaagaa 1440
catgtcacta tccgtaagga atcacaaacg tttgctacag ttacctaca gaatttcttc 1500
cgtctgtatg aaaaactcgc aggtatgacg ggaacagcaa ttacggaatc taaagagttt 1560
aaagagattt ataactctta tgtattgcag gtgcccacgt ttaaagaatg tttgcgtgta 1620
gatcacaatg acgaatttta tatgacagag cgtgaaaagt accacgcgat tgttaaggaa 1680
attgcccgta tacatgccgt agggaaacccg attctcatag gaacggagtc tgtagagggt 1740
tctgagaaac tttctcgtat tttgagacaa aatcgcatag aacatacagt gttaaattgcg 1800
aaaaatcatg ctcaagaagc agagatcatt gcagcagcag gaaagctggg agctgtgact 1860
gtagctacca atatggctgg ccgtggtaca gatattaagc tggatgaaga agctgtagtt 1920
gttgagggtc tccatgttat tggtagcagt cggcaccaat cagccgcat agataggcag 1980
ttgcgcgggc gttgcgcacg tttaggagat cctgggttcg cgaaattttt cctatctttt 2040
gaagatcgcc tgatgcgctt atttgcacg cccaagttaa atgccttgat tcgtcatttc 2100
cgctctctg aaggagaggg tatgtcggat cctatgttca ataagctcat tgaaacagca 2160
cagaaacggg tggaagcaag aaactatact attcgaaagc atactcttga gtagacgat 2220
gttatgaata ggcaaaggca gacgatctat gcttttcgta atgacgttat ccgctctgaa 2280
gatatctttg gtttagctaa ggaagcaata tctcatgttg cattaatgat cgcttcgttg 2340
atagttagcc gtgatcatcc tacagggaat tctcttccta ggctggaaga atggatgaac 2400
tattctttcc cactgcaatt gaatattgaa gaattgaaaa gattgaagtc tatagatgcc 2460
attgccgaac gggttgctga tgatctcata gaagttttcc agaataagtt tgcttctatg 2520
gtgcaggaaa ttaccgaagc agccggagaa aaagtcgatg ctaatggtgt ctgtaaagat 2580
gttattcgct cggtcatgat tatgcatatc gatgagcagt ggaaaattca tctttagat 2640
atggatttat tacgtagtga agtaggttta cgtactgtcg gtcagaaaga ccctcttatt 2700
gaatttaaac atgagtcggt cttactattc gaaagtctta ttcgcgatat tcgtattgct 2760
attgtaaagc atttgttccg tttagagttg acgatgacta gagaacagcg gcctcaaaat 2820
gtcgtgcctg ttgttgccac atctttccaa aataatgaaa atttcggtcc tttggaactc 2880
acagttatca gtgattctga cgatgaataa 2910

```

<210> 33

<211> 969

<212> PRT

<213> Chlamydia psittaci

<400> 33

```

Met Leu Asp Phe Leu Lys Arg Phe Phe Gly Ser Ser Gln Glu Arg Thr
  1           5           10          15

```

| | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Lys | Lys | Phe | Gln | Lys | Leu | Val | Asp | Lys | Val | Asn | Leu | Tyr | Asp | Glu | 20 | 25 | 30 |
| Met | Leu | Ala | Pro | Leu | Ser | Asp | Glu | Glu | Leu | Arg | Asn | Lys | Thr | Ala | Glu | 35 | 40 | 45 |
| Leu | Lys | Lys | Arg | Tyr | Gln | Asp | Gly | Glu | Ser | Leu | Asp | Asp | Met | Leu | Pro | 50 | 55 | 60 |
| Glu | Ala | Tyr | Ala | Val | Val | Lys | Asn | Val | Cys | Arg | Arg | Leu | Thr | Gly | Thr | 65 | 70 | 75 |
| Pro | Val | Glu | Val | Ser | Gly | Tyr | His | Gln | Asn | Trp | Asp | Met | Val | Pro | Tyr | 85 | 90 | 95 |
| Asp | Val | Gln | Val | Leu | Gly | Ala | Ile | Ala | Met | His | Lys | Gly | Phe | Ile | Thr | 100 | 105 | 110 |
| Glu | Met | Gln | Thr | Gly | Glu | Gly | Lys | Thr | Leu | Thr | Ala | Val | Met | Pro | Leu | 115 | 120 | 125 |
| Tyr | Leu | Asn | Ala | Leu | Thr | Gly | Lys | Pro | Val | His | Leu | Val | Thr | Val | Asn | 130 | 135 | 140 |
| Asp | Tyr | Leu | Ala | Gln | Arg | Asp | Cys | Glu | Trp | Val | Gly | Ser | Ile | Leu | Arg | 145 | 150 | 155 |
| Trp | Leu | Gly | Leu | Thr | Thr | Gly | Val | Leu | Ile | Ser | Gly | Ser | Pro | Leu | Glu | 165 | 170 | 175 |
| Lys | Arg | Lys | Asp | Ile | Tyr | Arg | Cys | Asp | Val | Val | Tyr | Gly | Thr | Ala | Ser | 180 | 185 | 190 |
| Glu | Phe | Gly | Phe | Asp | Tyr | Leu | Arg | Asp | Asn | Ser | Ile | Ala | Thr | Ser | Val | 195 | 200 | 205 |
| Asp | Glu | Gln | Val | Gly | Arg | Gly | Phe | Tyr | Phe | Ala | Ile | Ile | Asp | Glu | Val | 210 | 215 | 220 |
| Asp | Ser | Ile | Leu | Ile | Asp | Glu | Ala | Arg | Thr | Pro | Leu | Ile | Ile | Ser | Gly | 225 | 230 | 235 |
| Pro | Gly | Glu | Lys | His | Asn | Pro | Val | Tyr | Phe | Glu | Leu | Lys | Asp | Lys | Val | 245 | 250 | 255 |
| Ala | Asp | Leu | Val | Gln | Leu | Gln | Arg | Glu | Leu | Cys | Asn | Gln | Leu | Ala | Leu | 260 | 265 | 270 |
| Glu | Ala | Arg | Arg | Gly | Leu | Glu | Leu | Phe | Leu | Asp | Met | Asp | Ile | Leu | Pro | 275 | 280 | 285 |
| Lys | Asp | Lys | Lys | Val | Ile | Glu | Ala | Ile | Ser | Glu | Phe | Cys | Arg | Ser | Leu | 290 | 295 | 300 |
| Trp | Leu | Val | Ser | Lys | Gly | Met | Pro | Leu | Asn | Arg | Val | Leu | Arg | Arg | Val | 305 | 310 | 315 |

| | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| Arg | Glu | His | Pro | Asp | Leu | Arg | Ala | Met | Ile | Asp | Lys | Trp | Asp | Thr | Tyr | |
| | | | | 325 | | | | | 330 | | | | | 335 | | |
| Tyr | His | Ala | Glu | Gln | Asn | Lys | Glu | Glu | Ser | Ile | Glu | Lys | Leu | Ser | Gln | |
| | | | 340 | | | | | 345 | | | | | 350 | | | |
| Leu | Tyr | Ile | Ile | Val | Asp | Glu | His | Asn | Asn | Asp | Phe | Glu | Leu | Thr | Asp | |
| | | 355 | | | | | 360 | | | | | 365 | | | | |
| Arg | Gly | Met | Gln | Gln | Trp | Val | Asp | Lys | Ala | Gly | Gly | Ser | Ala | Glu | Asp | |
| | 370 | | | | | 375 | | | | | 380 | | | | | |
| Phe | Val | Met | Met | Asp | Met | Gly | His | Glu | Tyr | Ala | Leu | Ile | Asp | Gly | Asp | |
| 385 | | | | | 390 | | | | | 395 | | | | | 400 | |
| Asp | Thr | Leu | Ser | Pro | Thr | Glu | Lys | Ile | Asn | Arg | Lys | Ile | Ala | Ile | Ser | |
| | | | | 405 | | | | | 410 | | | | | 415 | | |
| Glu | Glu | Asp | Thr | Arg | Arg | Lys | Ala | Arg | Ala | His | Gly | Leu | Arg | Gln | Leu | |
| | | | 420 | | | | | 425 | | | | | 430 | | | |
| Leu | Arg | Ala | His | Leu | Leu | Met | Glu | Arg | Asp | Val | Asp | Tyr | Ile | Val | Arg | |
| | | 435 | | | | | 440 | | | | | 445 | | | | |
| Asn | Asp | Gln | Ile | Val | Ile | Ile | Asp | Glu | His | Thr | Gly | Arg | Pro | Gln | Pro | |
| | 450 | | | | | 455 | | | | | 460 | | | | | |
| Gly | Arg | Arg | Phe | Ser | Glu | Gly | Leu | His | Gln | Ala | Ile | Glu | Ala | Lys | Glu | |
| 465 | | | | | 470 | | | | | 475 | | | | | 480 | |
| His | Val | Thr | Ile | Arg | Lys | Glu | Ser | Gln | Thr | Phe | Ala | Thr | Val | Thr | Leu | |
| | | | 485 | | | | | | 490 | | | | | 495 | | |
| Gln | Asn | Phe | Phe | Arg | Leu | Tyr | Glu | Lys | Leu | Ala | Gly | Met | Thr | Gly | Thr | |
| | | | 500 | | | | | 505 | | | | | 510 | | | |
| Ala | Ile | Thr | Glu | Ser | Lys | Glu | Phe | Lys | Glu | Ile | Tyr | Asn | Leu | Tyr | Val | |
| | | 515 | | | | | 520 | | | | | 525 | | | | |
| Leu | Gln | Val | Pro | Thr | Phe | Lys | Glu | Cys | Leu | Arg | Val | Asp | His | Asn | Asp | |
| | 530 | | | | | 535 | | | | | 540 | | | | | |
| Glu | Phe | Tyr | Met | Thr | Glu | Arg | Glu | Lys | Tyr | His | Ala | Ile | Val | Lys | Glu | |
| 545 | | | | | 550 | | | | | 555 | | | | | 560 | |
| Ile | Ala | Arg | Ile | His | Ala | Val | Gly | Asn | Pro | Ile | Leu | Ile | Gly | Thr | Glu | |
| | | | | 565 | | | | | 570 | | | | | 575 | | |
| Ser | Val | Glu | Val | Ser | Glu | Lys | Leu | Ser | Arg | Ile | Leu | Arg | Gln | Asn | Arg | |
| | | | 580 | | | | | 585 | | | | | 590 | | | |
| Ile | Glu | His | Thr | Val | Leu | Asn | Ala | Lys | Asn | His | Ala | Gln | Glu | Ala | Glu | |
| | | 595 | | | | | 600 | | | | | 605 | | | | |
| Ile | Ile | Ala | Ala | Ala | Gly | Lys | Leu | Gly | Ala | Val | Thr | Val | Ala | Thr | Asn | |
| | 610 | | | | | 615 | | | | | 620 | | | | | |

| | | | | | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ala | Gly | Arg | Gly | Thr | Asp | Ile | Lys | Leu | Asp | Glu | Glu | Ala | Val | Val | 625 | 630 | 635 | 640 |
| Val | Gly | Gly | Leu | His | Val | Ile | Gly | Thr | Ser | Arg | His | Gln | Ser | Arg | Arg | 645 | 650 | 655 | |
| Ile | Asp | Arg | Gln | Leu | Arg | Gly | Arg | Cys | Ala | Arg | Leu | Gly | Asp | Pro | Gly | 660 | 665 | 670 | |
| Ser | Ala | Lys | Phe | Phe | Leu | Ser | Phe | Glu | Asp | Arg | Leu | Met | Arg | Leu | Phe | 675 | 680 | 685 | |
| Ala | Ser | Pro | Lys | Leu | Asn | Ala | Leu | Ile | Arg | His | Phe | Arg | Pro | Pro | Glu | 690 | 695 | 700 | |
| Gly | Glu | Ala | Met | Ser | Asp | Pro | Met | Phe | Asn | Lys | Leu | Ile | Glu | Thr | Ala | 705 | 710 | 715 | 720 |
| Gln | Lys | Arg | Val | Glu | Ala | Arg | Asn | Tyr | Thr | Ile | Arg | Lys | His | Thr | Leu | 725 | 730 | 735 | |
| Glu | Tyr | Asp | Asp | Val | Met | Asn | Arg | Gln | Arg | Gln | Thr | Ile | Tyr | Ala | Phe | 740 | 745 | 750 | |
| Arg | Asn | Asp | Val | Ile | Arg | Ser | Glu | Asp | Ile | Phe | Gly | Leu | Ala | Lys | Glu | 755 | 760 | 765 | |
| Ala | Ile | Ser | His | Val | Ala | Leu | Met | Ile | Ala | Ser | Leu | Ile | Val | Ser | Arg | 770 | 775 | 780 | |
| Asp | His | Pro | Thr | Gly | Asn | Ser | Leu | Pro | Arg | Leu | Glu | Glu | Trp | Met | Asn | 785 | 790 | 795 | 800 |
| Tyr | Ser | Phe | Pro | Leu | Gln | Leu | Asn | Ile | Glu | Glu | Leu | Lys | Arg | Leu | Lys | 805 | 810 | 815 | |
| Ser | Ile | Asp | Ala | Ile | Ala | Glu | Arg | Val | Ala | Asp | Asp | Leu | Ile | Glu | Val | 820 | 825 | 830 | |
| Phe | Gln | Asn | Lys | Phe | Ala | Ser | Met | Val | Gln | Glu | Ile | Thr | Glu | Ala | Ala | 835 | 840 | 845 | |
| Gly | Glu | Lys | Val | Asp | Ala | Asn | Gly | Val | Cys | Lys | Asp | Val | Ile | Arg | Ser | 850 | 855 | 860 | |
| Val | Met | Ile | Met | His | Ile | Asp | Glu | Gln | Trp | Lys | Ile | His | Leu | Val | Asp | 865 | 870 | 875 | 880 |
| Met | Asp | Leu | Leu | Arg | Ser | Glu | Val | Gly | Leu | Arg | Thr | Val | Gly | Gln | Lys | 885 | 890 | 895 | |
| Asp | Pro | Leu | Ile | Glu | Phe | Lys | His | Glu | Ser | Phe | Leu | Leu | Phe | Glu | Ser | 900 | 905 | 910 | |
| Leu | Ile | Arg | Asp | Ile | Arg | Ile | Ala | Ile | Val | Lys | His | Leu | Phe | Arg | Leu | 915 | 920 | 925 | |

Glu Leu Thr Met Thr Arg Glu Gln Arg Pro Gln Asn Val Val Pro Val
 930 935 940

Val Ala Thr Ser Phe Gln Asn Asn Glu Asn Phe Gly Pro Leu Glu Leu
 945 950 955 960

Thr Val Ile Ser Asp Ser Asp Asp Glu
 965

<210> 34

<211> 577

<212> DNA

<213> Chlamydia psittaci

<400> 34

gttgatgctg cagttattcc aggggaacttc gccattgcag ggggaatctg tccgtataaa 60
 aacagtctat acctagaaga tgtccgtact tccaataca ccaatgtcgt tgcatacgt 120
 gctgaagata tggaagactc gagaatgcat aaactaaaac agctattgca aagcagttct 180
 gtgcaggatt tctttaatac gaaatataag gggatctttt tatcgtagta acacatctgg 240
 atggcttagg gaagagttga gccaccccgt tctccgtagg tttaaggcat attgggaaac 300
 gattttcttg aattttttga aaaactttga ctgtttttct tttgattatt cgaagcagat 360
 gtatgtcgag tatggcggtt ttagggccca gaggtccttt cagttctcct tttacatggt 420
 ctctataccc aaccaccta aaaatgcact tgctagggtc cattcctata gttggcatat 480
 acattggagc gaagcggata gccgccgttg ctcaatatca tagaatgtgt agagcgaata 540
 caggagtgtc tcaggtgatt attcaggatt caggatt 577

<210> 35

<211> 76

<212> PRT

<213> Chlamydia psittaci

<400> 35

Val Asp Ala Ala Val Ile Pro Gly Asn Phe Ala Ile Ala Gly Gly Ile
 1 5 10 15

Cys Pro Tyr Lys Asn Ser Leu Tyr Leu Glu Asp Val Arg Thr Ser Gln
 20 25 30

Tyr Thr Asn Val Val Val Ile Arg Ala Glu Asp Met Glu Asp Ser Arg
 35 40 45

Met His Lys Leu Lys Gln Leu Leu Gln Ser Ser Ser Val Gln Asp Phe
 50 55 60

Phe Asn Thr Lys Tyr Lys Gly Ile Phe Leu Ser Gln
 65 70 75

<210> 36

<211> 804

<212> DNA

<213> Chlamydia psittaci

<400> 36

atgaaaaaaa tcacaatact ctcgttactt gcttttagcca tctctttaac aggttggtgc 60

```

aagaattcag aaggagtctt gcggattgcg gcgagtccca cgccacatgc agagcttctt 120
tatagtttag aaaaggaggc tcaatccctt ggattgcaat tgaaaatact tcccatagat 180
gattaccgtg tacctaaccg tttgctttta gataagcaaa tagaggcaaa ttattttcaa 240
catgaagatt tcttaaaaga tgagtgtgct cggtagcaat gcgaaggaaa acttgcgatt 300
ttggctaagg tacattttaga acctatgggt ttatatctta ataaaacca gtctctcgaa 360
gagcttaaag tcaaggaaca gctacgtata gcggttccta tagatagaac aaacgaacaa 420
cgtgcgctag acttattgcg agactgcaat ttgattagtt acaaagaagc ttctcatcta 480
gatatacccg caaaagatgt ctttggttgt ggagggaata aggtaacgat tatagagatg 540
gcagcacctt tattagatct ttctttacca gacgttgatg ctgcagttat tccagggaac 600
ttcgccattg cagggggaat ctgtccgtat aaaaacagtc tatacctaga agatgtccgt 660
acttcccaat acaccaatgt cgttgctcata cgtgctgaag atatggaaga ctcgagaatg 720
cataaactaa aacagctatt gcaaagcagt tctgtgcagg atttctttta tacgaaatat 780
aaggggatct ttttatcgca gtaa 804

```

<210> 37

<211> 267

<212> PRT

<213> Chlamydia psittaci

<400> 37

```

Met Lys Lys Ile Thr Ile Leu Ser Leu Leu Ala Leu Ala Ile Ser Leu
  1              5              10              15

Thr Gly Cys Cys Lys Asn Ser Glu Gly Val Leu Arg Ile Ala Ala Ser
      20              25              30

Pro Thr Pro His Ala Glu Leu Leu Tyr Ser Leu Glu Lys Glu Ala Gln
      35              40              45

Ser Leu Gly Leu Gln Leu Lys Ile Leu Pro Ile Asp Asp Tyr Arg Val
      50              55              60

Pro Asn Arg Leu Leu Leu Asp Lys Gln Ile Glu Ala Asn Tyr Phe Gln
      65              70              75              80

His Glu Asp Phe Leu Lys Asp Glu Cys Ala Arg Tyr Gln Cys Glu Gly
      85              90              95

Lys Leu Ala Ile Leu Ala Lys Val His Leu Glu Pro Met Gly Leu Tyr
      100              105              110

Ser Asn Lys Thr Gln Ser Leu Glu Glu Leu Lys Val Lys Glu Gln Leu
      115              120              125

Arg Ile Ala Val Pro Ile Asp Arg Thr Asn Glu Gln Arg Ala Leu Asp
      130              135              140

Leu Leu Arg Asp Cys Asn Leu Ile Ser Tyr Lys Glu Ala Ser His Leu
      145              150              155              160

Asp Ile Thr Ala Lys Asp Val Phe Gly Cys Gly Gly Lys Lys Val Thr
      165              170              175

Ile Ile Glu Met Ala Ala Pro Leu Leu Val Ser Ser Leu Pro Asp Val
      180              185              190

```

Asp Ala Ala Val Ile Pro Gly Asn Phe Ala Ile Ala Gly Gly Ile Cys
 195 200 205
 Pro Tyr Lys Asn Ser Leu Tyr Leu Glu Asp Val Arg Thr Ser Gln Tyr
 210 215 220
 Thr Asn Val Val Val Ile Arg Ala Glu Asp Met Glu Asp Ser Arg Met
 225 230 235 240
 His Lys Leu Lys Gln Leu Leu Gln Ser Ser Ser Val Gln Asp Phe Phe
 245 250 255
 Asn Thr Lys Tyr Lys Gly Ile Phe Leu Ser Gln
 260 265

<210> 38

<211> 402

<212> DNA

<213> Chlamydia psittaci

<400> 38

catgtattttt acgcaaaaaa taaacggtat aactcctgct tacaagccgc gctataccac 60
 aataatatcc cgacaaccgt gtacacaaac cttattgata tcgtgaagaa aaattcttca 120
 ctaatcacga agtacttttc catcaaaca c gatgcttaa atctaaaaga tttccatttt 180
 tatgatgttt atgctcccct aagtcagtc aaagagaaaa aatatacggt ccaagaagct 240
 gtggatctta tctatactag cctttctcct ctaggaacgg aatacattga taccttaaaa 300
 caggggttaa caactcaagg ctgggtagat aaatacgaaa atcttaataa acgctccgga 360
 gcctatttctt cgggatgtta cgatagccac ccttatgtcc tc 402

<210> 39

<211> 134

<212> PRT

<213> Chlamydia psittaci

<400> 39

His Val Phe Tyr Ala Lys Asn Lys Arg Tyr Asn Ser Cys Leu Gln Ala
 1 5 10 15
 Ala Leu Tyr His Asn Asn Ile Pro Thr Thr Val Tyr Thr Asn Leu Ile
 20 25 30
 Asp Ile Val Lys Lys Asn Ser Ser Leu Ile Thr Lys Tyr Phe Ser Ile
 35 40 45
 Lys Gln Arg Cys Leu Asn Leu Lys Asp Phe His Phe Tyr Asp Val Tyr
 50 55 60
 Ala Pro Leu Ser Gln Ser Lys Glu Lys Lys Tyr Thr Phe Gln Glu Ala
 65 70 75 80
 Val Asp Leu Ile Tyr Thr Ser Leu Ser Pro Leu Gly Thr Glu Tyr Ile
 85 90 95
 Asp Thr Leu Lys Gln Gly Leu Thr Thr Gln Gly Trp Val Asp Lys Tyr
 100 105 110

Glu Asn Leu Asn Lys Arg Ser Gly Ala Tyr Ser Ser Gly Cys Tyr Asp
 115 120 125

Ser His Pro Tyr Val Leu
 130

<210> 40

<211> 1827

<212> DNA

<213> Chlamydia psittaci

<400> 40

```

atgagcgtag aattcaacaa gcaacaagtc cgtccaagaa gtgaaatttc ccctcaagat 60
tggtgggata tcaccccctt atatctaaat agaaaagcat ggaaagcaga tcttgattct 120
ttcggattaa aaacagacgg ctacacctac tggcccgctc ttcaagcaac gcaataccaa 180
ctggacaact cagaatctct actatcctta ttaactactc tcttctctat tgagagaaaa 240
ttaaacaacac tctacgttta cgctcatctg actcatgatc aggatattac aaatcaagaa 300
ggcatcgcag atcttaaatc tatcacgcat ctacatacct tatttgccga agaaacctct 360
tggtgtacaac ccgctttaac cagcctatcg gaatctctca ttgctcagca cctatcagct 420
ccctgttttag ctctttatag attctattta gagaaaatct ttagactatc tatacacaca 480
ggcactcctg gagaagaaaa aattctcgct tccgccttta ctctcttga agtagccagt 540
aaggcatttt ctcttttaag tgactctgaa attccctttg ggcaagctac agactcagaa 600
ggaaactctc acccgctttc tcatgcactg gcttcattgt atatgcaatc cacagatcgg 660
gaattacgaa aaacatccta cctagcaciaa tgtgaaagat atcatagtta ccgacatacc 720
tttgctaact tactcaatgg gaaaatccaa gcccatgtat tttagcaciaa aaataaacgg 780
tataactcct gcttacaagc cgcgctatac cacaataata tcccgacaa cgtgtacaca 840
aaccttattg atatcgtgaa gaaaaattct tcactaatca cgaagtactt ttccatcaaa 900
caacgatgct taaatctaaa agatttccat ttttatgatg tttatgctcc cctaagtcag 960
tccaaagaga aaaaatatac gttccaagaa gctgtggatc ttatctatac tagcctttct 1020
cctctaggaa cggaatacat tgatacctta aaacaggggt taacaactca aggctgggta 1080
gataaatacg aaaatcttaa taaacgctcc ggagcctatt cttagggatg ttacgatagc 1140
cacccttatg tcctcctaaa ctatacaggc accctgtatg atgtatccgt cattgcccac 1200
gaaggcggac acagtatgca ctcgatattt agtaggaagc atcaaccttt ccatgacgct 1260
caatatccta ttttccttgc tgaaattgct tctaccttaa atgaaatgct tcttatggat 1320
tccatgctga aggagagcga ctcaaaagaa gagaaaatca ccattctgac acgatgtttg 1380
gataccatct tctctacact attccgtcag gtattattcg cctcttttga atacgatatt 1440
catcacgcag cagaacatgg ggttcctcta actgaagaat acctatcctc aacttacaag 1500
aatttacaaa atgagtttta cggagaaatt atcacatttg atgtcctgtc gaacatagaa 1560
tgggcaagaa ttcttcattt ctattacaat ttctacgtat accaatatgc aacgggcatt 1620
atagccgccc tgtgcttttt agaaaaaatt cttaacaacg aagataacgc tcttaactcc 1680
tatctcaact ttttaaaaag tgggtgatca gatttcccct tagaaatctt aaaaaaatca 1740
ggattagata tgggcacagt tgagccaatc caaaaagctt tttgctttat cgagaaaaaa 1800
atccaggagc tatcatcttt aatttga 1827

```

<210> 41

<211> 608

<212> PRT

<213> Chlamydia psittaci

<400> 41

Met Ser Val Glu Phe Asn Lys Gln Gln Val Arg Pro Arg Ser Glu Ile
 1 5 10 15

Ser Pro Gln Asp Cys Trp Asp Ile Thr Pro Leu Tyr Leu Asn Arg Lys

| 20 | | | | | 25 | | | | | 30 | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Trp | Lys | Ala | Asp | Leu | Asp | Ser | Phe | Gly | Leu | Lys | Thr | Asp | Gly | Ser |
| | | 35 | | | | | 40 | | | | | 45 | | | |
| Pro | Thr | Trp | Pro | Ala | Leu | Gln | Ala | Thr | Gln | Tyr | Gln | Leu | Asp | Asn | Ser |
| | 50 | | | | | 55 | | | | | 60 | | | | |
| Glu | Ser | Leu | Leu | Ser | Leu | Leu | Thr | Thr | Leu | Phe | Ser | Ile | Glu | Arg | Lys |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 |
| Leu | Asn | Lys | Leu | Tyr | Val | Tyr | Ala | His | Leu | Thr | His | Asp | Gln | Asp | Ile |
| | | | | 85 | | | | | 90 | | | | | 95 | |
| Thr | Asn | Gln | Glu | Gly | Ile | Ala | Asp | Leu | Lys | Ser | Ile | Thr | His | Leu | His |
| | | | 100 | | | | | 105 | | | | | 110 | | |
| Thr | Leu | Phe | Ala | Glu | Glu | Thr | Ser | Trp | Val | Gln | Pro | Ala | Leu | Thr | Ser |
| | | 115 | | | | | 120 | | | | | 125 | | | |
| Leu | Ser | Glu | Ser | Leu | Ile | Ala | Gln | His | Leu | Ser | Ala | Pro | Cys | Leu | Ala |
| | 130 | | | | | 135 | | | | | 140 | | | | |
| Pro | Tyr | Arg | Phe | Tyr | Leu | Glu | Lys | Ile | Phe | Arg | Leu | Ser | Ile | His | Thr |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 |
| Gly | Thr | Pro | Gly | Glu | Glu | Lys | Ile | Leu | Ala | Ser | Ala | Phe | Thr | Pro | Leu |
| | | | | 165 | | | | | 170 | | | | | 175 | |
| Glu | Val | Ala | Ser | Lys | Ala | Phe | Ser | Ser | Leu | Ser | Asp | Ser | Glu | Ile | Pro |
| | | 180 | | | | | | 185 | | | | | 190 | | |
| Phe | Gly | Gln | Ala | Thr | Asp | Ser | Glu | Gly | Asn | Ser | His | Pro | Leu | Ser | His |
| | | 195 | | | | | 200 | | | | | 205 | | | |
| Ala | Leu | Ala | Ser | Leu | Tyr | Met | Gln | Ser | Thr | Asp | Arg | Glu | Leu | Arg | Lys |
| | 210 | | | | | 215 | | | | | 220 | | | | |
| Thr | Ser | Tyr | Leu | Ala | Gln | Cys | Glu | Arg | Tyr | His | Ser | Tyr | Arg | His | Thr |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 |
| Phe | Ala | Asn | Leu | Leu | Asn | Gly | Lys | Ile | Gln | Ala | His | Val | Phe | Tyr | Ala |
| | | | | 245 | | | | | 250 | | | | | 255 | |
| Lys | Asn | Lys | Arg | Tyr | Asn | Ser | Cys | Leu | Gln | Ala | Ala | Leu | Tyr | His | Asn |
| | | | 260 | | | | | 265 | | | | | 270 | | |
| Asn | Ile | Pro | Thr | Thr | Val | Tyr | Thr | Asn | Leu | Ile | Asp | Ile | Val | Lys | Lys |
| | | 275 | | | | | 280 | | | | | 285 | | | |
| Asn | Ser | Ser | Leu | Ile | Thr | Lys | Tyr | Phe | Ser | Ile | Lys | Gln | Arg | Cys | Leu |
| | 290 | | | | | 295 | | | | | 300 | | | | |
| Asn | Leu | Lys | Asp | Phe | His | Phe | Tyr | Asp | Val | Tyr | Ala | Pro | Leu | Ser | Gln |
| 305 | | | | | 310 | | | | | 315 | | | | | 320 |
| Ser | Lys | Glu | Lys | Lys | Tyr | Thr | Phe | Gln | Glu | Ala | Val | Asp | Leu | Ile | Tyr |

| 325 | | | | | | 330 | | | | | | 335 | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Thr | Ser | Leu | Ser | Pro | Leu | Gly | Thr | Glu | Tyr | Ile | Asp | Thr | Leu | Lys | Gln |
| | | | 340 | | | | | 345 | | | | | 350 | | |
| Gly | Leu | Thr | Thr | Gln | Gly | Trp | Val | Asp | Lys | Tyr | Glu | Asn | Leu | Asn | Lys |
| | | 355 | | | | | 360 | | | | | 365 | | | |
| Arg | Ser | Gly | Ala | Tyr | Ser | Ser | Gly | Cys | Tyr | Asp | Ser | His | Pro | Tyr | Val |
| | 370 | | | | | 375 | | | | | 380 | | | | |
| Leu | Leu | Asn | Tyr | Thr | Gly | Thr | Leu | Tyr | Asp | Val | Ser | Val | Ile | Ala | His |
| 385 | | | | | 390 | | | | | 395 | | | | | 400 |
| Glu | Gly | Gly | His | Ser | Met | His | Ser | Tyr | Phe | Ser | Arg | Lys | His | Gln | Pro |
| | | | | 405 | | | | | 410 | | | | | 415 | |
| Phe | His | Asp | Ala | Gln | Tyr | Pro | Ile | Phe | Leu | Ala | Glu | Ile | Ala | Ser | Thr |
| | | | 420 | | | | | 425 | | | | | 430 | | |
| Leu | Asn | Glu | Met | Leu | Leu | Met | Asp | Ser | Met | Leu | Lys | Glu | Ser | Asp | Ser |
| | | 435 | | | | | 440 | | | | | 445 | | | |
| Lys | Glu | Glu | Lys | Ile | Thr | Ile | Leu | Thr | Arg | Cys | Leu | Asp | Thr | Ile | Phe |
| | 450 | | | | | 455 | | | | | 460 | | | | |
| Ser | Thr | Leu | Phe | Arg | Gln | Val | Leu | Phe | Ala | Ser | Phe | Glu | Tyr | Asp | Ile |
| 465 | | | | | 470 | | | | | 475 | | | | | 480 |
| His | His | Ala | Ala | Glu | His | Gly | Val | Pro | Leu | Thr | Glu | Glu | Tyr | Leu | Ser |
| | | | | 485 | | | | | 490 | | | | | 495 | |
| Ser | Thr | Tyr | Lys | Asn | Leu | Gln | Asn | Glu | Phe | Tyr | Gly | Glu | Ile | Ile | Thr |
| | | | 500 | | | | | 505 | | | | | 510 | | |
| Phe | Asp | Val | Leu | Ser | Asn | Ile | Glu | Trp | Ala | Arg | Ile | Pro | His | Phe | Tyr |
| | | 515 | | | | | 520 | | | | | 525 | | | |
| Tyr | Asn | Phe | Tyr | Val | Tyr | Gln | Tyr | Ala | Thr | Gly | Ile | Ile | Ala | Ala | Leu |
| | 530 | | | | | 535 | | | | | 540 | | | | |
| Cys | Phe | Leu | Glu | Lys | Ile | Leu | Asn | Asn | Glu | Asp | Asn | Ala | Leu | Asn | Ser |
| 545 | | | | | 550 | | | | | 555 | | | | | 560 |
| Tyr | Leu | Asn | Phe | Leu | Lys | Ser | Gly | Gly | Ser | Asp | Phe | Pro | Leu | Glu | Ile |
| | | | | 565 | | | | | 570 | | | | | 575 | |
| Leu | Lys | Lys | Ser | Gly | Leu | Asp | Met | Gly | Thr | Val | Glu | Pro | Ile | Gln | Lys |
| | | | 580 | | | | | 585 | | | | | 590 | | |
| Ala | Phe | Cys | Phe | Ile | Glu | Lys | Lys | Ile | Gln | Glu | Leu | Ser | Ser | Leu | Ile |
| | | 595 | | | | | 600 | | | | | 605 | | | |

<210> 42
 <211> 1517
 <212> DNA
 <213> Chlamydia psittaci

<400> 42
 gcgttagatt cggaagagct gaaagagcaa ataaacaatc taaaagagcg tttatgggat 60
 gcacaatcca ctctacaaca agatcaaaat aaactatcgc aagaacattt tgaagctgtc 120
 agtgtgatca ttgatttaat caatgggtgat ctgaatgata tagctgagca tacgcaacaa 180
 aacttacaaa ccaaaaaaga agaagaacac gagtccgttg cccgtaagat ggtcaattgg 240
 gtgtcttctg gagaagaagt gttaaataga gcccttctct acttctcaga taggaatgga 300
 gaacgggaaa atttagcaga ctttttataaa gtacagtatg ctgttcaaag agcaacgcaa 360
 agagcagaac tttttgctag tatcgtagga actacggtaa gtagtataaa gacgataatg 420
 accacacaat taggttaaca tggacgaatt gacgacagat ttcgataccc tcatgtcgca 480
 attgaacgac gtacacttga ctaccgttgt cggtcgtata actgaagtcg tcggtatggt 540
 aattaaagct gtcgttccca atgtacgcgt tggggaggta tgcttagtta aacgttatgg 600
 tatggagccg ctctgtgaccg aagtcgtcgg cttcacacaa aatttcgctt ttttatcgcc 660
 actaggagaa cttactggag tcagcccttc ttcagagggt attcccacag gtctgccttt 720
 gtatatccgt gcaggtaacg gtcttttagg tcgtgtattg aatgggtctg gagaacctat 780
 cgactccgag atcaaaggac ctttggttga tgttaacgaa acctaccctg tgtttcgcgc 840
 tccaccagat ccattgcata gagaaaaatt aagaacaatt ttatccaccg gcgtgcggtg 900
 tatcgacggg atgctcacag tcgccagagg ccagcgtata ggcatTTTTT ctggagctgg 960
 ggtgggtaaa tcgtctctct tgggaatgat cgctagaaac gcggaagaag ccgatgtcaa 1020
 tgtgattgct ctcatcggag agcggggccg agagggtcgt gaatttatcg agggcgatct 1080
 cggagaagaa ggaatgaaac gttcgggtgat cgctcgtctc acttcagatc aatcctcaca 1140
 gttgcgatta aatgctgctt acgtaggcac cgctatagca gagtattttc gtgatcaggg 1200
 caaaaccgta gttttgatga tggattctgt cacccgattt gcccgagccc taagagaagt 1260
 cgggtctagct gccggagaac cgccagctcg aggaggatac acaccttctg tattctcaac 1320
 tttgcctagg ttattagaac gttccggagc ttcggataaa ggaacaatca cagcctttta 1380
 cacagtactt gttgccgggg atgatatgaa tgaaccggtc gctgatgaag ttaaatacgat 1440
 tcttgatggg caggttgctt tgtctaacgc tttagctcag gcataccatt atcctgctat 1500
 tgatgtctta gcatcta 1517

<210> 43
 <211> 145
 <212> PRT
 <213> Chlamydia psittaci

<400> 43
 Ala Leu Asp Ser Glu Glu Leu Lys Glu Gln Ile Asn Asn Leu Lys Glu
 1 5 10 15
 Arg Leu Trp Asp Ala Gln Ser Thr Leu Gln Gln Asp Gln Asn Lys Leu
 20 25 30
 Ser Gln Glu His Phe Glu Ala Val Ser Val Ile Ile Asp Leu Ile Asn
 35 40 45
 Gly Asp Leu Asn Asp Ile Ala Glu His Thr Gln Gln Asn Leu Gln Thr
 50 55 60
 Lys Lys Glu Glu Glu His Glu Ser Val Ala Arg Lys Met Val Asn Trp
 65 70 75 80
 Val Ser Ser Gly Glu Glu Val Leu Asn Arg Ala Leu Leu Tyr Phe Ser
 85 90 95

Asp Arg Asn Gly Glu Arg Glu Asn Leu Ala Asp Phe Leu Lys Val Gln
 100 105 110

Tyr Ala Val Gln Arg Ala Thr Gln Arg Ala Glu Leu Phe Ala Ser Ile
 115 120 125

Val Gly Thr Thr Val Ser Ser Ile Lys Thr Ile Met Thr Thr Gln Leu
 130 135 140

Gly
 145

<210> 44
 <211> 669
 <212> DNA
 <213> Chlamydia psittaci

<400> 44
 atggtagatc ctttgaagct tttcccaaag ctagactccg agaaagaaac agcttctata 60
 cagaagcctt taggaactcc tttagccagt gagttacata aggaagttcc tgcattttct 120
 ttagggacgg cagcagactc cttgaataaa aatatagagg atgtcaagcc taaccctatg 180
 gcgatgatgc aagacagaaa ctctaacatt atcgatcctg aactggaaga ggcgttagat 240
 tcggaagagc tgaaagagca aataaacaat ctaaaagagc gtttatggga tgcacaatcc 300
 actctacaac aagatcaaaa taaactatcg caagaacatt ttgaagctgt cagtgtgatc 360
 attgatttaa tcaatggtga tctgaatgat atagctgagc atacgcaaca aaacttaca 420
 accaaaaaag aagaagaaca cgagtcggtt gcccgtaaga tgggtcaattg ggtgtcttct 480
 ggagaagaag tgttaaatag agcccttctc tactttctcag ataggaatgg agaacgggaa 540
 aatttagcag acttttttaa agtacagtat gctgttcaaa gagcaacgca aagagcagaa 600
 ctttttgcta gtatcgtagg aactacggta agtagtataa agacgataat gaccacacaa 660
 ttaggttaa 669

<210> 45
 <211> 222
 <212> PRT
 <213> Chlamydia psittaci

<400> 45
 Met Val Asp Pro Leu Lys Leu Phe Pro Lys Leu Asp Ser Glu Lys Glu
 1 5 10 15

Thr Ala Ser Ile Gln Lys Pro Leu Gly Thr Pro Leu Ala Ser Glu Leu
 20 25 30

His Lys Glu Val Pro Ala Phe Ser Leu Gly Thr Ala Ala Asp Ser Leu
 35 40 45

Asn Lys Asn Ile Glu Asp Val Lys Pro Asn Pro Met Ala Met Met Gln
 50 55 60

Asp Arg Asn Ser Asn Ile Ile Asp Pro Glu Leu Glu Glu Ala Leu Asp
 65 70 75 80

Ser Glu Glu Leu Lys Glu Gln Ile Asn Asn Leu Lys Glu Arg Leu Trp
 85 90 95

Asp Ala Gln Ser Thr Leu Gln Gln Asp Gln Asn Lys Leu Ser Gln Glu
 100 105 110
 His Phe Glu Ala Val Ser Val Ile Ile Asp Leu Ile Asn Gly Asp Leu
 115 120 125
 Asn Asp Ile Ala Glu His Thr Gln Gln Asn Leu Gln Thr Lys Lys Glu
 130 135 140
 Glu Glu His Glu Ser Val Ala Arg Lys Met Val Asn Trp Val Ser Ser
 145 150 155 160
 Gly Glu Glu Val Leu Asn Arg Ala Leu Leu Tyr Phe Ser Asp Arg Asn
 165 170 175
 Gly Glu Arg Glu Asn Leu Ala Asp Phe Leu Lys Val Gln Tyr Ala Val
 180 185 190
 Gln Arg Ala Thr Gln Arg Ala Glu Leu Phe Ala Ser Ile Val Gly Thr
 195 200 205
 Thr Val Ser Ser Ile Lys Thr Ile Met Thr Thr Gln Leu Gly
 210 215 220

<210> 46

<211> 1329

<212> DNA

<213> Chlamydia psittaci

<400> 46

atggacgaat tgacgacaga tttcgatacc ctcatgtcgc aattgaacga cgtacacttg 60
 actaccgttg tcggtcgtat aactgaagtc gtcggtatgt taattaaagc tgtcgttccc 120
 aatgtacgcg ttgggggaggt atgcttagtt aaacgttatg gtatggagcc gctcgtgacc 180
 gaagtcgctcg gcttcacaca aaatttcgct tttttatcgc cactaggaga acttactgga 240
 gtcagccctt cttcagaggt tattcccaca ggtctgcctt tgtatatccg tgcaggtaac 300
 ggtcttttag gtcgtgtatt gaatgggtctg ggagaaccta tcgactccga gatcaaagga 360
 ccttttggttg atgttaacga aacctaccct gtgttttcgcg ctccaccaga tccattgcat 420
 agagaaaaat taagaacaat tttatccacc ggcggtgcggt gtatcgacgg tatgctcaca 480
 gtcgccagag gccagcgtat aggcattttt gctggagctg ggggtgggtaa atcgtctctc 540
 ttgggaatga tcgctagaaa cgcggaagaa gccgatgtca atgtgattgc tctcatcgga 600
 gagcggggcc gagagggttcg tgaatttatc gagggcgatc tcggagaaga aggaatgaaa 660
 cgttcggtga tcgtcgtctc tacttcagat caatcctcac agttgcgatt aaatgctgct 720
 tacgtaggca ccgctatagc agagtatttt cgtgatcagg gcaaaaccgt agttttgatg 780
 atggattctg tcacccgatt tgcccagagc ctaagagaag tcggtctagc tgccggagaa 840
 ccgccagctc gaggaggata cacaccttct gtattctcaa ctttgcctag gttattagaa 900
 cgttccggag cttcggataa aggaacaatc acagcctttt acacagtact tgttgccggg 960
 gatgatatga atgaaccggt cgctgatgaa gttaaatacga ttcttgatgg tcacgttgctc 1020
 ttgtctaacg ctttagctca ggcataccat taccctgcta ttgatgtctt agcatctatc 1080
 agccgattgc tgacagcaat tgttcctgag gaacaacgac gcatcatagg aaaagcccga 1140
 gaggtgctgg caaaatacaa agcaaacgaa atgcttatac gtattggaga atatcgccga 1200
 gggtcggatc gtgaagtgga ttttgctata gatcacattg ataaattgaa cagattctta 1260
 aagcaagata ttcatgaaaa aacaaattac gaggaagcct cgcaacagct tcgggctatt 1320
 ttccgataa 1329

<210> 47

<211> 442

<212> PRT

<213> Chlamydia psittaci

<400> 47

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Asp | Glu | Leu | Thr | Thr | Asp | Phe | Asp | Thr | Leu | Met | Ser | Gln | Leu | Asn |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |
| Asp | Val | His | Leu | Thr | Thr | Val | Val | Gly | Arg | Ile | Thr | Glu | Val | Val | Gly |
| | | | 20 | | | | | 25 | | | | | 30 | | |
| Met | Leu | Ile | Lys | Ala | Val | Val | Pro | Asn | Val | Arg | Val | Gly | Glu | Val | Cys |
| | | 35 | | | | | 40 | | | | | 45 | | | |
| Leu | Val | Lys | Arg | Tyr | Gly | Met | Glu | Pro | Leu | Val | Thr | Glu | Val | Val | Gly |
| | 50 | | | | | 55 | | | | | 60 | | | | |
| Phe | Thr | Gln | Asn | Phe | Ala | Phe | Leu | Ser | Pro | Leu | Gly | Glu | Leu | Thr | Gly |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 |
| Val | Ser | Pro | Ser | Ser | Glu | Val | Ile | Pro | Thr | Gly | Leu | Pro | Leu | Tyr | Ile |
| | | | | 85 | | | | | 90 | | | | | 95 | |
| Arg | Ala | Gly | Asn | Gly | Leu | Leu | Gly | Arg | Val | Leu | Asn | Gly | Leu | Gly | Glu |
| | | | 100 | | | | | 105 | | | | | 110 | | |
| Pro | Ile | Asp | Ser | Glu | Ile | Lys | Gly | Pro | Leu | Val | Asp | Val | Asn | Glu | Thr |
| | | 115 | | | | | 120 | | | | | 125 | | | |
| Tyr | Pro | Val | Phe | Arg | Ala | Pro | Pro | Asp | Pro | Leu | His | Arg | Glu | Lys | Leu |
| | 130 | | | | | 135 | | | | | 140 | | | | |
| Arg | Thr | Ile | Leu | Ser | Thr | Gly | Val | Arg | Cys | Ile | Asp | Gly | Met | Leu | Thr |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 |
| Val | Ala | Arg | Gly | Gln | Arg | Ile | Gly | Ile | Phe | Ala | Gly | Ala | Gly | Val | Gly |
| | | | | 165 | | | | | 170 | | | | | 175 | |
| Lys | Ser | Ser | Leu | Leu | Gly | Met | Ile | Ala | Arg | Asn | Ala | Glu | Glu | Ala | Asp |
| | | | 180 | | | | | 185 | | | | | 190 | | |
| Val | Asn | Val | Ile | Ala | Leu | Ile | Gly | Glu | Arg | Gly | Arg | Glu | Val | Arg | Glu |
| | | 195 | | | | | 200 | | | | | 205 | | | |
| Phe | Ile | Glu | Gly | Asp | Leu | Gly | Glu | Glu | Gly | Met | Lys | Arg | Ser | Val | Ile |
| | 210 | | | | | 215 | | | | | 220 | | | | |
| Val | Val | Ser | Thr | Ser | Asp | Gln | Ser | Ser | Gln | Leu | Arg | Leu | Asn | Ala | Ala |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 |
| Tyr | Val | Gly | Thr | Ala | Ile | Ala | Glu | Tyr | Phe | Arg | Asp | Gln | Gly | Lys | Thr |
| | | | | 245 | | | | | 250 | | | | | 255 | |
| Val | Val | Leu | Met | Met | Asp | Ser | Val | Thr | Arg | Phe | Ala | Arg | Ala | Leu | Arg |
| | | | 260 | | | | | 265 | | | | | 270 | | |

Glu Val Gly Leu Ala Ala Gly Glu Pro Pro Ala Arg Gly Gly Tyr Thr
 275 280 285
 Pro Ser Val Phe Ser Thr Leu Pro Arg Leu Leu Glu Arg Ser Gly Ala
 290 295 300
 Ser Asp Lys Gly Thr Ile Thr Ala Phe Tyr Thr Val Leu Val Ala Gly
 305 310 315 320
 Asp Asp Met Asn Glu Pro Val Ala Asp Glu Val Lys Ser Ile Leu Asp
 325 330 335
 Gly His Val Val Leu Ser Asn Ala Leu Ala Gln Ala Tyr His Tyr Pro
 340 345 350
 Ala Ile Asp Val Leu Ala Ser Ile Ser Arg Leu Leu Thr Ala Ile Val
 355 360 365
 Pro Glu Glu Gln Arg Arg Ile Ile Gly Lys Ala Arg Glu Val Leu Ala
 370 375 380
 Lys Tyr Lys Ala Asn Glu Met Leu Ile Arg Ile Gly Glu Tyr Arg Arg
 385 390 395 400
 Gly Ser Asp Arg Glu Val Asp Phe Ala Ile Asp His Ile Asp Lys Leu
 405 410 415
 Asn Arg Phe Leu Lys Gln Asp Ile His Glu Lys Thr Asn Tyr Glu Glu
 420 425 430
 Ala Ser Gln Gln Leu Arg Ala Ile Phe Arg
 435 440

<210> 48

<211> 477

<212> DNA

<213> Chlamydia psittaci

<400> 48

cttcttgcag atgccgactc tgtcaacctt gcaactggat tcaacggctc cactagtga 60
 actttcaatg ttaaacaac agataatgct gacgggacaa catatatctt aggcagcgcg 120
 atcacctttg aacacataaa tcaattaaaa ccagcaaaca ctagctgttt tgctaataca 180
 gctggagatc taacgtttac tgggaatcga cgacttctct atttcaataa tatttcatca 240
 acagcgaaag gtgccgctat cagcacaact gcggatggta agacactcac aatatccggg 300
 gctctacaac tgattttcta catgtcgcca agattggcca cgggaaatgg cgtcatttat 360
 tctaatagct ctgtactcat cgagaacaat tctcaaggta gctcgggact gaataagtct 420
 gcagggaaag gcgtctttat ttgttgtgag aaaagtacgg atgtgggagc tacatca 477

<210> 49

<211> 159

<212> PRT

<213> Chlamydia psittaci

<400> 49

Leu Leu Ala Asp Ala Asp Ser Val Asn Leu Ala Thr Gly Phe Asn Gly

| | | | |
|---|-----|-----|-----|
| 1 | 5 | 10 | 15 |
| Ser Thr Ser Glu Thr Phe Asn Val Lys Gln Thr Asp Asn Ala Asp Gly | 20 | 25 | 30 |
| Thr Thr Tyr Ile Leu Gly Ser Ala Ile Thr Phe Glu His Ile Asn Gln | 35 | 40 | 45 |
| Leu Lys Pro Ala Asn Thr Ser Cys Phe Ala Asn Thr Ala Gly Asp Leu | 50 | 55 | 60 |
| Thr Phe Thr Gly Asn Arg Arg Leu Leu Tyr Phe Asn Asn Ile Ser Ser | 65 | 70 | 75 |
| Thr Ala Lys Gly Ala Ala Ile Ser Thr Thr Ala Asp Gly Lys Thr Leu | 85 | 90 | 95 |
| Thr Ile Ser Gly Ala Leu Gln Leu Ile Phe Tyr Met Ser Pro Arg Leu | 100 | 105 | 110 |
| Ala Thr Gly Asn Gly Val Ile Tyr Ser Asn Ser Ser Val Leu Ile Glu | 115 | 120 | 125 |
| Asn Asn Ser Gln Gly Ser Ser Gly Leu Asn Lys Ser Ala Gly Lys Gly | 130 | 135 | 140 |
| Val Phe Ile Cys Cys Glu Lys Ser Thr Asp Val Gly Ala Thr Ser | 145 | 150 | 155 |

<210> 50

<211> 591

<212> DNA

<213> Chlamydia psittaci

<400> 50

```

acctttgaac acataaatca attaaaacca gcaaacacta gctgttttgc taatacagct 60
ggagatctaa cgtttactgg gaatcgacga cttctctatt tcaataatat ttcataca 120
gcgaaaggtg ccgctatcag cacaactgcg gatggtaaga cactcacaat atccggggct 180
ctacaactga ttttctacat gtcgccaaga ttggccacgg gaaatggcgt catttattct 240
aatagctctg tactcatcga gaacaattct caaggtagct cgggactgaa taagtctgca 300
gggaaaggcg tctttatttg ttgtgagaaa agtacggatg tgggagctac atcaccgaca 360
ttaatcatac ggaataacgg agagtttctt actgtaggta atgcagctac tagctctgga 420
ggagcgatth atgcggagaa aatgatctta tcctcaggag gatatacaaa atttcaatcc 480
aatgttagct atgatcaagg tggggccatt gccattgctc ctaatggaga aattagtctc 540
tccgcggata aaggaaatat cgtctttgaa agaaacctta aaattgccaa c 591

```

<210> 51

<211> 197

<212> PRT

<213> Chlamydia psittaci

<400> 51

| | | | | |
|---|---|---|----|----|
| Thr Phe Glu His Ile Asn Gln Leu Lys Pro Ala Asn Thr Ser Cys Phe | 1 | 5 | 10 | 15 |
|---|---|---|----|----|

| | | | | | | |
|-------------|-------------|------------|-------------|-------------|-------------|-----|
| <400> 52 | | | | | | |
| atgcagggaa | tactaatgaa | aaactctatt | tatgggggttt | tactgttttc | ctctttttgcc | 60 |
| ttatccactg | ctaccaaaact | tcttgagat | gccgactctg | tcaaccttgc | aactggattc | 120 |
| aacggctcca | ctagtgaaac | tttcaatgtt | aaacaaacag | ataatgctga | cgggacaaca | 180 |
| tatattctag | gcagcgcgat | cacctttgaa | cacataaatc | aattaaacc | agcaaacact | 240 |
| agctgtttttg | ctaatacagc | tggagatcta | acgtttactg | ggaatcgacg | acttctctat | 300 |
| ttcaataata | tttcatcaac | agcgaaagg | gccgctatca | gcacaactgc | ggatggtaag | 360 |
| acactcacia | tatccggggc | tctacaactg | atthttctaca | tgtcgccaag | attggccacg | 420 |
| ggaaatggcg | tcattttattc | taatagctct | gtactcatcg | agaacaattc | tcaaggtagc | 480 |
| tcgggactga | ataagtctgc | agggaaggc | gtcttttattt | gttgtgagaa | aagtacggat | 540 |
| gtgggagcta | catcaccgac | attaatcata | cggaataacg | gagagtthct | tactgtagg | 600 |
| aatgcagcta | ctagctctgg | aggagcgatt | tatgcggaga | aatgatctt | atcctcagga | 660 |
| ggatatacaa | aattttcaatc | caatgttagc | tatgatcaag | gtggggccat | tgccattgct | 720 |
| cctaattggag | aaatttagtct | ctccgcggat | aaaggaaata | tcgtcttttga | aagaaacctt | 780 |
| aaaattgcca | acaaacaaaa | tactcccaat | gccattcacc | taggagacaa | tgcgaaattt | 840 |

```

cttcaattac gtgctgctaa caacaaagcc atattttttt atgacccgat tacaaccacg 900
ggatctgtgg cagatcggct aattattaat aactcgcaag gagaagcctc gacttacgat 960
ggggcgattg tatttttctag tctcaactta ttcactcatt cccctgaatg taaactctct 1020
tcatttttctc aaggtcttac ttttagcggca ggatcattag ttttagaaga ggggggtatgt 1080
gtacaagctc cgtctttttga tcaacgtgct cactcccaac tattcatgaa tcctgggacg 1140
aagttacaag ctacccagaa catctcggta aagaatctcc atctcaatct taatagaata 1200
gcagaagagc cggcgtatat caccacaaca gacgatgctt ctagtgtgga catttgcgga 1260
cctgtagtta tgcataataga tgatgagatc ttctataatc agacagtatt agcaaatgag 1320
ttgtctgtag agtgttttaa tctcagttct ccacatctcg ataatatcac tattgatgac 1380
gttccccgag tgcctatcat gacgttagaa tcgcatcgtg gttatcaagg tacatgggaa 1440
atctcttgga aagagcaacc taaacttacc tttgggaagg cgactatcgc gcctaataag 1500
cagatgcacc ttatttgga accttctggg tacgttcctt tctcaggggg aactggagag 1560
tttacgacat ctttagtgcc taatagctta tggaatctct ttttagatac acgtttttct 1620
caacaagcga ttgagaaaca tgctgtatct tcaggtaacg gtatatggat ttcctccatg 1680
accaatfctt ttcttcaagg ttctacgaac aacaaccacg gctttcgtca taagagttca 1740
ggatataaccg caggggggaaa aatacaaaca cttcaagatg atatctttag tgtcagtttt 1800
tctcagctat ttgggagatc taaggatttt ggatctgcca catctaagga tacattccta 1860
tcgggctcta tctatgctca gcattcgaga cgcttacttc ctataatgag attccttgca 1920
ggaacatcaa catatagacc gcgactctta ctgagtattc ccaagaatct tcctatcaat 1980
tttgatgttc ttgtgagtta cagctatgac agtaaccaca tgaaagtaca aaaattctaa 2040

```

<210> 53

<211> 679

<212> PRT

<213> Chlamydia psittaci

<400> 53

```

Met Gln Gly Ile Leu Met Lys Asn Ser Ile Tyr Gly Val Leu Leu Phe
  1              5              10             15

Ser Ser Phe Ala Leu Ser Thr Ala Thr Lys Leu Leu Ala Asp Ala Asp
      20              25              30

Ser Val Asn Leu Ala Thr Gly Phe Asn Gly Ser Thr Ser Glu Thr Phe
      35              40              45

Asn Val Lys Gln Thr Asp Asn Ala Asp Gly Thr Thr Tyr Ile Leu Gly
      50              55              60

Ser Ala Ile Thr Phe Glu His Ile Asn Gln Leu Lys Pro Ala Asn Thr
      65              70              75              80

Ser Cys Phe Ala Asn Thr Ala Gly Asp Leu Thr Phe Thr Gly Asn Arg
      85              90              95

Arg Leu Leu Tyr Phe Asn Asn Ile Ser Ser Thr Ala Lys Gly Ala Ala
      100             105             110

Ile Ser Thr Thr Ala Asp Gly Lys Thr Leu Thr Ile Ser Gly Ala Leu
      115             120             125

Gln Leu Ile Phe Tyr Met Ser Pro Arg Leu Ala Thr Gly Asn Gly Val
      130             135             140

Ile Tyr Ser Asn Ser Ser Val Leu Ile Glu Asn Asn Ser Gln Gly Ser
      145             150             155             160

```

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Gly | Leu | Asn | Lys | Ser | Ala | Gly | Lys | Gly | Val | Phe | Ile | Cys | Cys | Glu |
| | | | | 165 | | | | | 170 | | | | | 175 | |
| Lys | Ser | Thr | Asp | Val | Gly | Ala | Thr | Ser | Pro | Thr | Leu | Ile | Ile | Arg | Asn |
| | | | 180 | | | | | 185 | | | | | 190 | | |
| Asn | Gly | Glu | Phe | Leu | Thr | Val | Gly | Asn | Ala | Ala | Thr | Ser | Ser | Gly | Gly |
| | | 195 | | | | | 200 | | | | | 205 | | | |
| Ala | Ile | Tyr | Ala | Glu | Lys | Met | Ile | Leu | Ser | Ser | Gly | Gly | Tyr | Thr | Lys |
| | 210 | | | | | 215 | | | | | 220 | | | | |
| Phe | Gln | Ser | Asn | Val | Ser | Tyr | Asp | Gln | Gly | Gly | Ala | Ile | Ala | Ile | Ala |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 |
| Pro | Asn | Gly | Glu | Ile | Ser | Leu | Ser | Ala | Asp | Lys | Gly | Asn | Ile | Val | Phe |
| | | | | 245 | | | | | 250 | | | | | 255 | |
| Glu | Arg | Asn | Leu | Lys | Ile | Ala | Asn | Lys | Gln | Asn | Thr | Pro | Asn | Ala | Ile |
| | | | 260 | | | | | 265 | | | | | 270 | | |
| His | Leu | Gly | Asp | Asn | Ala | Lys | Phe | Leu | Gln | Leu | Arg | Ala | Ala | Asn | Asn |
| | | 275 | | | | | 280 | | | | | 285 | | | |
| Lys | Ala | Ile | Phe | Phe | Tyr | Asp | Pro | Ile | Thr | Thr | Thr | Gly | Ser | Val | Ala |
| | 290 | | | | | 295 | | | | | 300 | | | | |
| Asp | Arg | Leu | Ile | Ile | Asn | Asn | Ser | Gln | Gly | Glu | Ala | Ser | Thr | Tyr | Asp |
| 305 | | | | | 310 | | | | | 315 | | | | | 320 |
| Gly | Ala | Ile | Val | Phe | Ser | Ser | Leu | Asn | Leu | Phe | Thr | His | Ser | Pro | Glu |
| | | | | 325 | | | | | 330 | | | | | 335 | |
| Cys | Lys | Leu | Ser | Ser | Phe | Ser | Gln | Gly | Leu | Thr | Leu | Ala | Ala | Gly | Ser |
| | | | 340 | | | | | 345 | | | | | 350 | | |
| Leu | Val | Leu | Glu | Glu | Gly | Val | Cys | Val | Gln | Ala | Pro | Ser | Phe | Asp | Gln |
| | | 355 | | | | | 360 | | | | | 365 | | | |
| Arg | Ala | His | Ser | Gln | Leu | Phe | Met | Asn | Pro | Gly | Thr | Lys | Leu | Gln | Ala |
| | 370 | | | | | 375 | | | | | 380 | | | | |
| Thr | Gln | Asn | Ile | Ser | Val | Lys | Asn | Leu | His | Leu | Asn | Leu | Asn | Arg | Ile |
| 385 | | | | | 390 | | | | | 395 | | | | | 400 |
| Ala | Glu | Glu | Pro | Ala | Tyr | Ile | Thr | Thr | Thr | Asp | Asp | Ala | Ser | Ser | Val |
| | | | | 405 | | | | | 410 | | | | | 415 | |
| Asp | Ile | Cys | Gly | Pro | Val | Val | Met | His | Ile | Asp | Asp | Glu | Ile | Phe | Tyr |
| | | | 420 | | | | 425 | | | | | | 430 | | |
| Asn | Gln | Thr | Val | Leu | Ala | Asn | Glu | Leu | Ser | Val | Glu | Cys | Leu | Asn | Leu |
| | | 435 | | | | | 440 | | | | | 445 | | | |
| Ser | Ser | Pro | His | Leu | Asp | Asn | Ile | Thr | Ile | Asp | Asp | Val | Pro | Ala | Val |
| | 450 | | | | | 455 | | | | | 460 | | | | |

Pro Ile Met Thr Leu Glu Ser His Arg Gly Tyr Gln Gly Thr Trp Glu
 465 470 475 480
 Ile Ser Trp Lys Glu Gln Pro Lys Leu Thr Phe Gly Lys Ala Thr Ile
 485 490 495
 Ala Pro Asn Lys Gln Met His Leu Ile Trp Lys Pro Ser Gly Tyr Val
 500 505 510
 Pro Phe Ser Gly Gly Thr Gly Glu Phe Thr Thr Ser Leu Val Pro Asn
 515 520 525
 Ser Leu Trp Asn Leu Phe Leu Asp Thr Arg Phe Ser Gln Gln Ala Ile
 530 535 540
 Glu Lys His Ala Val Ser Ser Gly Asn Gly Ile Trp Ile Ser Ser Met
 545 550 555 560
 Thr Asn Ser Phe Leu Gln Gly Ser Thr Asn Asn Asn His Gly Phe Arg
 565 570 575
 His Lys Ser Ser Gly Tyr Thr Ala Gly Gly Lys Ile Gln Thr Leu Gln
 580 585 590
 Asp Asp Ile Phe Ser Val Ser Phe Ser Gln Leu Phe Gly Arg Ser Lys
 595 600 605
 Asp Phe Gly Ser Ala Thr Ser Lys Asp Thr Phe Leu Ser Gly Ser Ile
 610 615 620
 Tyr Ala Gln His Ser Arg Arg Leu Leu Pro Ile Met Arg Phe Leu Ala
 625 630 635 640
 Gly Thr Ser Thr Tyr Arg Pro Arg Leu Leu Leu Ser Ile Pro Lys Asn
 645 650 655
 Leu Pro Ile Asn Phe Asp Val Leu Val Ser Tyr Ser Tyr Asp Ser Asn
 660 665 670
 His Met Lys Val Gln Lys Phe
 675

<210> 54

<211> 487

<212> DNA

<213> Chlamydia psittaci

<400> 54

acctcgagag aggattctct tagtgtggct ttctgtcagt tatttgcaaa agataaagac 60
 taccttgtaa gcaagaacgc cgcaaacgtc tatgcggggt ctgtatatatta tcagcatgtg 120
 agcaagtttg atgatctcac gcgggttattt aatgggccta acacgtggtg ttcagggttt 180
 tctaaagaga ttcctatattt cttggatgca caaattacct attgccacac ggccaacaac 240
 atgacaacgt cctatacaga ctatcctgaa gtgaaagggt cttgggggtaa tgataccctg 300
 ggcttaactt tgtctactag cgtacctatc ccggtattta gttcttctat ctttgatagt 360
 tatgcaccgt ttgcaaaatt acaagttgtc tatgcgcacc aagatgactt taaagaacca 420

acaacagaag gccgggtctt tgaaagcagc gatcttctca acgtttctgt acctataggt 480
ataaaat 487

<210> 55
<211> 162
<212> PRT
<213> Chlamydia psittaci

<400> 55
Thr Ser Arg Glu Asp Ser Leu Ser Val Ala Phe Cys Gln Leu Phe Ala
1 5 10 15
Lys Asp Lys Asp Tyr Leu Val Ser Lys Asn Ala Ala Asn Val Tyr Ala
20 25 30
Gly Ser Val Tyr Tyr Gln His Val Ser Lys Phe Asp Asp Leu Thr Arg
35 40 45
Leu Phe Asn Gly Pro Asn Thr Cys Cys Ser Gly Phe Ser Lys Glu Ile
50 55 60
Pro Ile Phe Leu Asp Ala Gln Ile Thr Tyr Cys His Thr Ala Asn Asn
65 70 75 80
Met Thr Thr Ser Tyr Thr Asp Tyr Pro Glu Val Lys Gly Ser Trp Gly
85 90 95
Asn Asp Thr Leu Gly Leu Thr Leu Ser Thr Ser Val Pro Ile Pro Val
100 105 110
Phe Ser Ser Ser Ile Phe Asp Ser Tyr Ala Pro Phe Ala Lys Leu Gln
115 120 125
Val Val Tyr Ala His Gln Asp Asp Phe Lys Glu Pro Thr Thr Glu Gly
130 135 140
Arg Val Phe Glu Ser Ser Asp Leu Leu Asn Val Ser Val Pro Ile Gly
145 150 155 160
Ile Lys

<210> 56
<211> 2781
<212> DNA
<213> Chlamydia psittaci

<400> 56
atgaggcctt ctttatataa gatttttaata tcgtcgacgc tgacgttacc aatatctttt 60
cacttctcgc aattgcatgc agaagtggct ttaactcaag aatctattct cgatgcaaatt 120
ggagcattca gtccgcaatc tacaagcact gcgggaggaa cgatttaciaa cgtcgagagt 180
gatatttcta ttgtagatgt aggacagaca gcggctcttg cttcctcagc ttttggttcag 240
actgcagaca acctaacttt caaagggaac aaccatagct tatccataac gaacgcgaat 300
gccggagcta atcctgcggg aattaacgtt aacactgccg ataagattct tacgctgaca 360
gatttttcta agttgagctt taaggaatgc ccatcttctc tagtgaatac tggaaaaggg 420

```

gctatgaaat ccggaggagc attaaactta gcgaataatg ccagtattct gtttgatcag 480
aactattccg ctgagaatgg tggagccatc tcttgcaaag ctttttctct aaccggctcg 540
agcaaagaaa tcagcttcac cactaactct actgcgaaaa aaggtggagc gattgctgct 600
acgggaatag ctcatctttc ggacaaccaa ggcacaatca gattttcttg gaacactgct 660
gtgaattctg ggggagcagt atattcagaa gcttctatga cgattgcagg taacaaccac 720
gttgctttta gcaacaatgc tgtttccggg tcatctgatg gttgcgggtg agctatccat 780
tgtagcaaaa caggttcagc accgaccctt actataagag ataacaaagt cttgattttt 840
gaggaaaata cttcttcagc aaaagggtgga gcgatttaca ccgataaact catattgact 900
tctggtgggc ctacggcatt tatcaataac aaagttaccc atgctacacc taagggtgga 960
gctattggta ttgctgccaa tggagaatgt agcttaaccg ctgaacatgg ggatattact 1020
tttgataata acctgatggc cacacaagac aatgctacaa taaaaagaaa tgccattaac 1080
attgaaggca atggtaaatt cgtcaactta cgtgcagcgt ctggaaagac gatttctttc 1140
tatgatccta tcacagttga aggtaatgct gctgatcttc tcactttgaa taaagctgag 1200
ggtgataaaa cgtataatgg aagaattatt ttttcaggag aaaagctcac tgaagaacaa 1260
gctgctgttg cggataacct aaagacaaca tttacacagc ctatcacttt agctgctggt 1320
gaacttggtg tacgcagcgg tgtggaagta gaagcaaaaa cagtcgtgca aacagcagga 1380
tctttgattc tgatggatgc aggcacaaag ttatccgcaa aaacagaaga tgctacactg 1440
acgaatctgg ctattaatcc gaatacctta gatgggaaaa aattcgccgt agtcgatgcc 1500
gttgctgctg ggaagaatgt gactttatca ggtgctattg gcgttattga tcctacaggg 1560
aagttttatg aaaaccataa gctaaatgat acgttagctt taggaggaat tcaactttct 1620
gggaaagggt cggtgacaac aaccaacgtg cctagtcatg ttgttggtgt tgctgaaacc 1680
cactatggtt atcaaggaaa ctggtctgtc agttgggtca aagataataa ctctgatcct 1740
aaaacacaaa cagcaatctt tacctggaat aaaacaggat atgttccaaa tcctgaacgt 1800
cgtgctccgc tagtactcaa tagccttttg ggatccttta tagatttacg ttctattcaa 1860
gatgtcttgg aacgtagtgt tgatagtatt cttgagacac gtcgtggttt gtgggtctct 1920
ggaattggga acttcttcca taaagatcgg aatgctgaaa atcgcaaatt ccgtcatatc 1980
agttcgggat atgtgttagg agccacaaca aatacctcga gagaggattc tcttagtgtg 2040
gctttctgtc agttatttgc aaaagataaa gactaccttg taagcaagaa cgccgcaaac 2100
gtctatgcgg gttctgtata ttatcagcat gtgagcaagt ttgatgatct cacgcggtta 2160
tttaatgggc ctaacacgtg ttgttcaggg ttttctaaag agattcctat tttcttggat 2220
gcacaaatta cctattgcca cacggccaac aacatgacaa cgtcctatac agactatcct 2280
gaagtgaag gttcttgggg taatgatacc ctgggcttaa ctttgtctac tagcgtacct 2340
atcccgggat ttagttcttc tatctttgat agttatgcac cgtttgcaaa attacaagtt 2400
gtctatgcgc accaagatga ctttaaagaa ccaacaacag aaggccgggt ctttgaaagc 2460
agcgatcttc tcaacgtttc tgtacctata ggtataaaat ttgagaaact ctctatgga 2520
gagagaagtg cttatgatct tacactgatg tatataacct atgtgtaccg tcataatcca 2580
agctgtatga caggattggc gatcaatgac gtttcctggt taaccacagc tacgaatctt 2640
gctagacaag ctttcatagt tcgcgcgggt aaccatattg ccttaacctc tgggtgttgag 2700
atgttcagtc agtttggttt cgaattacga agctcttcaa gaaattataa cgtagatctt 2760
ggcgctaagg tcgcgttcta a 2781

```

<210> 57

<211> 926

<212> PRT

<213> Chlamydia psittaci

<400> 57

```

Met Arg Pro Ser Leu Tyr Lys Ile Leu Ile Ser Ser Thr Leu Thr Leu
  1                      5                      10          15

```

```

Pro Ile Ser Phe His Phe Ser Gln Leu His Ala Glu Val Ala Leu Thr
      20                      25          30

```

```

Gln Glu Ser Ile Leu Asp Ala Asn Gly Ala Phe Ser Pro Gln Ser Thr
      35                      40          45

```

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Thr | Ala | Gly | Gly | Thr | Ile | Tyr | Asn | Val | Glu | Ser | Asp | Ile | Ser | Ile |
| 50 | | | | | | 55 | | | | | 60 | | | | |
| Val | Asp | Val | Gly | Gln | Thr | Ala | Ala | Leu | Ala | Ser | Ser | Ala | Phe | Val | Gln |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 |
| Thr | Ala | Asp | Asn | Leu | Thr | Phe | Lys | Gly | Asn | Asn | His | Ser | Leu | Ser | Ile |
| | | | | 85 | | | | | 90 | | | | | 95 | |
| Thr | Asn | Ala | Asn | Ala | Gly | Ala | Asn | Pro | Ala | Gly | Ile | Asn | Val | Asn | Thr |
| | | | 100 | | | | | 105 | | | | | 110 | | |
| Ala | Asp | Lys | Ile | Leu | Thr | Leu | Thr | Asp | Phe | Ser | Lys | Leu | Ser | Phe | Lys |
| | | 115 | | | | | 120 | | | | | 125 | | | |
| Glu | Cys | Pro | Ser | Ser | Leu | Val | Asn | Thr | Gly | Lys | Gly | Ala | Met | Lys | Ser |
| | 130 | | | | | 135 | | | | | 140 | | | | |
| Gly | Gly | Ala | Leu | Asn | Leu | Ala | Asn | Asn | Ala | Ser | Ile | Leu | Phe | Asp | Gln |
| 145 | | | | | 150 | | | | | 155 | | | | | 160 |
| Asn | Tyr | Ser | Ala | Glu | Asn | Gly | Gly | Ala | Ile | Ser | Cys | Lys | Ala | Phe | Ser |
| | | | | 165 | | | | | 170 | | | | | 175 | |
| Leu | Thr | Gly | Ser | Ser | Lys | Glu | Ile | Ser | Phe | Thr | Thr | Asn | Ser | Thr | Ala |
| | | | 180 | | | | | 185 | | | | | 190 | | |
| Lys | Lys | Gly | Gly | Ala | Ile | Ala | Ala | Thr | Gly | Ile | Ala | His | Leu | Ser | Asp |
| | | 195 | | | | | 200 | | | | | 205 | | | |
| Asn | Gln | Gly | Thr | Ile | Arg | Phe | Ser | Gly | Asn | Thr | Ala | Val | Asn | Ser | Gly |
| | 210 | | | | | 215 | | | | | 220 | | | | |
| Gly | Ala | Val | Tyr | Ser | Glu | Ala | Ser | Met | Thr | Ile | Ala | Gly | Asn | Asn | His |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 |
| Val | Ala | Phe | Ser | Asn | Asn | Ala | Val | Ser | Gly | Ser | Ser | Asp | Gly | Cys | Gly |
| | | | | 245 | | | | | 250 | | | | | 255 | |
| Gly | Ala | Ile | His | Cys | Ser | Lys | Thr | Gly | Ser | Ala | Pro | Thr | Leu | Thr | Ile |
| | | | 260 | | | | | 265 | | | | | 270 | | |
| Arg | Asp | Asn | Lys | Val | Leu | Ile | Phe | Glu | Glu | Asn | Thr | Ser | Ser | Ala | Lys |
| | | 275 | | | | | 280 | | | | | 285 | | | |
| Gly | Gly | Ala | Ile | Tyr | Thr | Asp | Lys | Leu | Ile | Leu | Thr | Ser | Gly | Gly | Pro |
| | 290 | | | | | 295 | | | | | 300 | | | | |
| Thr | Ala | Phe | Ile | Asn | Asn | Lys | Val | Thr | His | Ala | Thr | Pro | Lys | Gly | Gly |
| 305 | | | | | 310 | | | | | 315 | | | | | 320 |
| Ala | Ile | Gly | Ile | Ala | Ala | Asn | Gly | Glu | Cys | Ser | Leu | Thr | Ala | Glu | His |
| | | | | 325 | | | | | 330 | | | | | 335 | |
| Gly | Asp | Ile | Thr | Phe | Asp | Asn | Asn | Leu | Met | Ala | Thr | Gln | Asp | Asn | Ala |
| | | | 340 | | | | | 345 | | | | | 350 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Thr | Ile | Lys | Arg | Asn | Ala | Ile | Asn | Ile | Glu | Gly | Asn | Gly | Lys | Phe | Val |
| | | 355 | | | | | 360 | | | | | 365 | | | |
| Asn | Leu | Arg | Ala | Ala | Ser | Gly | Lys | Thr | Ile | Ser | Phe | Tyr | Asp | Pro | Ile |
| | 370 | | | | | 375 | | | | | 380 | | | | |
| Thr | Val | Glu | Gly | Asn | Ala | Ala | Asp | Leu | Leu | Thr | Leu | Asn | Lys | Ala | Glu |
| 385 | | | | | 390 | | | | | 395 | | | | | 400 |
| Gly | Asp | Lys | Thr | Tyr | Asn | Gly | Arg | Ile | Ile | Phe | Ser | Gly | Glu | Lys | Leu |
| | | | | 405 | | | | | 410 | | | | | 415 | |
| Thr | Glu | Glu | Gln | Ala | Ala | Val | Ala | Asp | Asn | Leu | Lys | Thr | Thr | Phe | Thr |
| | | | 420 | | | | | 425 | | | | | 430 | | |
| Gln | Pro | Ile | Thr | Leu | Ala | Ala | Gly | Glu | Leu | Val | Leu | Arg | Ser | Gly | Val |
| | | 435 | | | | | 440 | | | | | 445 | | | |
| Glu | Val | Glu | Ala | Lys | Thr | Val | Val | Gln | Thr | Ala | Gly | Ser | Leu | Ile | Leu |
| | 450 | | | | | 455 | | | | | 460 | | | | |
| Met | Asp | Ala | Gly | Thr | Lys | Leu | Ser | Ala | Lys | Thr | Glu | Asp | Ala | Thr | Leu |
| 465 | | | | | 470 | | | | | 475 | | | | | 480 |
| Thr | Asn | Leu | Ala | Ile | Asn | Pro | Asn | Thr | Leu | Asp | Gly | Lys | Lys | Phe | Ala |
| | | | | 485 | | | | | 490 | | | | | 495 | |
| Val | Val | Asp | Ala | Val | Ala | Ala | Gly | Lys | Asn | Val | Thr | Leu | Ser | Gly | Ala |
| | | | 500 | | | | | 505 | | | | | 510 | | |
| Ile | Gly | Val | Ile | Asp | Pro | Thr | Gly | Lys | Phe | Tyr | Glu | Asn | His | Lys | Leu |
| | | 515 | | | | | 520 | | | | | 525 | | | |
| Asn | Asp | Thr | Leu | Ala | Leu | Gly | Gly | Ile | Gln | Leu | Ser | Gly | Lys | Gly | Ser |
| | 530 | | | | | 535 | | | | | 540 | | | | |
| Val | Thr | Thr | Thr | Asn | Val | Pro | Ser | His | Val | Val | Gly | Val | Ala | Glu | Thr |
| 545 | | | | | 550 | | | | | 555 | | | | | 560 |
| His | Tyr | Gly | Tyr | Gln | Gly | Asn | Trp | Ser | Val | Ser | Trp | Val | Lys | Asp | Asn |
| | | | | 565 | | | | | 570 | | | | | 575 | |
| Asn | Ser | Asp | Pro | Lys | Thr | Gln | Thr | Ala | Ile | Phe | Thr | Trp | Asn | Lys | Thr |
| | | | 580 | | | | | 585 | | | | | 590 | | |
| Gly | Tyr | Val | Pro | Asn | Pro | Glu | Arg | Arg | Ala | Pro | Leu | Val | Leu | Asn | Ser |
| | | 595 | | | | | 600 | | | | | 605 | | | |
| Leu | Trp | Gly | Ser | Phe | Ile | Asp | Leu | Arg | Ser | Ile | Gln | Asp | Val | Leu | Glu |
| | 610 | | | | | 615 | | | | | 620 | | | | |
| Arg | Ser | Val | Asp | Ser | Ile | Leu | Glu | Thr | Arg | Arg | Gly | Leu | Trp | Val | Ser |
| 625 | | | | | 630 | | | | | 635 | | | | | 640 |
| Gly | Ile | Gly | Asn | Phe | Phe | His | Lys | Asp | Arg | Asn | Ala | Glu | Asn | Arg | Lys |
| | | | | 645 | | | | | 650 | | | | | 655 | |

Phe Arg His Ile Ser Ser Gly Tyr Val Leu Gly Ala Thr Thr Asn Thr
 660 665 670
 Ser Arg Glu Asp Ser Leu Ser Val Ala Phe Cys Gln Leu Phe Ala Lys
 675 680 685
 Asp Lys Asp Tyr Leu Val Ser Lys Asn Ala Ala Asn Val Tyr Ala Gly
 690 695 700
 Ser Val Tyr Tyr Gln His Val Ser Lys Phe Asp Asp Leu Thr Arg Leu
 705 710 715 720
 Phe Asn Gly Pro Asn Thr Cys Cys Ser Gly Phe Ser Lys Glu Ile Pro
 725 730 735
 Ile Phe Leu Asp Ala Gln Ile Thr Tyr Cys His Thr Ala Asn Asn Met
 740 745 750
 Thr Thr Ser Tyr Thr Asp Tyr Pro Glu Val Lys Gly Ser Trp Gly Asn
 755 760 765
 Asp Thr Leu Gly Leu Thr Leu Ser Thr Ser Val Pro Ile Pro Val Phe
 770 775 780
 Ser Ser Ser Ile Phe Asp Ser Tyr Ala Pro Phe Ala Lys Leu Gln Val
 785 790 795 800
 Val Tyr Ala His Gln Asp Asp Phe Lys Glu Pro Thr Thr Glu Gly Arg
 805 810 815
 Val Phe Glu Ser Ser Asp Leu Leu Asn Val Ser Val Pro Ile Gly Ile
 820 825 830
 Lys Phe Glu Lys Leu Ser Tyr Gly Glu Arg Ser Ala Tyr Asp Leu Thr
 835 840 845
 Leu Met Tyr Ile Pro Asp Val Tyr Arg His Asn Pro Ser Cys Met Thr
 850 855 860
 Gly Leu Ala Ile Asn Asp Val Ser Trp Leu Thr Thr Ala Thr Asn Leu
 865 870 875 880
 Ala Arg Gln Ala Phe Ile Val Arg Ala Gly Asn His Ile Ala Leu Thr
 885 890 895
 Ser Gly Val Glu Met Phe Ser Gln Phe Gly Phe Glu Leu Arg Ser Ser
 900 905 910
 Ser Arg Asn Tyr Asn Val Asp Leu Gly Ala Lys Val Ala Phe
 915 920 925

<210> 58

<211> 559

<212> DNA

<213> Chlamydia psittaci

<400> 58

```

tgtgttcatt ctttagcagg agttgcattt acgttgtttc tctgtgagca tatgtttacc 60
aatatgcttg cttcttctta ttttaaggaa ggcagtgggt ttgttcagtt agtgagcaaa 120
tttcatcaga ttcttggtct gaagatcata gaaattgttt ttttagccct accgtttact 180
tgtcacgcta tcctaggtat tttctatctt tttcaagcgc aaactaattc acgggcttct 240
gacggcagaa aacccgcgtt aatctatgcg agaaatcttg cctatacttg gcagagaaga 300
actgcttgga ttttactttt cggctcttatt tttcacgtag ttcagtttcg ttttcttcgt 360
tattcctattc atgtagagct gcatgggcaa acatactatg ttgtcgatat tgacgcttct 420
cggtatgchg cgatagtgcg gggtaacaaa ggatttttta ctataaattt ttcagctcct 480
caacttgaaa cgattcggtt ggataaagag gatcttgacg gcagcgcagt ttctcaatta 540
ttagacagaa aagcgtatc                                     559

```

<210> 59

<211> 186

<212> PRT

<213> Chlamydia psittaci

<400> 59

```

Cys Val His Ser Leu Ala Gly Val Ala Phe Thr Leu Phe Leu Cys Glu
 1           5           10           15

His Met Phe Thr Asn Met Leu Ala Ser Ser Tyr Phe Lys Glu Gly Ser
          20           25           30

Gly Phe Val Gln Leu Val Ser Lys Phe His Gln Ile Pro Gly Leu Lys
          35           40           45

Ile Ile Glu Ile Val Phe Leu Ala Leu Pro Phe Thr Cys His Ala Ile
 50           55           60

Leu Gly Ile Phe Tyr Leu Phe Gln Ala Gln Thr Asn Ser Arg Ala Ser
 65           70           75           80

Asp Gly Arg Lys Pro Ala Leu Ile Tyr Ala Arg Asn Leu Ala Tyr Thr
          85           90           95

Trp Gln Arg Arg Thr Ala Trp Ile Leu Leu Phe Gly Leu Ile Phe His
          100          105          110

Val Val Gln Phe Arg Phe Leu Arg Tyr Pro Ile His Val Glu Leu His
          115          120          125

Gly Gln Thr Tyr Tyr Val Val Asp Ile Asp Ala Ser Arg Tyr Ala Ala
          130          135          140

Ile Val Arg Gly Thr Gln Gly Phe Phe Thr Ile Asn Phe Ser Ala Pro
          145          150          155          160

Gln Leu Glu Thr Ile Arg Leu Asp Lys Glu Asp Leu Asp Gly Ser Ala
          165          170          175

Val Ser Gln Leu Leu Asp Arg Lys Ala Tyr
          180          185

```

<210> 60

<211> 687

<212> DNA

<213> Chlamydia psittaci

<400> 60

```

atgatgaatg aaaaggaatc atgttctgag gctactcaga ggtcatggaa gtactacact 60
agctttgttt tacgttgtgt tcattcttta gcaggagttg catttacgtt gtttctctgt 120
gagcatatgt ttaccaatat gcttgcttct tcttatttta aggaaggcag tggttttgtt 180
cagttagtga gcaaatttca tcagattcct ggtctgaaga tcatagaaat tgttttttta 240
gccctaccgt ttacttggtca cgctatccta ggtattttct atctttttca agcgcaaact 300
aattcacggg cttctgacgg cagaaaaccc gcgttaatct atgcgagaaa tcttgcctat 360
acttggcaga gaagaactgc ttggatttta cttttcggtc ttatttttca cgtagttcag 420
tttcgttttc ttcgttatcc tattcatgta gagctgcatg ggcaaacata ctatgttgtc 480
gatattgacg cttctcggta tgcggcgata gtgcggggta cacaaggatt ttttactata 540
aatttttcag ctctcaact tgaaacgatt cgtttgata aagaggatct tgacggcagc 600
gcagtttctc aattattaga cagaaaagcg tatctcctga ctctaatgt tggaccgctt 660
ttctttatgt tgttcgggat tcttttag                                     687

```

<210> 61

<211> 228

<212> PRT

<213> Chlamydia psittaci

<400> 61

```

Met Met Asn Glu Lys Glu Ser Cys Ser Glu Ala Thr Gln Arg Ser Trp
  1                      5                      10          15

Lys Tyr Tyr Thr Ser Phe Val Leu Arg Cys Val His Ser Leu Ala Gly
          20                      25          30

Val Ala Phe Thr Leu Phe Leu Cys Glu His Met Phe Thr Asn Met Leu
          35                      40          45

Ala Ser Ser Tyr Phe Lys Glu Gly Ser Gly Phe Val Gln Leu Val Ser
          50                      55          60

Lys Phe His Gln Ile Pro Gly Leu Lys Ile Ile Glu Ile Val Phe Leu
          65                      70          75          80

Ala Leu Pro Phe Thr Cys His Ala Ile Leu Gly Ile Phe Tyr Leu Phe
          85                      90          95

Gln Ala Gln Thr Asn Ser Arg Ala Ser Asp Gly Arg Lys Pro Ala Leu
          100                     105          110

Ile Tyr Ala Arg Asn Leu Ala Tyr Thr Trp Gln Arg Arg Thr Ala Trp
          115                     120          125

Ile Leu Leu Phe Gly Leu Ile Phe His Val Val Gln Phe Arg Phe Leu
          130                     135          140

Arg Tyr Pro Ile His Val Glu Leu His Gly Gln Thr Tyr Tyr Val Val
          145                     150          155          160

Asp Ile Asp Ala Ser Arg Tyr Ala Ala Ile Val Arg Gly Thr Gln Gly
          165                     170          175

```

Phe Phe Thr Ile Asn Phe Ser Ala Pro Gln Leu Glu Thr Ile Arg Leu
180 185 190

Asp Lys Glu Asp Leu Asp Gly Ser Ala Val Ser Gln Leu Leu Asp Arg
195 200 205

Lys Ala Tyr Leu Leu Thr Pro Asn Val Gly Pro Leu Phe Phe Met Leu
210 215 220

Phe Gly Ile Leu
225